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Abstract
There are currently more than 100 million single nucleotide polymorphisms (SNPs),
which are the most frequent and basic type of genetic variation. The availability of
over 110,000 three-dimensional protein structures allows the structural context of
many SNPs to be examined in atomic detail. Interfaces are essential sites for protein
function and adaptation, and key in a majority of biological processes. A computa-
tional framework, ProIntVar, was developed for mapping SNPs onto the structures
to allow the features of variation at domain-domain and domain-ligand interfaces to
be studied. ProIntVar allows the systematic analysis of genetic variation in protein
structure interaction surfaces by integrating structural and sequencing data from
several biological databases and resources. Protein domains and variants were anal-
ysed in the context of structural clusters (SCs) and functional families (FunFams),
which are derived from structurally and functionally related protein domains in
Superfamilies classified in CATH (Class, Architecture, Topology, Homologous Su-
perfamily). Multiple structural alignments were generated by STAMP for each
CATH SC and FunFam, using an improved protocol that leads to improvement
of the structural superimposition and resulting structure-based alignments. The
structural alignments were extended with similar protein sequences by HMM-based
xix
sequence search. These sequences are believed to be structurally/functionally ho-
mologous and thus a rich source of novel insight into the structural context and
potential consequences of a vast number of genetic variants. The characterisa-
tion of both disease-associated and non-disease germline variants, as well as so-
matic variation, was performed. The analysis of non-synonymous SNPs (nsSNPs)
was stratified by annotation and potential consequence and focused particularly on
domain-domain and domain-ligand interaction interfaces. Domain interactions were
screened and further classified by mode of interaction as clustered by iRMSD (inter-
action root-mean-square deviation). The results corroborate previous observations
that pathogenic mutations are enriched at key sites, such as structurally conserved
domain-ligands interfaces and the protein core. Examination of genetic variation at
such hot-spots in the context of domain families helps to infer which variants are
more likely to affect protein activity and function in a broader evolutionary sense.
The most drastic features shared by pathogenic variants were identified to prioritise
the analysis of nsSNPs currently thought to be neutral, but potentially disruptive.
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Chapter 1
Introduction
This Chapter reviews the state of the art in the two main areas covered in this
Thesis: 1) protein structures and interactions, and 2) genetic variation. This is
followed by a brief overview of the approaches undertaken to improve upon current
methods of analysis of genetic variation at protein domain interfaces.
1.1 Background
The central dogma of molecular biology (Crick, 1970) unveils the sequential transfer
of information from the genetic material to its translated products known as proteins.
DNA is replicated, then transcribed into RNA. After a series of processing steps,
which includes splicing, the RNA molecule is translated into proteins. Proteins
are considered the most important machinery of the cell (Gutteridge and Thornton,
2005; Scaiewicz and Levitt, 2015) and perform nearly every function required for life.
Proteins participate extensively in interactions, which are fundamental to virtually
all biochemical processes (Alves et al., 2002; Nooren and Thornton, 2003b; Russell
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et al., 2004; Schuster-Böckler and Bateman, 2008; Marsh and Teichmann, 2015).
Genetic variation and the accumulation of sequence variation is an important source
of variability within and across populations, and an important driver of evolution
inherent to all living organisms (Nei et al., 2010; Simonti and Capra, 2015). The
study of sequence variation is key to the identification of random mutations linked to
impairment of protein function, through the disruption of interaction interfaces and
contact networks (Sunyaev et al., 2001; Wang and Moult, 2001; Ramensky et al.,
2002; Yue and Moult, 2006; Stefl et al., 2013).
There has been a tremendous increase in the amount of biological data being
generated over the last decades. This includes a dramatic increase in the availability
of genomics, proteomics, and structural data, among others. According to data from
the Genomes Online Database (GOLD) database, there were only 350 active genome
sequencing projects in 1997 (Bernal et al., 2001), which had increased to 11,472 by
2011 (Pagani et al., 2012). The genomes of over 11,006 organisms have now been
fully sequenced in comparison to only 48 in 1997. Associated with these genetics
studies is the identification of sequence variations (genetic variants). dbSNP (Sherry
et al., 1999) accounted for a mere 4,713 unique variants in 1999. This number
increased rapidly and accounted for more than 60 million genetic variants in 2013
(Chen et al., 2010).
Another major data source is proteomics, where the number of public datasets
and experiments in the Proteomics Identifications Database (PRIDE) increased dra-
matically to over 25,853 in 2012, accounting for more than 10 million identified pro-
teins in over 320 species (Vizcáıno et al., 2013). The emergence of proteomics-based
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techniques has also lead to a remarkable increase in the availability of protein-
protein interactions data. The Molecular Interaction database (IntAct) contained
around 2,200 binary interactions in 2004 (Hermjakob et al., 2004), which increased
to 430,134 interactions in 2013 (Orchard et al., 2014). In a similar trend, there were
5,009 protein structures deposited in the Protein Data Bank (PDB) in 1996 (West-
brook et al., 2002), which increased to over 100,000 structures in 2014 (Gutmanas
et al., 2014).
The fields of biological sciences that traditionally studied small datasets related
to their particular area of expertise have also evolved in response to this data deluge.
The huge demand for interpretation and analysis of these vast amounts of data
is being managed by the emerging field of bioinformatics (Bayat, 2002; Ouzounis
and Valencia, 2003). Bioinformatics is an interdisciplinary field that draws from
biological sciences (biology, biochemistry, genetics); medicine (populations, cells,
cancer, etc.), computer science (software development, database technology, artificial
intelligence, etc.); as well as physics and maths (mathematical modelling, statistics,
etc.) (Roos, 2001; Bayat, 2002; Chicurel, 2002; Larranaga, 2006; Hamelryck, 2009;
Berman et al., 2007; Pruitt et al., 2003; Xia and Levitt, 2004; Aloy and Russell,
2006; Taylor, 2007; Maglott et al., 2011). Major challenges in biological sciences
and bioinformatics persist regarding interpretation and functional annotation of the
large datasets generated. The functional annotation of protein interactions and the
potential consequences of genetic variation are among those that are addressed in
this Thesis.
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1.2 Proteins
Proteins are linear polymers of amino acids. The distinct sequence of amino acid
residues in a polypeptide chain determines the three-dimensional (3D) structure of
the folded protein. The amino acid sequence is referred to as the primary structure.
Secondary structure is the local conformation of the polypeptide chain, which is
stabilised by hydrogen bonding and the properties of peptide bonds between amino
acid residues. The dominant secondary structure elements (SSEs) in proteins are
α-helices and β-strands. These regular structures are distributed within irregular,
generally ordered loops, turns or coils, as well as disordered loop regions, which are
referred to as random coils. Loop regions are often located at the surface of the
protein, and in addition to simply serving as transitions between regular structures,
often harbour active sites in enzymes (Worth et al., 2009).
The arrangement of the secondary structure elements in space is referred to as
the tertiary structure. The tertiary structure is locally governed by the interactions
between amino acid residue side chains. Globally, and most importantly, the tertiary
structure results from the hydrophobic effect (Kumar and Nussinov, 2002), where
residues with hydrophobic side chains are packed into the core of the protein, away
from the solvent. In the hydrophobic core of the protein, the polarity of the polypep-
tide backbone is neutralised by hydrogen bonding in SSEs. Buried polar residues
form hydrogen bonds with other polar residues or the polypeptide backbone and
in some cases with integral water molecules contained inside the protein. Charged
residues in the hydrophobic core form ionic interactions with residues of opposite
charge. Disulphide bonds formed between Cys residues are the only type of covalent
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interaction formed between amino acid residues. Disulphide bonds further stabilise
tertiary structure, but they are not found in all proteins. The structure-stabilising
role of interactions between buried residues has been hypothesised long ago, but
the contribution of surface residues to protein stability was also observed (Strickler
et al., 2006).
Quaternary structure refers to the organisation of monomers in multi-subunit
proteins, stabilised by similar interactions as the secondary and tertiary structures.
The interfaces between monomers are often thought to be hydrophobic and thus
resemble the cores of globular proteins. This has been shown to be true for homod-
imeric proteins, because they rarely occur as monomers, and hence their interaction
surfaces are permanently buried within the protein-protein complex. Heteromers,
instead, often occur and function as monomers in solution and thus the interfaces
of transient complexes exhibit a more hydrophilic nature (Janin and Chothia, 1990;
Jones and Thornton, 1996, 1997). These interfaces could not be as hydrophobic
as those of homodimers because a large solvent-exposed hydrophobic area on the
protein would be energetically unfavourable (Jones and Thornton, 1996). The prop-
erties of protein interactions are further explored in Section 1.6.
1.3 Protein sequence
The sequences of over 40 million proteins have been determined and collected in bio-
logical sequence databases (Cochrane et al., 2010). The Universal Protein Resource
(UniProt) (The UniProt Consortium, 2015) is one of the largest protein information
databases, and it consists of the UniProt Knowledgebase (UniProtKB), the UniProt
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Reference Clusters (UniRef), and the UniProt Archive (UniParc). The UniProtKB
database is the central unit of the UniProt database, and is a collection of sequence
and functional information on proteins, with a comprehensive selection of annota-
tions for each protein. It contains detailed information about gene products, partial
lists of mutations and links to other data sources. The UniProtKB can be split into
two essential parts: the UniProtKB/SwissProt, which contains fully manually an-
notated records with additional information taken from the scientific literature and
manually evaluated computational analysis, and the UniProtKB/TrEMBL, which
consists of automatically generated entries that await full manual annotation.
A great effort has been made over the last decades to annotate the protein se-
quences with relevant and accurate information. Functional annotation involves sev-
eral properties of protein function including post-translational modifications (PTMs),
expression levels, transcriptome, biomolecular interactions and cellular location.
Complementary sequence annotation features are provided by many databases such
as the Gene Ontology (GO) (Harris et al., 2004), Enzyme Commission (EC) (Bairoch,
2000), the Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa and Goto,
2000), and Protein Families (Pfam) (Bateman et al., 2004) databases.
1.4 Protein structure
The major public repository for structural data is the worldwide Protein Data Bank
(PDB) central archive of macromolecular structural data (Westbrook et al., 2002;
Berman et al., 2003, 2007). The PDB is an archival database for macromolecu-
lar structures established in 1971 by Brookhaven National Laboratory, New York,
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as a public domain repository. The first version of the PDB contained only seven
structures. There has been a dramatic increase in the number of deposited struc-
tures since then, and projects such as the ‘Structural Genomics Initiatives’, aimed
at solving the three-dimensional structure of selected protein families and protein
complexes, known to be potential drug targets or important players in key pathways
for disease (Xie and Bourns, 2005; Arkin and Wells, 2004; Mullard, 2012; Ivanov
et al., 2013). This led to a remarkable increase in the number of available protein
structures in the PDB (Velankar et al., 2010), which recently surpassed the 100,000
mark. Figure 1.1 shows the cumulative increase in the number of macromolecular
structures available in the PDB over the last 40 years.
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Figure 1.1: The exponential growth in the number of macromolecular
structures deposited in the worldwide Protein Data Bank (wwPDB). Data
obtained from http://www.rcsb.org/pdb/static.do?p=general_information/
pdb_statistics/index.html as accessed in November 2016.
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1.4.1 Experimental methods
The most commonly used experimental techniques for solving 3D structures are X-
ray crystallography (Gilliland and Ladner, 1996; Carpenter et al., 2008; Wlodawer
et al., 2007; Shi, 2014), Nuclear Magnetic Resonance (NMR) (Luca et al., 2004;
Englander and Mayne, 1992; Kwan et al., 2011) and Cryo-(transmission) Electron
Microscopy (cryoEM) (Saibil, 2000; Nickell et al., 2006; Jonic and Vénien-Bryan,
2009). X-ray crystallography can obtain atomic level resolution (1.5 Å or lower),
whereas cryoEM usually produces images of lower resolution (≥3.0 Å). Each method
determines the 3D structure of proteins exploring different protein properties and
experimental conditions. This means that not all structures can be determined by
any one of the methods, and it is now common practice to use these complementary
techniques to solve the structure of proteins. This is especially true for bigger protein
complexes (Lander et al., 2012; Lengyel et al., 2014; Hashem et al., 2013; Jackson
et al., 2015; Schröder, 2015). There are additional techniques that can provide
insight into the shape of macromolecules, such as Small Angle X-ray Scattering
(SAXS) (Putnam et al., 2007) and Fluorescence Resonance Energy Transfer (FRET)
(Lilley and Wilson, 2000; Schuler and Eaton, 2008). The techniques for purification
and preparation of the target protein samples, as well as the experimental techniques
themselves, are under constant active development. Among the most prominent
emerging techniques is MicroED that uses protein microcrystals (Shi et al., 2013;
Nannenga and Gonen, 2014).
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1.4.1.1 X-ray crystallography
X-ray crystallography provides detailed atomic models and produces the highest
resolution 3D structures, in comparison to other 3D structure determination meth-
ods (Shi, 2014). Of the more than 100,000 entries in the PDB, about 90% were
determined by this technique. It has also contributed to more than a dozen Nobel
prizes over the years.
Figure 1.2 illustrates the process of solving the crystal structure of macromolecules
by X-ray diffraction (Gilliland and Ladner, 1996). Individual steps in structure de-
termination include: 1) getting a protein crystal suitable for the experiment, with
adequate quality and size; 2) obtaining the diffraction pattern with the appropriate
wavelength; 3) evaluating the diffraction pattern to get the lattice parameters (unit
cell), symmetry (space group) and diffraction intensities; 4) solving the electron den-
sity Fourier transform equation, obtaining any information about the phases of the
diffracted beams (phase problem), which is a key point for the structural resolution;
5) building an initial structural model that fits the electron density by completing
the model locating the remaining atomic positions; 6) iteratively refining the model,
re-adjusting all atomic positions to get the best possible fit between the calculated
diffraction pattern and the experimental diffraction pattern, and finally; 7) validat-
ing the structural model obtained. Among these steps, crystallisation and solving
the phase problem constitute the hardest to resolve.
Crystallisation has remained a time-consuming trial and error approach that
often involves screening of many thousands of crystallisation conditions and testing
alternative protein constructs (Gilliland and Ladner, 1996). The proteins within a
9
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Figure 1.2: General diagram illustrating the process of solving the structure of
macromolecules by X-ray crystallography. The process broadly consists of the fol-
lowing steps: 1) getting a protein crystal with adequate quality and size; 2) obtaining
the diffraction pattern; 3) evaluating the diffraction pattern; 4) solving the electron
density Fourier transform; 5) building an initial structural model; 6) refining the
model; and finally; 7) validating the structural model obtained. Figure adapted
from http://www.xtal.iqfr.csic.es/Cristalografia/parte_07-en.html.
crystal are arranged in the same orientation, which leads to interference between
the diffracted waves and adds up in phase increasing the signal to a measurable
level. The diffraction pattern consists of spots of various intensities arranged on a
3D lattice in space which are then used to derived the position of atoms in the 3D
space.
To determine the structure of the protein both the amplitude and a phase must
10
1. Introduction 1.4. Protein structure
be determined. The amplitude is reasonably easy to find as it is directly propor-
tional to the brightness of the spots. To solve the phase problem, several approaches
are typically used, which involve using relationships between diffraction patterns of
similar crystals and different wavelengths of the same crystal (Figure 1.2). These
include: Molecular Replacement (MR), when the coordinates of a similar protein
are already available; Multiple Isomorphous Replacement (MIR), for when such
model is not available, which relies on the addition of heavy atoms into specific sites
within the unit cell without perturbing the crystal lattice; and lastly Multiwave-
length Anomalous Dispersion (MAD), which is an effective approach that relies on
the measurement difference produced by the introduction of one or more anoma-
lously scattering molecules such as selenomethionines. Given the amplitude and
phase of each position in reciprocal space, the electron density can be determined
by applying the Fourier transform equation. The electron density map is then inter-
preted in terms of a set of atomic coordinates, usually starting by the fitting of the
protein backbone. Once a preliminary model of the protein structure is obtained,
iterative re-phasing, model fitting and refinement, is performed until a final model
that leads to an agreement between the model and the data is generated (Wlodawer
et al., 2007).
1.4.2 Structural data
Although historically macromolecule structures were stored in the PDB-file format,
a new exchange format has been adopted. Macromolecular Crystallographic In-
formation File (mmCIF) [http://mmcif.pdb.org/] is based on the Self Defining
Text Archival and Retrieval (STAR) (Hall, 1991) format, and an expansion of the
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Crystallographic Information File (CIF) format, which is the International Union of
Crystallography (IUCr) standard for representing small molecules. The PDB for-
mat could not adequately accommodate a large amount of data associated with a
single macromolecular complex structure (Bourne et al., 1997). All structural data
in mmCIF consists of categories of information represented as tables and keyword-
value pairs. Each data item is defined in the PDBx Exchange Data Dictionary, and
chemical descriptions of all monomers and ligands in the structures are provided
in the PDB Chemical Component Dictionary and Biologically Interesting molecule
Reference Dictionary (BIRD).
1.4.2.1 Quality of the protein models
Several validation metrics have been developed to assess the quality of protein struc-
ture models (Brunger, 1992; Domagalski et al., 2014). Many quantitative measures
have been devised that correlate with model quality, including resolution, R-factor
and R-free, Ramachandran distribution, distribution of deviations from ideal geom-
etry, Molprobity’s clash-score (Hintze et al., 2016), among others. Nevertheless, no
single parameter is sufficient to conclusively determine whether a given structure is
of high or low quality, and quality depends on the context. All structures deposited
and organised in the PDB are submitted through a validation server (Gore et al.,
2012) in order to assess how well the protein model fits the data. Additionally, every
structure is compared to other structures in the PDB using a variety of established
validation methods (Gore et al., 2012; Velankar et al., 2013). Validation reports are
provided for all structures covering experimental information, data and refinement
statistics, as well as validation information. The main summary metrics currently
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provided for each structure are R-free, clash-score, Ramachandran and side-chain
outliers, as well as Real Space R-value Z-score (RSRZ) outliers.
The majority of the structures in the PDB have resolutions ranging from 1.6 Å
to 2.8 Å, and it is estimated that at this resolution they are likely to have errors
associated with them (Jones et al., 1991; Acharya and Lloyd, 2005). These errors
include the atomic positions, the planarity of peptide bonds, bond lengths, bond
angles and torsion angles. Most of these errors occur in regions of high mobility or
multiple conformations (Hintze et al., 2016).
1.4.2.2 Problems with the structural data
Although the information found in PDB structures are clearly invaluable, high-
throughput analysis of the structures is difficult due to the heterogeneous and in-
consistent nature of the data. Inconsistencies result from a variety of sources: crystal
structures with multiple-occupancy atoms; inconsistent presence of water molecules;
inconsistent presence of hydrogen atoms; atoms with missing electron density; struc-
tures consisting solely of Cα backbone atoms; structures containing non-standard
amino acid residue types (naturally-occurring or engineered modifications forming
part of the polypeptide backbone); among others. Additionally, many of the prob-
lems stem from the fact that the PDB is not a relational database (Schierz et al.,
2007). The situation has improved considerably through the efforts of the PDB re-
mediation project (Henrick et al., 2007), as well as the recently introduced validation
server (Gore et al., 2012).
X-ray crystallography has several limitations related to the fact that it only pro-
duces an average picture of a structure, the structure of the protein complex in
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crystal form. Structures solved by NMR do not present this problem and can be
used to complement the X-ray structures. Nonetheless, structures are solved in a set
of conformations (ensembles) which raise the problem of choosing the best model
representation of the protein (Mao et al., 2014). It is also common that large macro-
molecular complexes are impossible to crystallise as a whole. The usual strategy is
to cut the protein into manageable pieces, which then raises another challenge of
reassembling all units in the proper orientation and arrangement. Structures solved
at lower resolutions (for example by cryoEM) are increasingly used as guides to help
model the structure of such large complexes (Lawson et al., 2011; Patwardhan et al.,
2014).
1.4.2.3 Artefacts in the structures
One way in which the field of X-ray crystallography has been developed into a high-
throughput technology is to use automated methods to test multiple conditions.
Usually, many parameters such as the pH, the temperature and the concentration
of the additives (organic solvents and crystallisation buffers) are varied to aid the
crystallisation of the molecules. Additionally, crystallisation is performed using
artificially high protein concentrations, which can lead to the formation of extensive
non-specific crystal packing interfaces. There are several examples of protein crystal
structures which display non-biological interactions (see below Section 1.4.2.5).
Many macromolecular structures in the PDB are of partial or modified proteins
(e.g. engineered mutants and modified residues, truncated proteins, synthetic con-
structs or chimeric constructs, and purification/expression tags). Common missing
segments in the structures are usually observed for tails and loops that due to their
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more disordered nature are not packed in the same exact orientation in the crys-
tal. Discontinuities in the structures are particularly troublesome when performing
structure to sequence mapping (overviewed in Section 1.4.2.6).
1.4.2.4 Ligand artefacts
Ligand artefacts are commonly observed in the PDB structures. In addition to
artefact ligand molecules found in solvents and crystallisation additives, many lig-
ands correspond to substrate analogues or inhibitors that compete with the natural
molecules for binding. Many of these are not believed to be biologically meaningful.
In order to address this issue, it has been common practice to establish exclusion
lists of compounds considered to be crystallisation artefacts which are kept out
from structure analysis (Powers et al., 2006; Schreyer and Blundell, 2009; Roy and
Zhang, 2012; Elokely and Doerksen, 2013; Niedzialkowska et al., 2016). One major
drawback of this approach is the fact that some ligands might be irrelevant for a par-
ticular protein structure and yet essential for others (e.g. metal ions). Since making
a comprehensive list of artefact compounds is hard and might lead to additional
analysis artefacts, other approaches which take into account contextual knowledge
have been developed (Yang et al., 2012).
1.4.2.5 Biological assemblies
The 3D atomic coordinates that appear in PDB entries are those of the asymmetric
unit (AsymUnit). The AsymUnit is a set of atoms which, when operated on by
the crystallographic symmetry operations defined by the space-group, generates the
complete crystal. The AsymUnit may not be the biologically relevant unit of the
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structure, and so may lack some key protein-protein interactions (Jefferson et al.,
2006). As such, although the AsymUnit can represent the biologically functional
assembly of the protein, often it comprises only a portion of a biological molecule.
A biological unit or biological assembly (BioUnit) is a macromolecular complex
that is believed to represent the functional form of a molecule. Since it is non-
trivial to determine the BioUnit for most PDB structures, studies of protein-protein
interactions have mostly ignored the additional interactions that are potentially
available.
An additional problem is that some of the interactions seen in the AsymUnit
of the crystal may be artefacts of crystallisation and therefore may not be bio-
logically relevant. The problem of reliably distinguishing biologically significant
assemblies from crystal contacts is non-trivial, and several approaches have been
proposed (Valdar and Thornton, 2001; Mintseris and Weng, 2003; Bahadur et al.,
2004; Bernauer et al., 2008; Krissinel and Henrick, 2007). The PDB provides infor-
mation on the BioUnit for each deposition. This information has been traditionally
provided by depositors and more recently supplemented by supporting information
from the UniProt, the Protein Quaternary Structure (PQS) (Henrick and Thorn-
ton, 1998), and Proteins, Interfaces, Structures and Assemblies at the PDB in Eu-
rope (PDBePISA or simply PISA) (Krissinel and Henrick, 2007). PDBePISA is a
widely-used method, which identifies functional interactions by analysing properties
of the interaction surface between chains. Once interactions have been determined,
PDBePISA generates a new set of coordinates for the biologically most likely Bi-
oUnits. Given the importance of working with BioUnits, the PDBe recently started
providing precomputed assemblies in mmCIF format (Velankar et al., 2016).
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Figure 1.3 illustrates the process of generating BioUnits from the AsymUnit by
applying biologically relevant symmetry operations and/or removing crystal packing
artefacts. As illustrated in Figure 1.3 B and C, there are several instances where
the asymmetric unit of a crystal contains non-biological interaction interfaces.
Biological Assembly 1PDB entry
Symmetry Operation Applied
Biological Assembly 1PDB entry
Biological Assemblies 1 and 2
Symmetry Operation Applied 
and Crystal Packing 
Artefacts Removed
Crystal Packing 
Artefacts Removed
PDB entry
A
B
C
Figure 1.3: Generating biological assemblies from the asymmetric unit by apply-
ing biologically relevant symmetry operations and/or by removing crystal packing
artefacts. Examples provided depict: A) generation of a biological assembly (Bi-
oUnit) by applying symmetry operations to the asymmetric unit (AsymUnit); B)
generation of two BioUnits by removing crystal packing artefact interactions, and;
C) generating a BioUnit by applying symmetry operations and simultaneously re-
moving artefact crystal packing. Figure adapted from Jefferson et al., 2006.
1.4.2.6 Structure to sequence mapping
‘Structure to sequence mapping’ (or sequence to structure mapping) refers to the
accurate mapping between a protein’s sequence, as observed in a PDB structure,
to a corresponding sequence record (e.g. UniProtKB entry). Ideally, this mapping
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is performed at the level of individual residues observed in the structure, but it is
somewhat non-trivial due to the various structural problems described in Section
1.4.2.3. The main benefits of performing structure to sequence mapping are that
available sequence residue annotations can trivially be transferred to PDB struc-
tures. The Structure Integration with Function, Taxonomy and Sequence (SIFTS)
resource (Velankar et al., 2013) has developed methods to align the sequences using
additional annotations and manual inspection in order to provide the structure to
sequence mappings. The SIFTS protocol is now routinely applied to all newly solved
structures as part of the deposition and validation process in the PDB (Velankar
et al., 2013).
1.5 Protein domains
Domains are considered to be the minimal and fundamental functional units of
proteins and are usually associated with a specific biological role (Orengo et al.,
1994; Ponting and Russell, 2002; Orengo and Thornton, 2005; Bornberg-Bauer et al.,
2005). Although with a considerable diversity (Reeves et al., 2006; Taylor, 2007),
most domains show similarities in sequence or structure, which reflects their origin
from a common ancestor and allows them to be grouped into a hierarchy of families,
superfamilies and folds. Domain analysis indicates that a limited set of thermo-
dynamically stable folds have emerged in nature (Thornton et al., 1999; Holm and
Sander, 1999). Each domain forms a compact 3D structure and often can be found
independently folded (Hubbard et al., 1997; Kummerfeld and Teichmann, 2009).
Many proteins consist of several structural domains, and a particular domain may
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appear in a variety of different proteins (Bhaskara and Srinivasan, 2011; Han et al.,
2007; Björklund et al., 2005). Fold recurrence means that few newly-solved do-
mains are found to have new folds. This observation has been used to detect similar
domains in a query structure by looking within a library of previously classified do-
mains. Nevertheless, both the number of known folds and types of domain-domain
interactions that have been identified is believed to be far from complete (Garma
et al., 2012).
1.5.1 Protein structure classification
Several methods have been developed to identify and classify protein domains ob-
served in the PDB structures (Redfern et al., 2007; Dengler et al., 2001; Lo Conte
et al., 2000; Orengo et al., 2002; Holm and Sander, 1996). Class, Architecture,
Topological motif and Homologous Superfamily (CATH) (Orengo et al., 2002) and
Structural Classification of Proteins (SCOP) (Lo Conte et al., 2000) are the two
main hierarchical domain classification systems. Domains are classified in CATH
according to sequence, structural and functional similarity using both automated
and manual approaches. Unlike CATH, boundary assignment and classification in
SCOP is entirely achieved by manual inspection and curation. Evolutionary Clas-
sification of Protein Domains (ECOD) (Cheng et al., 2015) is a new hierarchical
classification system that groups structure domains mainly according to sequence
similarity.
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1.5.1.1 CATH
Figure 1.4 overviews the four levels of the CATH structural classification hierarchy.
Domains are initially classified according to their secondary structure content (α-
helix, β-strand, mixed α and β, or very little secondary structure content). They are
further classified according to Architecture, which refers to the gross arrangement
of SSEs in the 3D space, independent of their connectivity. Next, Topology groups
are determined by both the arrangement of SSEs and their connectivity. Finally,
domains are clustered into the same Homologous Superfamily provided that clear
indication of an evolutionary relationship exist. Superfamily-level domains share
Figure 1.4: Overview of the CATH (Class, Architecture, Topology and Homolo-
gous Superfamily) structural classification hierarchy. Domains in CATH are organ-
ised according to four hierarchy levels comprising Class, Architecture, Topology and
Homologous Superfamily. Figure from Maleki et al., 2013.
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significant structure, sequence and/or functional similarity. Lower levels comprise
subfamilies of domains at different levels of sequence similarity (45, 60, 95, 100 per-
centage sequence identity (PID)). Domains under the Superfamily level are further
grouped according to structural similarity in Structural Clusters (SCs). In recent
years, CATH was expanded to classify domains under Superfamily level, according
to functional similarity, i.e. grouping domains into Functional Families (FunFams)
(Sillitoe et al., 2013).
The FunFam protocol involves profile-profile-based clustering of each domain
sequence in each Superfamily to identify functional families (Sillitoe et al., 2013; Das
et al., 2015a). The algorithm recognises evolutionary signals in cluster alignments,
such as highly conserved positions and specificity-determining positions, which are
used to improve functional coherence. For this, functional information is also used
and obtained from resources such as GO (Harris et al., 2004), EC (Bairoch, 2000),
and Pfam (Bateman et al., 2004). Hidden Markov Models (HMMs) profiles (Eddy,
1998) built from FunFams structural seed multiple sequence alignments (MSAs)
were recently made available for function prediction and protein annotation in a new
protocol called FunFHMMer (Das et al., 2015b). As a result of these developments,
both structure and (predicted) sequence domains are now included in FunFams,
which enables the analysis of domains and particularly domain interactions in the
context of a larger protein universe. This helps to increase the CATH coverage of the
current set of protein structures in the PDB, as well as in the prediction/classification
of domains in newly solved structures or entire proteomes (which include many
proteins with no structure available).
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1.5.1.2 SCOP
In SCOP, the first level in the hierarchy is Class with five major classes: all α-helix,
all β-strand, α/β, α + β and multi-domain (structures that are composed of two or
more domains that belong to different classes). Next is Fold (there is no Architecture
in SCOP). The Fold group describes how SSEs are arranged and their connectivity
(topology). Proteins in the same SCOP fold share the same relative arrangement
of major SSEs with the same topology. Although proteins in the same fold from
different superfamilies may share a common evolutionary origin, such relationships
typically cannot be distinguished from rare cases of convergent evolution. Then, the
Superfamily level groups domain structures thought to be evolutionarily related.
The Family level groups closely related domains which are likely to have similar
structures and functions. Proteins in the same SCOP Superfamily are believed to
share a common evolutionary origin despite having low or undetectable sequence
similarity. SCOP’s last biggest update was performed in June 2009, but the project
is currently being developed as two distinct hierarchies, SCOP2 (Andreeva et al.,
2014) and SCOPe (Fox et al., 2014).
1.5.2 Multiple domain definitions
Domain assignments vary according to the domain definition used. For example,
Hadley and Jones, 1999, Veretnik et al., 2004, and Jefferson et al., 2007a, inves-
tigated the differences between CATH and SCOP structure-based domain assign-
ments and found that there are instances where a domain in one classification has no
equivalent in the other, despite the overall high degree of correspondence between
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the two classifications. Domains within the same CATH or SCOP Superfamily share
structural and functional similarities that suggest a common evolutionary ancestry
but may not share a detectable sequence similarity. There are some Superfamilies
that, despite having a significant number of sequence diverse relatives (<35% PID),
have a high degree of structural conservation. A classic example is that of SUMO
and Ubiquitin which show high structural similarity despite low sequence identity
(Gill, 2004). Domain relatives within these Superfamilies have highly similar func-
tions, and it is likely that the structural conservation is largely due to functional
constraints.
1.5.3 Sequence-based domain predictions
CATH and SCOP classification hierarchies have been used to detect domain se-
quence relatives in genome and protein sequence databases. CATH predictions are
provided by Gene3D (Lees et al., 2012). An average coverage of 50% of domain
sequences is achieved for an average genome, which is even higher for bacterial
organisms. For SCOP, SUPERFAMILY provides similar genome-wide predictions
(Gough et al., 2001). Unlike CATH and SCOP which classify domains according to
structure, Pfam (Bateman et al., 2004) classifies domains based on sequence simi-
larity. For Pfam, domain predictions are also available for multiple genomes. There
are ∼25% of domain sequences within a genome that can be assigned to structurally
uncharacterised Pfam families.
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1.6 Protein interactions
Most biological mechanisms, including transcription, translation, cell cycle con-
trol, signal transduction, transport, cellular motion, and secretion, are mediated
by protein-protein interactions (PPI) and protein-ligand interactions (PLI) (Keskin
et al., 2008; Pazos and Valencia, 2008; Khan et al., 2011). Therefore, determination
of an organism’s protein interactions (the interactome) is fundamental to decipher
the mechanisms underlying cellular function (Okada et al., 2005). Additionally,
many disease states are associated with protein interactions. A greater understand-
ing of an organism’s interactome network aids in determining which proteins are
involved in disease, and has received much interest based on the potential for drug-
targeting protein interactions (Blundell et al., 2006; Archakov et al., 2003).
Since the seminal work by Chothia and Janin, 1975, several studies have been car-
ried out on the physicochemical characterisation of protein interfaces to understand
the rules of molecular recognition. General principles of protein-protein interactions
have been proposed (Hubbard and Argos, 1994; Jones and Thornton, 1996; Valdar
and Thornton, 2001; Gao et al., 2004; Bahadur et al., 2004). Many authors defined
measures for interface size, shape complementarity, protrusion, segmentation and
secondary structure. Overall, interfaces have a tendency to be polar, uncharged and
hydrophobic; and usually display a planar protruding shape, good shape comple-
mentarity and an overall high solvent accessible area (Jones and Thornton, 1996;
Janin and Chothia, 1990; Jones and Thornton, 1997; Hubbard and Argos, 1994; Ar-
gos, 1988). Protein-protein interactions are held together by non-covalent forces in-
cluding hydrogen bonds (between polar groups), ionic attractions (between charged
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groups, also known as salt-bridges), Van der Waals forces (between molecules that
have been polarised into dipoles), and hydrophobic interactions (among non-polar
groups in aqueous solution).
Interacting proteins often have large surface patches that are in direct contact
with each other. Especially enzymes, that select their substrates specifically, ex-
hibit a high degree of shape complementarity onto their substrates. To account for
conformational flexibility of protein-protein interactions, Koshland, 1958, proposed
the ‘induced fit theory’ as a revision to the lock and key model first postulated in
1894 by Emil Fischer (Fischer, 1894). According to the latter theory, substrates are
not rigidly docked to their enzymes, but constantly perform small rearrangements
of their side chains. Shape complementarity is a purely structural feature and hence
does not translate directly into sequence representations. However, shape comple-
mentarity can be the result of a long evolutionary process involving mutations on
one side and compensatory mutations on the opposite side of the interaction. These
correlated mutations are detectable at sequence level (Halperin et al., 2006; Marks
et al., 2012; Pazos and Valencia, 2008).
1.6.1 Properties of protein interfaces
Protein interactions can be categorised as inter-molecular or intra-molecular, ho-
modimers or heterodimers, transient or permanent and obligate or non-obligate
(Jones and Thornton, 1996; Nooren and Thornton, 2003b; Ofran and Rost, 2003).
A protein-protein (or domain-domain) interaction is classified as homodimer inter-
action if the interaction occurs between two identical chains or as a heterodimer
interaction if the interaction is between two non-identical chains. A domain-domain
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interaction can also be classified as a homodimer or heterodimer interaction depend-
ing on whether the two domains are identical or not. A domain-domain interaction
is classified as intra-molecular if both domains are from the same polypeptide chain
or intermolecular if the domains are from two different polypeptide chains. An
interaction is classified as transient if its components associate and dissociate in
vivo. In contrast, a permanent interaction is usually very stable and only exists in
its complexed form. An interaction is classified as obligate if its components are
not found as stable structures on their own in vivo whereas the components of a
non-obligate interaction are found as stable structures. Structurally or functionally
obligate interactions are usually permanent, whereas non-obligate interactions may
be transient or permanent (Nooren and Thornton, 2003b). Unfortunately, it can
be difficult to classify some interactions into these distinct types as proteins will
interact in different ways depending on the cellular environment. Besides, transient
interactions cannot be observed by any of the traditional structural determination
methods.
Lo Conte et al., 1999, analysed protein-protein interaction sites from a range
of different complex types including antigen-antibody complexes, protease-inhibitor
complexes, complexes involved in signal transduction and enzyme-inhibitor com-
plexes. Each of these complexes was formed by transient interactions where each
of the proteins involved in the interaction was observed independently of the com-
plex. On average protein-protein interaction interfaces were found to have the same
non-polar nature as the rest of the surface of the proteins. The authors found that
the size of the interface was related to the conformational changes that occurred
upon binding. Large interaction interfaces were observed when the binding of the
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complexes caused large conformational changes. Bridging water molecules are those
forming two hydrogen bonds, one to each interface side, and participate extensively
in hydrogen bonding at the interfaces (Teyra et al., 2011). Water molecules were
found to contribute to the binding in two ways: affecting the close packing of atoms
to ensure complementarity between the two surfaces and providing polar interactions
between the two interacting surfaces (Lo Conte et al., 1999).
Surface patches with high hydrophobicity are energetically unfavourable in an
aqueous solution, but favourable when in contact with other hydrophobic surfaces.
Hence, their occurrence can be linked to binding sites. Gallet et al., 2000, pro-
posed an interface detection method that predicts binding sites by analysing the
hydrophobicity distribution in sequences. In particular, permanent interactions be-
tween globular proteins were found to involve more hydrophobic residues. The
largest hydrophobic surface patches were often found to participate in protein bind-
ing, at least to some extent. Additionally, binding sites frequently show opposite
charges in opposite interfacing patches.
In 2003, Nooren and Thornton, investigated the properties of transient protein-
protein interaction interfaces (Nooren and Thornton, 2003a). They compared exper-
imentally validated transient homodimers which are known to exist as monomers
and dimers at physiological concentration to more stable, functionally validated,
transient (i.e. intracellular signalling) heterodimers. The weak interactions had dis-
sociation constants in the micromolar range whereas the most stable interactions
had binding affinities in the nanomolar range. The weak interactions were found
to be more planar and polar and to have a smaller contact size than the stronger
interactions. The stronger interactions also showed large conformational changes
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upon association and dissociation. According to Nooren and Thornton, 2003, hy-
drophobicity has less discriminative power for transient interactions, as transient
interactions are often established by hydrogen bonds from polar side chains.
Ofran and Rost, 2003, used a much larger data set to analyse different domain-
domain interfaces. They identified six different types of interfaces and found that
using just residue type or pairwise residue type they could discriminate between
different types of interface. The six interface types were within the same struc-
tural domain, between different domains, permanent, transient, homo-oligomers and
hetero-oligomers. All of the interfaces differed significantly from background residue
compositions, surface residues and internal residues. They predicted which of the
six types of interfaces a pool of 1000 residues belonged to with an accuracy ranging
from 63 to 100%.
Zhanhua et al., 2005, compared the interface properties of homodimers and het-
erodimers. The authors found that homodimers typically have a greater number of
interface residues and hydrogen bonds but the density of hydrogen bonds was greater
for heterodimers. They also found that charged hydrophilic residues were dominant
at heterodimer interfaces, in contrast to a dominance of hydrophobic residues at
homodimer interfaces.
Calculation of the electrostatic potential of protein-protein complexes revealed
that protein-protein interfaces display electrostatic complementarity (McCoy et al.,
1997). With the exception of covalent bonds, the bonds formed by hydrogen atoms
between a hydrogen donor and a hydrogen acceptor are the strongest contributors
to binding energies (McDonald and Thornton, 1994; Panigrahi and Desiraju, 2007).
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1.6.2 Key binding residues at the interfaces
Hot spots are interface residues that dominantly contribute to the binding free en-
ergy. Their identification requires experimental techniques such as alanine scanning
(Bogan and Thorn, 1998). Ma et al., 2003, found that structurally conserved residues
distinguish between binding sites and exposed protein surfaces. Halperin et al., 2004,
showed that hot spots are often observed to couple across protein-protein interfaces.
According to Keskin et al., 2005, hot spots reside in tightly packed, structurally
conserved regions that contribute dominantly to the stability of the interaction.
Structurally and functionally important residues are often well conserved (Hu
et al., 2000; Guharoy and Chakrabarti, 2010; Fiser et al., 1996). The identification
of binding sites based on evolutionary conservation, however, remains controversial.
While some authors claim a stronger conservation of interfaces than the rest of the
surface (Nooren and Thornton, 2003b; Bordner and Abagyan, 2005), others question
the statistical significance (Caffrey et al., 2004). A remaining problem is how to
clearly identify non-functional parts of the protein surface, as the knowledge about
interactions might be incomplete. Surface parts considered non-functional could be
important for yet unknown interactions. It is hence not sufficient to base binding site
detection solely on conservation scores. However, selective pressure often leads to the
conservation of important protein features, such as binding behaviour. Therefore, it
is generally beneficial to consider evolutionary conservation scores (Li et al., 2004;
Bordner and Abagyan, 2005).
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1.6.3 Experimental methods
Experimental methods to identify protein interactions can be classified into two
broad areas: traditional experimental methods and high-throughput methods. Low
throughput experimental techniques are highly accurate but time-consuming. The
high-throughput methods can determine genome-wide protein-protein interactions
in a fraction of the time taken by the traditional methods but are traditionally less
reliable. Among the traditional experimental methods are: immunoprecipitation
(Bergg̊ard et al., 2007a; Sambrook and Russell, 2006); FRET (Fluorescence Reso-
nance Energy Transfer) (Kenworthy, 2001); Mass Spectrometry and Quantitative
Proteomics (Bergg̊ard et al., 2007b; Kirkwood et al., 2013); and Tandem Affin-
ity Purification (TAP)-tags (Bergg̊ard et al., 2007b). Among the high-throughput
approaches is the yeast two-hybrid (Y2H) method (Fields, 2005). Although origi-
nally developed as a low-throughput method, Y2H has been developed into a high-
throughput method for determining binary protein-protein interactions. The Y2H
method has been applied to the human genome on a wide scale (Stelzl et al., 2005).
As many as 90% of known protein-protein interactions are thought to be missed by
the genome-wide Y2H projects (Ito et al., 2001) and both high false positive rate
and false negative rate also been observed (Sprinzak et al., 2003; von Mering et al.,
2002; Deane et al., 2002).
1.6.4 Computational methods
The field of protein-protein interaction prediction is one area of functional annota-
tion of proteins which has received a significant amount of attention. A wide range
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of computational methods has been developed. Many of these methods are designed
to improve the reliability of experimental methods, but others directly predict new
protein-protein interactions. The methods which directly predict new interactions
can be classified into genome-based, sequence-based and structure-based methods,
or a combination of them.
A field of protein-protein interaction prediction which particularly depends on
structural data is molecular docking. Molecular docking aims to predict ab initio
the structure of complexes from their component domains when the structure of
the individual component domains is known. Most molecular docking methods
assume that the proteins interact and try to determine the complex structure of the
two proteins when they are bound. There are many difficulties in calculating the
protein-protein interaction energetics directly from the coordinates of the complex.
A significant challenge is to cope with protein flexibility (Bonvin, 2006). Although
obtaining a precise atomic-level model of a docked pair of proteins is a difficult
problem, the results of CAPRI docking prediction experiments suggest progress has
been made for complexes where few conformational changes occur on binding (Janin
et al., 2003).
1.6.5 Databases of protein interactions
A more detailed picture of protein interactions is available from the analysis of
protein structures. This has prompted the use of 3D protein complexes to predict
interactions for homologous proteins. In addition to the basic information that two
proteins interact, 3D structures also provide detailed information about the specific
residue (or atoms depending on the resolution) contacts that mediate the interaction
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of two proteins. This is a significant advantage over other protein-protein interaction
predictive methods resulting in a more detailed data source that can be employed
to analyse the properties of protein-protein interfaces and analysis of variation.
The analysis and prediction of protein interaction sites from structural data is
limited by the availability of structural complexes. Several methods and accompa-
nying databases that use structure data to inform and predict protein interaction
interfaces have been developed. Among the most prominent are: 3did (3D inter-
acting domains) (Mosca et al., 2014), PIBASE (Davis and Sali, 2005), SCOPPI
(Winter, 2006), PSIBase (Gong et al., 2005), PRISM (Baspinar et al., 2014), Mod-
Base (Pieper et al., 2011) and iPfam (Finn et al., 2014b). These methods rely heavily
on structural matching and homology. The principle is that if two proteins A and
B are seen to interact in a structure complex, then a homologue of A is predicted
to interact with a homologue of B.
A common thread among the newest databases, such as DIP (Salwinski et al.,
2004) and STRING (Franceschini et al., 2013), is the combination of prediction
methods and data from multiple sources, as well as literature mining. DIP employs
such methods to annotate protein-protein interaction data in addition to manual
review from expert biologists before submission to the database. STRING predicts
interactions based upon high-throughput experimental data, from the mining of
databases and literature, and from predictions based on genomic context analysis.
STRING annotates each prediction with a degree of certainty. The certainty of
interaction increases with the number of predictive methods which suggest interac-
tion.
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1.7 Genetic Variation
Recent advances in DNA sequencing technology, the so-called next-generation se-
quencing (NGS), indicate that it is increasingly routine to carry out whole-genome
sequencing on multiple individuals (Choi et al., 2009; Soon et al., 2013). NGS
projects have generated a very large catalogue of human variants, but the interpre-
tation of these data remains challenging. It is difficult to determine the functional
impact of genetic variation on individuals (Capriotti et al., 2012; Mirnezami et al.,
2012) and populations (Schofield and Hancock, 2012; Blair et al., 2013). These dif-
ficulties have become more pronounced and important as the scope of analysis has
expanded from monogenic disorders (Chong et al., 2015; Ng et al., 2009) to complex
diseases (Ward and Kellis, 2012). Improvements in sequencing technologies have
also allowed moving beyond studying associations in the exome. Several large-scale
genome projects have provided evidence that at least 80% of the human genome is
functional (ENCODE Project Consortium, 2012).
One prominent result of massive sequencing projects such as the 1,000 genomes
project (1kGP) (The 1000 Genomes Project Consortium, 2012) is an ever increasing
diversity and number of genetic variants that are identified in both protein and non-
protein coding regions of the genome. Single nucleotide polymorphisms (SNPs) are
among the most common types of genetic variation, accounting for 90% of known
sequence differences. Although many of these changes are neutral, currently there
are more than 100 million SNPs, the majority being identified for human, which give
rise to a large number of amino acid substitutions in proteins (The 1000 Genomes
Project Consortium, 2012). One of the major SNP databases is dbSNP (Sherry
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et al., 2001). Figure 1.5 shows the exponential increase in the number of both
Reference SNP clusters and validated SNPs, deposited in NCBI dbSNP database
since 2002.
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Figure 1.5: The exponential growth in the availability of genetic variation data
in dbSNP. dbSNP is provided by the NCBI and is one of the oldest and biggest
repositories for genetic variants. dbSNP contains validated entries and an ex-
ponentially increasing number of reference SNP clusters. Data obtained from
http://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi as accessed in
November 2016.
1.7.1 Types of genetic variation
Genetic variation occurs both within and among populations, supported by individ-
ual carriers of the variant genes. It can be divided into different forms according
to the size and type of genomic variation underpinning genetic change (Ward and
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Kellis, 2012; Zhang et al., 2010; Stankiewicz and Lupski, 2010; Huminiecki and Co-
nant, 2012; Kamburov et al., 2015). These include: small-scale sequence variation
(<1Kbp) such as substitutions and indels (Zhang et al., 2010); as well as large-
scale structural variation (SV) (>1Kbp) (Stankiewicz and Lupski, 2010; Gonzaga-
Jauregui et al., 2012), such as copy number variation (CNV) (copy number loss and
copy number gain) and rearrangement (translocation and inversion). Additionally,
there are other massive gene variation events that lead to changes in the number
of chromosomes (Huminiecki and Conant, 2012) (e.g. whole-genome duplication),
which can result in polyploidy (Huminiecki and Conant, 2012) or aneuploidy (Kam-
burov et al., 2015).
Variation can be categorised according to its location in the genome in coding
regions of genes, non-coding regions of genes or in the intergenic regions. The
majority of SNPs occur in non-coding regions (Syvänen, 2001). However, SNPs
that do occur in the coding region are important because they can affect a variety of
important biological and molecular activities such as stability (Casadio et al., 2011),
expression level (Heinzen et al., 2012) and protein function (Chasman and Adams,
2001). Nonetheless, recent studies (Prado-Montes de Oca et al., 2009; Visel et al.,
2010; Ward and Kellis, 2012) have shown that SNPs in non-coding regions may still
affect other activities such as gene splicing, gene expression and the sequence of
non-coding RNA.
It has been suggested that 20% of non-synonymous SNPs (nsSNPs) could po-
tentially damage proteins (Sunyaev et al., 2001). SNPs affect how an individual
responds to diseases (Wellcome Trust Case Control Consortium, 2007), drugs (Gia-
comini et al., 2007; Lahti et al., 2012; Ma and Lu, 2011) and environmental factors
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(Bresciani et al., 2013). On average, human DNA consists of a SNP for every 300
bases (Nelson et al., 2004). This means that for the whole genome (∼3 billion bases)
there would be roughly 10 million SNPs. More than 60,000 (35%) SNPs are located
in the coding regions of the genes (Sachidanandam et al., 2001). Half of these (nsS-
NPs) cause amino acid substitutions (Cargill et al., 1999). Contrastingly, an nsSNP
alters the amino acid sequence of a protein, while a synonymous SNP is a SNP
that does not change the sequence. Synonymous SNPs can, however, affect the ex-
pression of the gene product by interfering with normal mRNA splicing, leading to
abnormally short or long gene products. Synonymous coding SNPs may also cause
alterations in mRNA folding and translation of the protein (Kudla et al., 2009).
An nsSNP can be either missense or nonsense. A missense nsSNP results in a dif-
ferent amino acid, while a nonsense nsSNP change results in a premature stop codon.
Additionally, a missense nsSNP can either be a conservative or non-conservative
change. A non-conservative change results in a different residue with substantially
different physicochemical properties. Figure 1.6 illustrates the process of protein
translation and the main common variation events that take place throughout the
genome. Variation types included are: 1) regulatory; 2) splicing; 3) missense; 4)
synonymous SNP; and 5) nonsense variants.
1.7.2 Experimental methods
Different methods have been developed to detect SNPs. SNP detection has been
traditionally performed by sequence scanning and genotyping. Experimental tech-
niques include: Denaturing High-Performance Liquid Chromatography (DHLPC)
(Yu et al., 2001), direct DNA Sequencing (Berg et al., 1995), Microarray genotyping
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Figure 1.6: Different types of genetic variants according to their location in the
genome. Variants are categorised as: 1) regulatory; 2) splicing; 3) synonymous; 4)
missense; and 5) nonsense. Figure from Bendl et al., 2016.
(Maskos and Southern, 1992), and Mass Spectrometry (MS) (Ross et al., 1998).
Recent approaches to detecting genetic variants resulted from the massive improve-
ments in NGS technologies. Variant calling statistical methods are now routinely
applied to large-scale NGS sequencing data (Kwok and Duan, 2003; Nielsen et al.,
2011; Cheng et al., 2014). In addition to methods which detect germline genetic
variants by aligning reads from individual samples to a reference genome, somatic
variants can also be detected from multiple tissue samples within a single individual.
These variants correspond to mutations that are not present within the individual’s
germline cells but occurred de novo within groups of somatic cells. Many studies
on cancer are designed around investigating the profile of somatic mutations within
cancerous tissues. However, because of the high-throughput nature of most of these
efforts, many polymorphisms have not been experimentally characterised in terms
of their possible disease association.
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1.7.3 Main repositories for genetic variation
The most widely used variation databases are: dbSNP (Sherry et al., 2001), 1kGP
(The 1000 Genomes Project Consortium, 2012), HapMap (The International HapMap
Consortium, 2007), HGMD (Stenson et al., 2014), COSMIC (Forbes et al., 2015),
Phencode (Giardine et al., 2007), ExAC (Exome Aggregation Consortium (ExAC),
Cambridge, MA, 2016), and ESP (NHLBI GO Exome Sequencing Project (ESP),
Seattle, WA, 2016). The majority of these databases include links to genome
browsers and protein databases, to integrate and link genomic data and informa-
tion about the gene product to clinical and phenotypic information. The majority
of the known SNPs’ data are stored in the dbSNP database hosted by the NCBI.
The goal of dbSNP is to act as a primary database containing all known genetic
variations, including the location in the chromosome, the allele frequency, the asso-
ciated literature. Ensembl (Chen et al., 2010; Flicek et al., 2013; Cunningham et al.,
2015) and UniProt (The UniProt Consortium, 2015) are currently collecting and or-
ganising genetic variation from multiple databases (Chen et al., 2010; The UniProt
Consortium, 2015), which integrate well with the sequence information databases
and functional annotations they provide. This makes them the go-to providers for
obtaining comprehensive sets of annotated variants.
Among the most notable projects and variation resources are the 1kGP and the
UniProt Humsavar dataset. The 1kGP (The 1000 Genomes Project Consortium,
2012) is an international research collaboration focusing on genetic variation in hu-
mans. The primary goal of 1kGP is to create a comprehensive catalogue of human
genetic variation. Additionally, the aim is to estimate the population frequencies,
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haplotypes and linkage disequilibrium patterns. 1kGP also aims to support better
SNP calling and probe selection for genotyping platforms in future studies and for
the improvement of the human reference sequence.
UniProt Humsavar (Wu et al., 2006; Famiglietti et al., 2014) is a manually cu-
rated list of SNPs in human proteins developed by the UniProt Consortium (The
UniProt Consortium, 2015). The information is obtained from the literature, and
the SNPs have been mapped to protein sequences. The Humsavar list consists of
information such as the amino acid changes, the variant location in the protein se-
quence, the associated protein, the dbSNP identifier (if available) and the variant
disease status, i.e. whether it is associated with disease or not. All of the SNPs
in the Humsavar list are nsSNPs. The disease variant status is based on litera-
ture reports of disease association from the OMIM (Amberger et al., 2015). The
OMIM catalogues known Mendelian inherited diseases known to occur in humans.
More recently, the ClinVar database (Landrum et al., 2016) was developed to pro-
vide relationships among medically important variants and phenotypes. It contains
a more exhaustive list of curated variants when compared to UniProt Humsavar.
Other specialised databases such as SAAPdb (Hurst et al., 2009), contain lists of
structurally-mapping variants from multiple sources.
1.7.4 Consequences of genetic variation
There is a whole range of effects which genetic variation can have on the phenotype of
an individual. Mutations are usually classified into three groups, based on the fitness
change: 1) beneficial mutations increase the fitness of an individual; 2) neutral ones
lack a visible effect on the fitness; and 3) deleterious or pathogenic mutations that
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lower the overall fitness. Missense mutations account for approximately half of all
allelic variants underlying Mendelian human diseases (Stenson et al., 2014; Krawczak
et al., 2000; Hamosh, 2004). Thousands of rare heritable Mendelian disorders have
been linked to genes in which a single amino acid variation is both necessary and
sufficient to cause disease (Hamosh, 2004). In contrast, the combined effect of
different susceptibility genetic variants and environmental factors are thought to
result in common multi-factor diseases which have proven much more challenging
to study. Figure 1.7 shows a selection of disease-causing mutations that affect a
variety of proteins including uroporphyrinogen decarboxylase (Figure 1.7 A), von
Hippel-Lindau protein (Figure 1.7 B and C), p53 (Figure 1.7 D), von Willebrand
factor A1 (Figure 1.7 E), Factor IX (Figure 1.7 F and G), and transthyretin (Figure
1.7 H-I).
A missense mutation located at a site critical to protein function typically leads
to a disease phenotype. A critical site may be a catalytic residue or a residue
involved in ligand binding in an enzyme, or a residue involved in binding to partner
molecules. The disease phenotype in these cases may arise because of loss or gain
of function, or altered protein binding specificity or affinity, while the expression
or stability of the protein product is not necessarily affected. Translation initiation
codons can be affected by missense mutations as well, preventing the formation of
the protein product, or translation may start at the next possible ribosome starting
point, in which case the protein product would be truncated. The consequences
of missense mutations affecting functional sites are rather straightforward to define
when the protein in question is well known because information regarding the critical
residues is typically annotated in major protein databases. The Catalytic Site Atlas
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Figure 1.7: Examples of pathogenic mutations mapped onto protein structures.
A) Mutation of uroporphyrinogen decarboxylase homodimer Met165Arg (green) and
Leu195Phe (red). B) and C) Mutation of the von Hippel-Lindau protein Tyr98His
(red) and Arg167Gln (green) in complex with elongin B, elongin C and a HIF-1
peptide. D) The p53 tumour suppressor DNA-binding domain Arg273His (green) in
complex with DNA. E) The von Willebrand factor A1 domain Cys509Arg (green).
F and G) Mutation of Factor IX Ser365Arg (red). H and I) The transthyretin
tetramer Leu55Pro (red and blue) and in complex with two molecules of thyroxine
bound between subunits. J-L) Cu-Zn superoxide dismutase His46Arg, His48Gln,
Ala4Val in complex with zinc (orange) and copper (green) ions. For more details
refer to Steward et al., 2003. Figure adapted from Steward et al., 2003.
(Porter et al., 2004) is a specialised database for detailed annotations of known and
predicted enzyme catalytic residues.
Disease-associated mutations change the function or the structural stability pro-
teins, whereas residue differences between evolutionarily related proteins usually
conserve protein structure and function (Steward et al., 2003; Vitkup et al., 2003).
Pathogenic mutations tend to occur at positions conserved between species in evolu-
tion (Steward et al., 2003; Sunyaev et al., 2001; Shen et al., 2006; Miller and Kumar,
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2001; Ferrer-Costa et al., 2005), and classically, highly conserved positions in mul-
tiple sequence alignments often point to functional sites (Capra and Singh, 2007;
Panchenko et al., 2004; Chung et al., 2006). When considering structural mutations,
the level of conservation of the physicochemical properties between the wild type
and the substituting amino acid has an effect on the pathogenicity of the mutation,
so that conservative substitutions tend to be less frequently pathogenic than those
significantly altering the residue properties such as charge, hydrophobicity, or size
(Miller and Kumar, 2001; Tang et al., 2004; Stone and Sidow, 2005; Khan and Vihi-
nen, 2007; Briscoe et al., 2004). The hydrophobic nature of residues located in the
core of a protein tends to be conserved, and these residues can usually be identified
in multiple sequence alignments.
On the contrary, there is a low abundance of disease-causing mutations occurring
at positions that change in evolution (Miller and Kumar, 2001; Briscoe et al., 2004).
Consequently, sequence conservation and phylogenetic studies are powerful for the
prediction of functionally and structurally important residues in proteins. However,
mouse genome data revealed many pathogenic mutations in humans that are wild-
type residues in mouse orthologues (Mouse Genome Sequencing Consortium, 2002),
so it cannot be directly assumed that because the same residue type appears at
equivalent positions in close homologues, it will not lead to disease in humans. This
observation is partially explained by the fact that co-evolution of the sites vital to
the structure and/or function of a protein is rather common. When a critical site is
mutated, a compensating mutation occurs at a site that is functionally, energetically
of physically linked to that position. Analysis of covariant positions in multiple
sequence alignments may thus reveal conserved positions that are relevant to the
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function or structure of a protein (Halperin et al., 2006; Marks et al., 2012; Pazos
and Valencia, 2008).
Buried positions are more sensitive to pathogenic mutations than positions on
the surface of the protein, because alterations in such positions, especially in the
hydrophobic core of a protein, have the potential to cause greater disruption of
the overall structure of a protein (Terp et al., 2002; Steward et al., 2003; Sunyaev
et al., 2001; Vitkup et al., 2003). Residues at these positions form critical stability-
maintaining contacts with other residues, and these may be disrupted when a residue
is altered. Changes in the size (Buckle et al., 1996; Liu et al., 2000; Loladze et al.,
2002; Matthews, 1993), hydrophobicity (Liu et al., 2000; Matthews, 1993; Shortle
et al., 1990), or charge of the residue side chain at buried positions usually have
an effect on the structural stability of the protein (Chasman and Adams, 2001;
Sunyaev et al., 2001). Mutations at solvent accessible sites might interfere with the
interactions a protein forms with other molecules, or they may contribute to the
solubility or stability of a protein (Gribenko et al., 2009; Sunyaev et al., 2001; Wang
and Moult, 2003; Strickler et al., 2006).
1.7.5 Predicting the consequences of genetic variation
Understanding the molecular consequences of the mutations that cause human ge-
netic disease remains an important research challenge (Steward et al., 2003; Mooney,
2005; Ng and Henikoff, 2006; Karchin, 2009). Over the last years, several research
groups have developed computational techniques to predict the deleterious effects
of missense mutations (Dobson et al., 2006), as it aids for prioritising experimental
variant analysis. Methods range from those that use sequence information together
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with known features such as functionally important residues, secondary structure
and the location of buried residues (for example SIFT (Ng and Henikoff, 2003)), to
those that consider protein 3D structures (for example Polyphen-2 (Adzhubei et al.,
2013), SDM (Worth et al., 2011), I-Mutant 2.0 (Capriotti et al., 2005) and SNPs3D
(Yue et al., 2006)). Several methods have been developed by integrating the results
of previously developed prediction tools (for example Condel (González-Pérez and
López-Bigas, 2011) and PredictSNP (Bendl et al., 2014)). A couple of methods were
also developed specifically to predict changes in protein-protein binding (BeAtMu-
SiC (Dehouck et al., 2013) and SNP-IN (Zhao et al., 2014)). In addition to prediction
methods, some effort has been put into the functional analysis of genetic variants.
These range from evolutionary models for examining the mechanisms for generat-
ing and transmitting variation in evolving populations (Rivoire and Leibler, 2014),
to studies of the relevance of synonymous mutations as a driver in human cancers
(Supek et al., 2014).
SIFT and Polyphen-2 are the two most commonly used variation classifiers. SIFT
(Ng and Henikoff, 2003) uses sequence features to predict the effects of nsSNPs on
proteins. The program is based on the observation that conserved residues tend to
be more intolerant towards substitution than non-conserved residues. It estimates
positions that will be unfavourable to mutation based on tolerated mutations in
homologs. The SIFT program generates a list of homologous sequences using the
PSI-BLAST algorithm (Altschul et al., 1997) before aligning them to score the
probability for all the possible amino acid substitutions. Polyphen-2 (Adzhubei
et al., 2013) uses a hybrid approach that considers both sequence and structure
to distinguish between deleterious and non-deleterious nsSNPs. Polyphen-2 has an
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additional three structure-based predictive features that it uses in its scoring system,
the dihedral angles, secondary structure and accessible surface area (ASA).
1.8 Overview of this Thesis
The main aim of the work presented in this Thesis is to improve the current meth-
ods for the analysis of genetic variation in the context of rich structural information,
focusing particularly at interaction interfaces. This aim was prompted by the grow-
ing availability of both structural and genetic variation data, which presented as
a unique opportunity to push forward the scope of genetic variation analysis at
protein structure domain interfaces. Additionally, despite the fact that interaction
interfaces have been extensively studied, both computationally and experimentally,
and the fact that the involvement of binding impairment resulting from variation has
been linked to disease, there is tremendous scope for studying the structural and
functional consequences of variation using such an unprecedented structural and
variation coverage. This aim has been approached by developing integrative meth-
ods that allow structural and sequence data to be combined and enable the analysis
of variation on domain interaction interfaces, within a structural and evolutionary
perspective.
Chapter 2 explores the development of a new computational framework that al-
lows structural and sequence data to be combined to enable the study of genetic
variants on protein interfaces. ProIntVar (Protein Interactions and Variants) en-
compasses all the tools and methods necessary for the analysis of genetic variants
in the context of feature-rich protein structural data. Chapter 2 also overviews the
45
1. Introduction 1.8. Overview of this Thesis
datasets collected and organised in ProIntVar. ProIntVar provides a framework for
the seamless analysis of sparse structural data, sequence data, interaction data and
genetic variation data. It implements routines for generating biological assemblies,
defining protein interactions, annotating additional structural features in sites and
regions. It allows protein structure, protein sequence and genomic DNA sequence
to be cross-mapped. It incorporates generated structure-based MSAs for CATH
structural clusters and functional families, which are further extended with similar
protein sequences (Chapter 3). Finally, it annotates and organises genetic variation
from a large number of sources and repositories.
Considering domain-domain and domain-ligand interactions is a more reliable
approach to perform analysis of the effects of genetic variation in protein complexes
(Jones et al., 2000; Stein, 2004). To perform an enriched analysis of genetic variants
under a structural and evolutionary perspective, structure-based MSAs are gener-
ated for CATH structural and functional domain families. Chapter 3 focuses on im-
proving the quality of the structure-based MSAs by: 1) developing methods that take
advantage of the features of STAMP (Russell and Barton, 1992); and 2) exploring
the power of HMMs for extending the alignments and annotating them with homol-
ogous protein sequences. Hit sequences are believed to be structurally/functionally
homologous and thus a rich source of novel insight into the structural context and
potential consequences of a vast number of genetic variants.
Chapter 4 explores the overall analysis of genetic variants in protein families, in
the context of various structural regions and environments. The in-depth charac-
terisation of the variants across different environments by type of substitutions and
annotation is important, as it enables finding transitions that might be implicated
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in disease, and that can potentially affect protein stability, activity and function.
Analysis of the genetic variation that maps onto domain-domain and domain-ligand
interaction interfaces is further explored in Chapter 5.
Chapter 5 focuses on the overall analysis of genetic variants at structurally con-
served interface positions, and on the classification of domain-domain interactions.
The global trends of variation identified can be used to help prioritise variants and
protein families for further analysis. Three hand-picked domain families showing
variation mapped onto interaction sites were further analysed as proof-of-concept
examples.
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Chapter 2
Development of ProIntVar
2.1 Summary
This chapter overviews the general methods and the implementation details un-
derlying ProIntVar (Protein Interactions and Variants), the main computational
framework developed in this Ph.D. project. Since the development of ProIntVar
and its contents are central to all the studies performed and reported in the follow-
ing Chapters, ProIntVar is described in detail here. A brief comparison to similar
databases/systems is performed, followed by a final overview of the main unique
features of ProIntVar. Wherever necessary, the methods and datasets introduced in
this Chapter are revisited in more detail in the next Chapters.
2.2 Introduction
The analysis and prediction of the consequences of protein mutation have received
extensive attention from the scientific community in recent decades. Initial analysis
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of protein mutations was performed in order to identify those associated with dis-
ease states. Various Mendelian traits were linked to single point mutations and the
disease mechanisms identified (Steward et al., 2003; Krawczak et al., 2000; Hamosh,
2004; Stenson et al., 2014). The structural analysis of genetic variation was per-
formed on a case by case basis, until recent reports that focused on the characteri-
sation of these in hundreds of protein structures spanning dozens of protein families
(de Beer et al., 2013; Porta-Pardo et al., 2015; Peterson et al., 2010; Vázquez et al.,
2015). ProIntVar was developed in this work with the aim of characterising vast
genetic variation datasets in the context of an unprecedented number of protein
structures currently available. The general overview of the field necessary to under-
stand the contents of this chapter was provided in the main introduction, Chapter
1. Thus, the next Section will go straight to the contents and methods implemented
in ProIntVar.
2.3 Methods and Contents
2.3.1 Overview of ProIntVar
ProIntVar (Protein Interactions and Variants) has been developed in this work to
allow structure-centric analysis of genetic variants in proteins. Figure 2.1 overviews
the various components, i.e. methods and datasets, integrated in ProIntVar. ProInt-
Var enables integrative multiple-level mapping between proteins and their annotated
domains to protein sequences and known nsSNPs, disease-associated variants and
somatic mutations (Figure 2.1 A and D). The raw structural datasets obtained from
the PDBe were cross-mapped to UniProtKB and Ensembl (via SIFTS (Velankar
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et al., 2013)) and further annotated with information on biological assemblies, in-
teraction interfaces, secondary structure and relative solvent accessibility (RSA), as
described throughout this Chapter (Figure 2.1 B). Domain annotations were pro-
vided from the CATH (Class, Architecture, Topology and Homologous Superfamily)
resource (Sillitoe et al., 2015) for a subset of the protein structures. Additionally,
ProIntVar includes structure-based multiple sequence alignments (MSAs) generated
for protein domains annotated in CATH at structural clusters (SCs) and functional
families (FunFams) level, under Superfamily (SPF) (Figure 2.1 C). The following
Sections describe the full contents of ProIntVar in greater detail. In order to im-
prove the understanding of how the methods and datasets were integrated in this
work, Figure 2.2 shows a flowchart diagram highlighting the main raw data, datasets
generated and processing steps performed by ProIntVar.
2.3.2 Collecting and organising structural data
As described in Section 1.4, protein structures are deposited in the worldwide Pro-
tein Data Bank (wwPDB) central archive of macromolecular structures (Westbrook
et al., 2002; Berman et al., 2003, 2007). To be able to work with the volume of
structural data currently available, protein structures were downloaded from the
PDBe’s (Protein Data Bank in Europe) FTP server with the Rsync utility. Since
the PDB file format was due to be phased out and replaced by mmCIF format in
2016, mmCIF was used as the standard structure format avoiding the disruption of
making the transition later in the course of the project.
The various advantages of using mmCIF format are related to the way in which
the file format stores and annotates the structural data. Although mmCIF was
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Figure 2.1: Overview of the main methods and resources integrated in ProInt-
Var. A) Protein structure to protein sequence mapping is performed with the aid
of SIFTS. Protein sequence to genomic DNA coordinates is performed with the aid
of Ensembl/UniProtKB cross-reference tools to allow mapping of genetic variants.
B) ProIntVar integrates structural data from PDBe and secondary structure from
DSSP, as well as additional structural annotations generated in this work. C) Do-
main definitions are obtained from CATH. Structure-based multiple sequence align-
ments (MSAs) are generated in ProIntVar with an optimised protocol that relies on
STAMP. D) Missense variants are collected from several resources and databases
described in Section 2.3.13, through the Ensembl REST API and the EBI UniProt
Variation API. See the text for more details.
originally developed to describe small molecule structures, the format has been ex-
tensively developed to represent and describe larger macromolecular structures, such
as protein complexes and nucleic acids. In fact, mmCIF is ideal to represent large
structures which cannot be fully represented in the PDB file format, due to historical
limitations. Large structures previously split into multiple PDB files, are provided
in a single mmCIF file from 2016 onwards. The mmCIF format accommodates
table-like data structures and key-value data entries all defined by a descriptive set
of dictionaries for data categories, category groups and data items. For each of these
entities, the SMCRA (Structure, Model, Chain, Residue, Atom) model still applies
(Hamelryck and Manderick, 2003).
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Figure 2.2: Flowchart overviewing the main processing steps performed by ProInt-
Var in order to allow the analysis of genetic variants in the context of CATH protein
families, structure-based MSAs and interaction interfaces. Summary statistics are
provided for the main datasets generated, as are the names of key tools/methods
used by ProIntVar. For more information, please refer to the detailed description
provided throughout Chapter 2.
A particular PDB protein structure usually contains multiple different entities
commonly referred to as chains. Chains, as classically defined in the PDB-file format,
used to describe the structure of proteins and their related ligands, as well as other
molecule types, such as nucleic acids and sugars. The mmCIF file format introduced
a new way of organising the various molecules found in the structures, in which
chains are now viewed as entities. Entities can only be polymeric (protein, peptide
or nucleic acid), non-polymeric (varied-size molecules and ions), or water (defining
explicit water molecules). This means that a particular chain A in the PDB-format,
which defined the atoms of a particular protein bound to a ligand, will now be
described in the mmCIF as a polymeric entity A and a non-polymeric entity B. A
naming cross-reference is also available for maintaining compatibility with legacy
tools and databases.
In order to work with mmCIF structure files, several methods to read and analyse
the structures were developed in this work to extend PDBx, a Python module (West-
brook, J., 2012), which is a lightweight read/write set of tools for PDBx/mmCIF
files and its dictionaries. This module not only provides the ability to parse mm-
CIF files, but also to write out changes to the original files. This functionality is
useful for writing biological assemblies from the original mmCIF files (as described
in Section 2.3.4). Additional structure related annotations were downloaded from
the PDBe API, particularly regarding the quality and validation of the structures
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(Gore et al., 2012; Velankar et al., 2013, 2016).
Table 2.1 overviews the number of macromolecular structures determined by
X-ray crystallography, NMR, cryoEM and other techniques in the PDBe. The ma-
jority of the structures (89%) were determined by X-ray crystallography. To define
a uniform and high-quality structural dataset, protein structures were selected if
they were solved by X-ray crystallography, the resolution was ≤3.0 Å, the overall
quality was ≥10%, according to the PDBe API (‘summary of global absolute per-
centiles’ validation endpoint), and all atoms’ coordinates were present (i.e. not only
Cα atoms). The overall quality metric results from harmonic means of absolute
percentiles of geometric metrics (e.g. Ramachandran angles, clash score, side chains
clashes, etc.), reflections-based metrics (R-free, RSR (Real Space R-factor) Z-score)
and both these metrics taken together (Gore et al., 2012; Velankar et al., 2016).
As shown in Table 2.2, the structural dataset contained 115,031 protein macro-
molecular structures (release of 13th January 2016) (Figure 2.2). A list of obsolete
structures was also obtained from the PDBe FTP server so that datasets that ref-
erence those entries (e.g. CATH, see Section 2.3.8 for more information), could
Table 2.1: Breakdown of the experimental technique used to solve the structures
available in the PDBe. The 3D structure of macromolecules was determined by
X-ray crystallography, solution nuclear magnetic resonance (NMR), cryo-electron
microscopy (cryoEM) and other methods. The structural dataset was analysed as
of 13th of January 2016 and consists of a total of 115,031 structures.
Structure determination method Total count
X-ray crystallography 102,622
Nuclear Magnetic Resonance (NMR) 11,169
Cryo-electron Microscopy (cryoEM) 934
Other techniques 306
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Table 2.2: Overview of the macromolecular structures collected from the PDBe
and analysed in ProIntVar. The total number of PDBe structures, as well as those
for which there are SIFTS UniProtKB cross-reference mappings, is shown. Obsolete
structures were also obtained from the PDBe for maximising compatibility with
the domains defined in CATH. DSSP-based secondary structure annotation and
solvent accessibility could not be calculated for all the structures due to PDB-format
incompatibilities. A subset of protein structures was selected for further analysis in
ProIntVar. The structural dataset was analysed as of 13th of January 2016.
Description Total count
Structures in the PDBe 115,031
Obsolete structures in the PDBe, captured for compatibility
with CATH
3,377
Structures for which SIFTS contained cross-references to the
UniProtKB
109,316
Structures for which DSSP-based secondary structure and
solvent accessibility could be calculated
104,774
Structures selected for subsequent analysis in ProIntVar 84,110
be traced to a new PDB entry, when available. Structures were kept if structure-
sequence mapping was available as detailed in Section 2.3.3. This selection resulted
in a working set of 84,110 structures (Table 2.1 and Figure 2.2). The selected struc-
tures map to 29,351 unique UniProtKB protein sequences, from which 5,483 are
from human.
2.3.3 Mapping protein structure to protein sequence
Not all of the available macromolecular structures in the PDB are of proteins. As
summarised in Figure 2.3, the sequence to structure mapping was performed with
the aid of SIFTS (Structure Integration with Function, Taxonomy and Sequence)
(Velankar et al., 2013). SIFTS is a semi-automated process for maintaining up-to-
date cross-reference information between all protein chains in the PDBe and their
UniProt entries (The UniProt Consortium, 2015). SIFTS was also used to obtain
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Figure 2.3: Multi-level genomic DNA sequence to protein sequence to protein
structure mapping performed in ProIntVar. Protein structure to protein sequence
mapping (PDB to UniProt) is performed by SIFTS. Protein sequence to genomic
DNA sequence mapping (UniProt to Ensembl) is via UniProt ID mapping. As
illustrated, this process allows for cross-mapping analysis of genetic variation in the
context of protein structures and protein interactions.
cross-references between the PDBe and other biological databases, including Pfam
(Finn et al., 2014a), SCOP (Lo Conte et al., 2000), CATH (Sillitoe et al., 2015),
InterPro (Mitchell et al., 2015), and the NCBI taxonomy database (Federhen, 2012).
PDB to UniProtKB mappings were available from SIFTS for 109,316 PDB entries.
2.3.4 Generating biological assemblies
As introduced in Section 1.4.2.5, the 3D coordinates that appear in the structures
deposited in the PDBe are of the asymmetric unit (AsymUnit), the fraction of the
unit cell that has no further crystallographic symmetry. Biological assemblies have
been shown to provide a rich source of novel protein-protein interfaces that are not
considered when using the AsymUnit coordinates deposited in the PDB (Jefferson
et al., 2006; Bahadur et al., 2004; Bernauer et al., 2008). Thus, in the context of this
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project, the structure of BioUnits are preferred, since these extended the number of
interaction interfaces available for analysis.
Figure 2.4 overviews the process of generating biological assemblies from the
asymmetric unit structures. Biological Units (BioUnits) are obtained by: A) remov-
ing crystal packing artefacts; and by B) applying symmetry operations (translation
and rotation of atoms) to the various entities observed in the Asymmetric Unit, or
by a combination of both. The process can both reduce the number of entities,
as in the case of splitting the AsymUnit into multiple BioUnits (Figure 2.4 A), or
increase the number of entities (Figure 2.4 B), for example by duplication (dimeri-
sation in this example). For such cases that split the AsymUnit into two or more
BioUnits containing different entities, all the BioUnits were analysed separately and
in isolation.
Biological assembly annotations are defined in the mmCIF file and can have
multiple evidence sources. Annotations are typically obtained from either the struc-
ture’s depositors, from PDBe PISA/PQS (Krissinel and Henrick, 2007; Henrick and
Thornton, 1998) software analysis, or a combination of both. By parsing and pro-
cessing the mmCIF dictionaries that define the available biological assemblies and
their related annotations, biological assemblies were generated by applying sym-
metry operations (rotation and translation of the residues’ atoms) and/or removing
crystal packing artefacts, achieved by splitting the AsymUnit into multiple BioUnits.
The preferred biological assembly unit is defined and collected from the PDBe API
(PDB endpoint). In this work, BioUnits were generated, as opposed to using pre-
computed structures in PDB-format available from the PDB. Doing so removes
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Figure 2.4: Diagram illustrating how biological assemblies and interaction inter-
faces are defined in ProIntVar. Biological Units are usually generated by: A) remov-
ing crystal packing artefacts; or by B) applying symmetry operations (translation
and rotation of atoms) to the various entities observed in the Asymmetric Unit.
Interaction interfaces are screened and defined as an atom-atom distance measure
(d) which accounts for the atom’s Var der Waals radii as well as the number of
interacting interface residues.
one of the challenges in working with biological assemblies, namely the often non-
straightforward mapping between the chain names in the AsymUnit structure, and
their corresponding name in the BioUnit.
Table 2.3 overviews the generation of biological assemblies for the set of protein
structures selected in ProIntVar. BioUnits were generated for 19,547 structures,
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Table 2.3: Summary of the biological assemblies generated in ProIntVar. Biological
assemblies (BioUnits) were calculated for all structures in the structural subset.
The total number of entries for which the BioUnit is the same or differs from the
asymmetric unit (AsymUnit) are shown, as are the BioUnits that result in higher-
order oligomeric states (e.g. a dimeric AsymUnit produces a tetrameric BioUnit).
The structural subset dataset consists of 84,110 structures and was analysed as of
13th of January 2016.
Description Total count
Biological assembly is the same as the asymmetric unit 64,563
Biological assembly differs from the asymmetric unit 19,547
Biological assembly leads to a higher oligomeric state 19,199
while for the remaining 64,563 structures, the AsymUnit is believed to represent the
natural oligomeric state of the protein (Table 2.3 and Figure 2.2). It is possible,
though, that the resulting BioUnits are a subset (Figure 2.4 A) of the AsymUnit,
for cases where the AsymUnit exhibits artificial or non-biological interactions, which
might result from crystallisation artefacts (Krissinel and Henrick, 2007; Krissinel,
2011). These potentially arise from the experimental sample and crystallisation
process and are described in more detail in Section 1.4.2.3. A total of 19,199 BioUnits
calculated resulted in higher-order oligomeric structures that lead to an increase in
the number of interactions available for structural analysis.
2.3.5 Defining protein interaction interfaces
Interactions between proteins and protein-ligands were determined based on atomic
distance and performed as described in Jefferson et al., 2007b. Figure 2.4 B illus-
trates the process by which protein interactions and interacting residues are defined
in ProIntVar. An all-against-all atom distance is calculated for all atom-atom pairs
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that compose proteins and other entities observed in the structures. For speed pur-
poses, the distance algorithm was improved to initially screen residues falling within
10 Å from each other. If this distance threshold is met, then the 3D Euclidean
distance is captured and residue atoms were considered to interact if the distance
d = Ai + V DWi − Aj + V DWj, where Ai = (xi, yi, zi) and Aj = (xj, yj, zj) are the
relative positions of atom i and atom j in space, and where V DW is the Van der
Waals radii (Tsai et al., 1999) of atoms i and j, respectively. A protein residue is
classified as interacting when d ≤ 0.5 Å and any of its atoms interact with any other
atom of another protein residue or ligand. A minimum of 10 interacting residues
(in total) was set as a cut-off to define protein-protein interactions. This thresh-
old was chosen based on visual inspection of interaction interfaces and earlier work
to remove false interactions arising from crystal packing artefacts (Jefferson et al.,
2007b; Valdar and Thornton, 2001; Aloy et al., 2003). Since protein-ligand interac-
tions can occur at the single residue-ligand, no threshold on the minimum number
of interacting residues was set to define these interactions.
Protein interaction interfaces are held together by non-covalent forces including
hydrogen bonds, ionic attractions (salt-bridges), Van der Waals forces, hydrophobic
interactions, among others (Jones and Thornton, 1996; Janin and Chothia, 1990;
Jones and Thornton, 1997; Hubbard and Argos, 1994; Argos, 1988). In addition
to the atom distance measure, interaction types were computed based on standard
residue (or atom) physiochemical properties. Intermolecular interaction types were
calculated as defined in: Van der Waals (hydrophobic) (Voet and Voet, 2010); hydro-
gen bonds (McDonald and Thornton, 1994); salt-bridges (ionic interactions) (Ku-
mar and Nussinov, 2002); aromatic-aromatic stacking (Burley and Petsko, 1985);
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and disulphide bonds (Schmidt et al., 2006).
2.3.6 Removing crystallisation artefact ligands
As described in Section 1.4.2.4, it is common practice in structural biology to try
various combinations of buffers and crystallisation compounds in order to solve the
structures of proteins. This allows the optimal conditions to be identified, which
produce high-quality diffracting crystals. Various molecules (e.g., Glycerol, Ethy-
lene glycol) are often used as additives for solving the protein structures. Although
this constitutes a crucial step in attempting to solve the structures, the resulting
output might include molecules as well as interactions which are in many cases not
biologically relevant or meaningful. Protein structure entities such as nucleic acids
and a variety of ions, small molecules and sugars are herein referred as ligands. In
this project, the BioLiP (Yang et al., 2012) dataset was employed to help filter-
ing out such crystallisation artefacts (Figure 2.2). BioLiP (Yang et al., 2012) is a
semi-manually curated database for high-quality, biologically relevant ligand-protein
binding interactions that addresses this issue. The structure data are collected from
the PDB, with biological insights mined from literature and other theme-specific
databases. To construct a comprehensive and accurate database, BioLiP uses a
composite automated and manual procedure for examining the biological relevance
of every ligand observed in the structures. It enables cleaning of the protein struc-
tural dataset and allows a more meaningful analysis of protein-ligand interactions.
Table 2.4 shows the number of ligands observed in the structural dataset analysed
in ProIntVar. From a total of 334,124 non-unique ligands, 244,757 were observed in
the structures after crystal artefact filtering with BioLip (Yang et al., 2012). From
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Table 2.4: Number of ligands observed in the structures after BioLiP filtering. A
variety of ions, molecules, nucleic acids and peptides are observed in the structures.
The structural subset dataset was analysed as of 13th of January 2016 and consists
of 84,110 structures.
Description Total count
Ions and molecules of varied-size/complexity 228,376
Nucleic acids 10,758
Peptides (protein chains ≤ 30 residues) 5,623
these, 228,376 corresponded to ions and other molecules (10,956 unique), 5,623 to
small peptides (protein chains with length ≤30 residues) and 10,758 to nucleic acids.
The most common ligand types observed in the structures are nucleic acids, pep-
tides, various ions such as Zn, Ca, Mg, Mn, Fe, Cu, sulfates, phosphates, and other
molecules such as Heme-C, flavin adenine dinucleotide (FAD), adenosine diphos-
phate (ADP), adenosine triphosphate (ATP), flavin mononucleotide (FMN), α-d-
mannose (MAN), among others. The scope of the protein-protein interaction (PPI)
and protein-protein ligand (PLI) analysis in this project is currently limited to the
complexes for which there are structures of directly bound protein partners in the
PDB. Protein-protein and protein-ligand interaction interfaces were determined as
described in Section 2.3.5. The total number of protein-protein and protein-ligand
interactions observed in the filtered structural dataset was 161,222 and 242,809 in
total, respectively.
2.3.7 Defining structural features and sites
Additional structural features and sites (or regions) (Goldman et al., 1998) were
collected and analysed in ProIntVar (Figure 2.1 B). These include generating sec-
ondary structure annotations and computing the relative solvent accessibility of all
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protein residues. Secondary structure was calculated for each protein structure using
DSSP (Kabsch and Sander, 1983), which generates standardised secondary structure
assignments from the 3D structures (Figure 2.2). DSSP identifies intra-backbone
hydrogen bonds classifying eight types of secondary structure, including different
types of helix, strands and turns or loops. For simplicity these were reduced to
three main classification types: α-helix (H), β-sheet/strand (E) and turns or coil
(T). The relative solvent accessibility (RSA) was calculated from DSSP’s accessible
surface values. For every residue in the structures, RSA was calculated as described
by Ahmad et al., 2004:
RSA(x) =
ASA
SASA
(2.1)
where the accessible surface area (ASA) is divided by the total solvent accessibility
(SASA) of a standardised extended tripeptide Ala-X-Ala. X corresponds to the
amino acid residue for which the RSA is being calculated (Ahmad et al., 2004).
The total accessible surface values used for deriving RSA are shown in Table 2.5.
Residues were classified according to the degree of exposure to the solvent as acces-
sible (surface) where RSA > 25%, partially exposed where 5% < RSA ≤ 25%, or
buried (core) where RSA ≤ 5% (Cuff and Barton, 2000).
Table 2.5 shows a summary of amino acid properties, used in the various analysis
performed in this work. Amino acid properties include: monoisotopic atomic mass
(Knapp, 1996); average volume of buried residues, calculated from the surface area
of the side chain (Zamyatnin, 1972); hydrophobicity (Fauchère et al., 1988); total ac-
cessible surface area (Ahmad et al., 2004); and frequency of occurrence (abundance)
in the human proteome (de Beer et al., 2013).
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Table 2.5: Summary of amino acid properties. Amino acid names, one-letter and three-letter codes as well as reference amino acid
properties are provided.
Amino acid
3-letter
code
1-letter
code
Surface
areaa (Å2)
Volumeb
(Å3)
Atomic
massc (Da)
Hydro-
phobicityd
Human
proteomee (%)
Alanine Ala A 110.20 88.60 71.08 0.31 7.00
Arginine Arg R 229.00 173.40 103.14 1.54 5.63
Asparagine Asn N 146.40 114.10 128.13 -0.22 3.61
Aspartic acid Asp D 144.10 111.10 114.10 -0.60 4.77
Cysteine Cys C 140.40 108.50 57.05 0.00 2.29
Glutamic acid Glu E 174.70 138.40 147.18 1.79 7.13
Glutamine Gln Q 178.60 143.80 113.16 1.80 4.77
Glycine Gly G 78.70 60.10 137.14 0.13 6.54
Histidine His H 181.90 153.20 128.17 -0.99 2.64
Isoleucine Ile I 185.00 166.70 131.20 1.23 4.36
Leucine Leu L 183.10 166.70 113.16 1.70 10.00
Lysine Lys K 205.70 168.60 115.09 -0.77 5.80
Methionine Met M 200.10 162.90 129.12 -0.64 2.16
Phenylalanine Phe F 200.70 189.90 97.12 0.72 3.69
Proline Pro P 141.90 112.70 87.08 -0.04 6.23
Serine Ser S 117.20 89.00 156.19 -1.01 8.30
Threonine Thr T 138.70 116.10 101.11 0.26 5.29
Tryptophan Trp W 240.50 227.80 186.21 2.25 1.20
Tyrosine Tyr Y 213.70 193.60 99.13 1.22 2.66
Valine Val V 153.70 140.00 163.18 0.96 5.92
aTotal accessible surface area (Ahmad et al., 2004); baverage volume (Zamyatnin, 1972); cmonoisotopic atomic mass (Knapp, 1996);
dhydrophobicity (Fauchère et al., 1988); efrequency of occurrence in the human proteome (de Beer et al., 2013).
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2.3.8 Collecting domain definitions from CATH
Protein structure domain definitions were obtained from CATH (Class, Architec-
ture, Topology and Homologous Superfamily) (Sillitoe et al., 2015) and added to
ProIntVar (Figure 2.1 C and Figure 2.2). CATH was used as the main protein
domain classification here since the resource has a higher coverage in terms of anno-
tated structures, when compared to SCOP. Additionally, CATH has been reliably
maintained for around two decades and is still under active development.
The latest update to CATH v4.0.0 was made available on the 26th of March,
2013. As introduced in Section 1.5.1.1, CATH is a hierarchical classification of struc-
tural domains based on the analysis of their 3D structures. Since CATH domains
are classified according to sequence, structural and functional similarity, domains
clustered into the same Homologous Superfamily are expected to display an evo-
lutionary relationship, with domains sharing significant structure, sequence and/or
functional similarity and increasing levels of sequence similarity (45, 60, 95, 100%
sequence identity). Structural clusters (SCs) and functional families (FunFams) are
also defined below the Superfamily level in CATH, clustering together domains shar-
ing structural and functional features, respectively (Lees et al., 2012; Sillitoe et al.,
2013). As a result of the latest developments in the FunFam protocol in CATH (Das
et al., 2015a), both structural domains as well as sequence predicted domains (based
on FunFHMMer (Das et al., 2015b), refer to Section 1.5.1.1 for more information)
are included in FunFams. In the context of this work, only the structure-based
domains in FunFams were analysed since complementary methods were developed
in this Ph.D. project for the analysis of protein structures and sequence predicted
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domains (see Section 2.3.9 and Chapter 3 for more details).
In order to be able to work with as many CATH defined domains as possible,
CATH domain definitions originally assigned to obsolete protein structures were
transferred to the new PDB-remediated structures (based on PDBe identifier map-
ping) whenever possible. Additionally, to increase the confidence with which residues
from a particular protein chain define a particular CATH domain, the subset of pro-
tein structures in ProIntVar was processed so that CATH domain boundaries were
precisely mapped within the structures. This allowed annotation discrepancies to be
removed from the domain sequence ranges obtained from CATH and the actual PDB
residue-encoded sequences. This processing allowed a comprehensive set of CATH
domain annotations to be defined that are seamlessly represented in the structural
dataset in ProIntVar. A great deal of care was given to this processing step as it
underpins the rest of the work reported in this Thesis.
Domain definitions were obtained from CATH and structural analysis of domain-
domain interactions was performed (Figure 2.2). Table 2.6 summarises the contents
of the CATH classification hierarchy. There are currently 235,858 domains defined,
belonging to 4 classes, 40 architectures, 2,738 Homologous Superfamilies, 3,267 SCs
and 8,988 FunFams, covering 69,058 proteins structures (<70% of the entire PDB).
After filtering the structural dataset and mapping CATH domain boundaries to the
structures, the number of Superfamilies (SPFs) in ProIntVar is 2,340, with 3,276 SCs
and 8,988 FunFams. This corresponded to 164,692 unique CATH domains defined
for the entire filtered structural dataset. The number of SCs and FunFams is reduced
to 2,371 and 5,777, respectively, since families (SC or FunFam) that contain a single
domain are removed, as at least two domains are needed for performing structural
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alignment.
Table 2.6: Summary contents of the CATH structural classification hierarchy in
the ProIntVar structural dataset. Domains are organised in CATH following the
hierarchy from the top to the bottom, i.e. from Class to Architecture, to Topology,
to Homologous Superfamily (SPF). SPF are further sub-grouped into structural
clusters (SCs) and functional families (FunFams). The structural subset dataset
was analysed as of 13th of January 2016 and consists of 84,110 structures.
Description Total count
Class 4
Architecture 40
Topology 1,195
Homologous Superfamily (SPF) 2,340
Structural Clusters (SCs) 3,267
Functional Families (FunFams) 8,988
Unique Domains 164,692
Unique PDB Structures 54,580
Unique PDB Protein Chains 123,909
2.3.9 Generating multiple sequence alignments with STAMP
for CATH SCs and FunFams
In order to investigate genetic variation in the context of protein domain families
and to focus on key sites, such as interacting interfaces, structure-based multiple
sequence alignments (MSAs) were generated for CATH SC and FunFam domain
families. Structural alignment of domain structures and generation of a correspond-
ing structure-based sequence alignment is essential for the analysis of protein struc-
tural and functional families in an evolutionary perspective. The comparison of
protein structures can reveal distant evolutionary relationships that would not be
detected by sequence information alone, or by the analysis of highly similar human
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homologs. The analysis of variant sites throughout evolutionary history helps to
infer those likely to affect key determinant sites for maintaining domain structural
and functional integrity. Additionally, using structural alignments allows a deep
domain structural coverage to be obtained by extending the MSAs with protein do-
main sequences of unknown 3D structure, and in this way expanding the structural
coverage of the genetic variation/key sites analysis.
Since structure-based MSAs of all domains classified into SC and FunFam fami-
lies were not readily available from CATH, multiple structure alignments were gen-
erated in this work (Figure 2.1 C and Figure 2.2). MSAs were generated by the
STAMP (Structural Alignment of Multiple Proteins) program (Russell and Barton,
1992). A newly developed protocol for improving the structural alignment of do-
mains was developed, as was a new protocol for extension of the STAMP alignments
with similar sequences (Figure 2.2). The former involves fine tuning STAMP for the
needs of aligning sets of structure domains, varying in number and structural diver-
sity. The latter explores the power of Hidden Markov Model (HMM)-based sequence
techniques to improve detection of similar sequences. Taking advantage of reliable
STAMP multiple structure alignments, profile HMMs were built for each alignment,
and sequence searches performed against the set of reference proteomes for which
variation data is potentially available (see Section 2.3.11 for more details). Similar
sequences were then re-aligned back to the STAMP structure alignments, in this
way extending the structural alignments with additional protein sequences. The
methods, as well as the corresponding results and discussion, are explored in detail
in Chapter 3.
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2.3.10 Analysis of CATH domain interactions
Protein domain interactions were analysed in the context of the CATH hierarchy
for SCs and FunFams (Figure 2.1 C and Figure 2.2). Domain-domain interaction
interfaces were defined as described in Section 2.3.5. In order to be able to analyse
domain-domain interactions and to classify interactions by interaction interface, the
relative orientation of the interacting domain pair was determined using the iRMSD
method developed by Aloy et al., 2003, and further improved by Jefferson et al.,
2007b. This method determines if two interacting domains are in the same orien-
tation as another pair of interacting domains and thus if they are interacting with
the same interaction interfaces. The iRMSD method uses the sequence alignments
generated by STAMP (described in Section 2.3.9), to match equivalent positions
from each separate partner of the interaction pairs to determine the transformation
of one structure to another. Additional implementation details, as well as results
and discussion on the analysis of domain-domain interactions, are further detailed
in Chapter 5.
2.3.11 Collecting and organising sequence data
Protein sequence data was obtained from the UniProtKB database (The UniProt
Consortium, 2015). Protein sequences, as well as annotations, were obtained ei-
ther from the FTP server or UniProt’s download/API web-pages. Sequences were
obtained in FASTA format, whereas sequence annotations were downloaded in a
variety of file formats including GFF (General Feature Format), UniProtKB file for-
mat and JSON (JavaScript Object Notation). Genomic sequence data, namely for
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gene transcripts and transcript protein products were obtained from the Ensembl
resource database (Chen et al., 2010; Flicek et al., 2013; Cunningham et al., 2015)
through the Ensembl REST API, Variation API version 84 (Rios et al., 2010; Yates
et al., 2014) (Figure 2.2). The version of the human genome build used throughout
this work was the GRCh37 (Genome Reference Consortium Human Genome).
The sequences of complete reference proteomes (The UniProt Consortium, 2014)
were downloaded from UniProtKB’s FTP server. These sequence datasets were
used in the STAMP extension protocol as described in Section 2.3.9 and Section
3.3.2, aiming at increasing the coverage of the STAMP structure-based alignments
for genetic variants mapped to structurally/functionally similar protein sequences
(Figure 2.2).
2.3.12 Mapping genetic variants to protein sequence
Genome sequence to protein sequence mapping is necessary to populate genomic
features such as genetic variation entries onto a protein sequence (Figure 2.3). For
this mapping, UniProt sequence IDs (accession identifiers) were converted to three
main Ensembl stable identifiers, which include Gene, Transcript and Transcript
Protein Product (referred to simply as Protein in Ensembl) (Chen et al., 2010;
Flicek et al., 2013; Cunningham et al., 2015), using the Ensembl REST API (Yates
et al., 2014) (Figure 2.2). Every variation entry was then examined for mismatches
between the annotated variant sequence, the Ensembl transcript product sequence,
as well as the actual UniProtKB sequence. When mapping errors were detected
variants were dropped from the analysis.
To populate genomic features such as genetic variation entries onto a protein
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sequence, protein sequence to DNA genomic coordinates was performed (Figure
2.3). This ID mapping is possible since the Ensembl database maintains a protocol
for cross-referencing its stable IDs to other external sequence resources, such as the
UniProt. Ensembl-UniProt cross-references are generated by the UniProt-Ensembl
extensive cross-mapping collaboration effort, through projects such as Reference
Proteomes (The UniProt Consortium, 2014), to map all protein sequences available
in UniProtKB to the underlying genomic assemblies (The UniProt Consortium,
2014; Herrero et al., 2016).
2.3.13 Collecting and organising genetic variants
The analysis of genetic variation in this study focuses on variants that occur in
the protein-coding regions of genes: non-synonymous (missense) single nucleotide
polymorphisms (nsSNPs); stop gained/lost variants; frameshift variants; and inser-
tion/deletion (non-frameshift) variants. Genetic variation data was obtained from
the Ensembl database (Chen et al., 2010; Flicek et al., 2013; Cunningham et al.,
2015) through the Ensembl REST API (Rios et al., 2010; Yates et al., 2014) as
well as the UniProt Variation API endpoint (The UniProt Consortium, 2015) (Fig-
ure 2.2). For each entry, a series of annotations were stored including: source and
original accession identifier; type of substitution; amino acid change, if any; clinical
relevance, disease information and disease identifier (from OMIM (Online Mendelian
Inheritance in Man [http://omim.org/] (Amberger et al., 2015)), if available); chro-
mosome location; and Ensembl identifiers for Gene, Transcript and Protein; phe-
notypes and genotypes related information, if available; and Polyphen-2 (Adzhubei
et al., 2010) and SIFT (Kumar et al., 2009) prediction scores. All of the raw data
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from these data sources was pre-processed through the same pipeline, to increase
consistency across variation sources. Table 2.7 summarises the original sources of
genetic variation data obtained from the Ensembl and UniProt variation resources.
Only human variation was obtained from the Ensembl and UniProt Variation APIs.
Careful pre-processing of the variation information was performed in ProIntVar
such that overlapping information was maintained but key unique annotations were
preserved and highlighted. Genetic variants were therefore classified according to the
primary variation source: UniProt, Ensembl, dbSNP, 1kGP, ExAC, ESP, COSMIC,
Humsavar, ClinVar, HapMap, PhenCode, DVGa, HGMD-public, and OMIM; and
source curation type: manual or automated. Finally, variants were further organised
based on the variant annotation as: germline nsSNPs, disease-associated variants (a
subset of germline variants), and somatic mutations.
Genetic variation was collected and organised in ProIntVar for three main subsets
of protein sequences: proteins in the PDB dataset not covered by CATH domain
classification (PDB subset); CATH classified subset of the PDB (CATH subset),
and lastly, hit sequences that extended the STAMP structural alignments (STAMP
extended subset) (Section 3.3.2). The total variant counts shown were obtained
for the full-length protein sequences, which are expected not to be covered by the
entirety of the protein structures and protein domains. If a particular variation is
mapped to multiple structures, only a single instance of the variant is added to the
total count.
The number of uniquely mapped UniProtKB sequences for the PDB subset was
10,395, which resulted in 292,217 unique missense variants. 16,124 protein sequences
in the CATH subset resulted in 503,397 unique missense variants. Lastly, 306,579
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Table 2.7: Summary of genetic variation sources as collected from the Ensembl
and UniProt variation APIs. Missense variants were collected from the UniProt
API Variation endpoint (The UniProt Consortium, 2015) as well as the Ensembl
REST API (Rios et al., 2010; Yates et al., 2014).
Source From Curation
dbSNP (Sherry et al., 2001) Ensembl Automated
1kGP (The 1000 Genomes Project Consortium,
2012)
Ensembl Automated
COSMIC (Forbes et al., 2015) Ensembl Automated
HGMD-public (Stenson et al., 2014) Ensembl Automated
ClinVar (Landrum et al., 2016) Ensembl Automated
OMIM (Amberger et al., 2015) Ensembl Automated
PhenCode (Giardine et al., 2007) Ensembl Automated
HapMap (The International HapMap Consortium,
2007)
Ensembl Automated
ExAC (Exome Aggregation Consortium (ExAC),
Cambridge, MA, 2016)
UniProt Automated
ESP (NHLBI GO Exome Sequencing Project (ESP),
Seattle, WA, 2016)
UniProt Automated
Humsavar (Wu et al., 2006; Famiglietti et al., 2014) UniProt Manual
1kGP - 1000 Genomes Project; COSMIC - Catalogue of Somatic Mutations in Cancer;
HGMD-public - Human Gene Mutation Database; ClinVar - Archive of Interpreta-
tions of Clinically Relevant Variants; PhenCode - Phenotypes for ENCODE; HapMap
- Haplotype Map; ExAC - Exome Aggregation Consortium; ESP - Exome Sequencing
Project.
sequences searched to extend the STAMP multiple structure alignments, resulted
in 1,581,889 variants (Figure 2.2). This included coverage of an extra 8,069 protein
sequences from human. Table 2.8 summarises variation sources and annotations
as organised in ProIntVar. The total counts shown are not cumulative since the
same unique variant can be simultaneously collected from multiple sources. Overall
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analysis of genetic variants in the context of protein structures is further explored
in Chapter 4 and Chapter 5.
2.3.14 Implementation and data analysis
The ProIntVar computational framework was developed in Python [https://www.
python.org/] and related technologies. Data analysis and processing were per-
formed with Python and R (R Core Development Team, 2016) [https://www.
r-project.org/]. Plotting and visualisation were performed in R with the aid
of ggplot2 [http://ggplot2.org/]. Figures of protein structures were generated
using UCSF Chimera (Pettersen et al., 2004). MSAs and dendrograms were gener-
ated with the aid of Jalview (Waterhouse et al., 2009).
Statistical analysis was performed using the R core statistical package (R Core
Development Team, 2016). Sample distributions were compared using the non-
parametric Mann-Whitney-Wilcoxon test, or otherwise indicated in the text. A
p-value lower than 0.05 was considered indicative of statistical significance. Sample
correlation analysis (r) was calculated as the Pearson correlation coefficient. Amino
acid variant counts and frequencies observed for the three variation classes were
compared using Fisher’s exact test implemented in the R package (R Core Devel-
opment Team, 2016). Given the nature of Fisher’s exact test, the p-values provided
were not corrected for multiple comparisons.
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Table 2.8: Overview of the genetic variants organised in ProIntVar. Genetic vari-
ants were collected from Ensembl and UniProt for the full-length UniProtKB pro-
teins that are cross-mapped to three main structural subsets: PDB (not CATH-
covered), CATH, and STAMP-extended. These are organised in ProIntVar accord-
ing to the source, preprocessing (manual or automated), and annotation (germline
nsSNPs, disease-associated variants, and somatic mutations). The total number of
unique variants for which SIFT and Polyphen-2 prediction scores, as well as minor
allele frequencies (MAF), could be obtained, are also shown.
Variation annotation PDB CATH STAMP extended
dbSNP 46,581 173,966 389,326
1kGP 30,716 52,980 185,696
ExAC 171,736 296,590 974,684
ESP 38,201 66,347 222,594
HGMD-public 3,416 6,581 17,041
COSMIC 84,656 145,154 442,471
Humsavar 5,859 14,513 19,909
ClinVar 1,809 9,431 6,602
HapMap 428 2,011 3,430
PhenCode 1,215 4,544 1,811
OMIM 3,479 10,541 9,136
Manually curated 5,932 14,659 20,123
Automated 288,653 493,432 1,573,150
Germline nsSNPs 200,530 341,479 1,124,043
Somatic mutations 84,391 143,584 441,992
Disease variants 7,296 18,334 15,854
MAF 6,348 10,020 40,945
Polyphen-2 212,875 360,016 1,179,332
SIFT 142,022 235,433 784,352
dbSNP (Sherry et al., 2001), ExAC (Exome Aggregation Consortium (ExAC),
Cambridge, MA, 2016), 1kGP (The 1000 Genomes Project Consortium, 2012),
ESP (NHLBI GO Exome Sequencing Project (ESP), Seattle, WA, 2016), HGMD-
public (Stenson et al., 2014), COSMIC (Forbes et al., 2015), Humsavar (Wu et al.,
2006; Famiglietti et al., 2014), ClinVar (Landrum et al., 2016), HapMap (The
International HapMap Consortium, 2007), PhenCode (Giardine et al., 2007), and
OMIM (Amberger et al., 2015).
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2.3.15 ProIntVar web-server
A preliminary non-public web-server for ProIntVar has been developed to allow
easy access to the results generated in this work. Similarly to the ProIntVar com-
putational framework, the web-server was implemented in Python [https://www.
python.org/]. The Flask [http://flask.pocoo.org/] Python web-framework was
used to develop the ProIntVar web-server as it allows for easy development of
RESTful APIs. The ProIntVar web-server gives access to multiple structural align-
ments, domain-domain iRMSD classifications as well as genetic variation informa-
tion. Datasets can be browsed and downloaded from the web-server. A search
toolbox allows common database IDs (including UniProtKB, CATH, Ensembl and
Variation) to be searched for, providing a convenient and quick access point to lookup
the analysis results. Results are visualised mainly through sortable tables and in-
teractive plots. Protein structures with highlighted residues can also be visualised
with LiteMol [https://webchemdev.ncbr.muni.cz/LiteMol/].
The ProIntVar web-server and database will be provided at http://www.compbio.
dundee.ac.uk/ProIntVar at a later time. While the main purpose of ProIntVar is
to allow access to the structural and sequence analysis performed in this work, it
can be used as a generic tool for the analysis of variants in the protein structures.
Access to the source code and documentation on how to deploy a local install of the
software will be provided at a later stage, through the main project web-page.
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2.4 Comparison to other tools/systems
Several tools/web-servers are available that support the analysis of genetic variation
mapped to protein structure, with varying degrees of overlap and focus on structural
analysis. Tools that allow analysis and visualisation of variants in structures include:
SAAPdb (Cavallo and Martin, 2005), MutDB (Dantzer et al., 2005), ColiSNP (Kono
et al., 2007), LS-SNP/PDB (Ryan et al., 2009), VnD (Yang et al., 2011), SNPdbe
(Schaefer et al., 2012), and MSV3d (Luu et al., 2012). Cancer3D (Porta-Pardo
et al., 2015) is a recently-developed web-server tool that focuses particularly on
cancer somatic mutations from a variety of cancers and cell/tissue types. DMDM
(Peterson et al., 2010) focuses on mapping variants on domains, while Structure-
PPi (Vázquez et al., 2015) focuses on cancer mutations mapped onto protein-protein
interaction interfaces.
The Single Amino Acid Polymorphism database (SAAPdb) (Hurst et al., 2009)
links single nucleotide polymorphisms (SNPs) to phenotype alterations. SNP data is
linked to a gene sequence, to determine whether the mutation occurred in a coding
region; if so, the protein sequence and the mutated variations are displayed. When-
ever possible, mutations are mapped onto protein structures, allowing the effect of
the mutations on protein structure with the clinical phenotype to be investigated.
LS-SNP/PDB (Ryan et al., 2009) is a resource for genome-wide annotation of hu-
man nsSNPs, which uses an automated, high-throughput pipeline for mapping the
variants onto PDB structures and annotates several biologically relevant features.
Although systems such as LS-SNP/PDB and SAAPdb initially seemed to be promis-
ing to be used as the main framework in this Thesis, they were not flexible enough
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to allow thorough analysis of variation in the context of protein structure domain
families and interaction interfaces. Additionally, none of these tools support the
study of recently identified missense variants and newly solved structures.
2.5 Conclusions
ProIntVar is the main computational framework developed in this Ph.D. project.
It encompasses all the tools and methods necessary for the analysis of genetic vari-
ants in the context of feature-rich protein structural data. A general overview of
the datasets collected and organised in ProIntVar were overviewed in this Chapter.
Additional method details and results are fully described in the following Chapters.
The main key features incorporated and highlighted in the ProIntVar computa-
tional framework are:
• ProIntVar provides a framework for the seamless analysis of sparse structural
data, sequence data, interaction data and genetic variation data.
• It implements routines for generating biological assemblies, defining protein
interactions, annotating additional structural features in sites and regions.
• It allows protein structure, protein sequence and genomic DNA sequence to
be cross-mapped.
• It incorporates structure-based multiple sequence alignments for CATH struc-
tural clusters and functional families, which were further extended with similar
protein sequences.
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• It allows the comprehensive analysis of protein domain families and explo-
ration of protein interfaces across different protein families from a structural
perspective.
• It provides an integrative environment for the analysis of genetic variants in
the context of proteins structures (atomic detail), as well as in the context of
protein domain families (evolutionary detail).
• Finally, it annotates and organises genetic variation from a large set of sources
and databases.
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Chapter 3
Analysis of protein domain
families
3.1 Summary
Structural alignment of similar protein structures and generation of a corresponding
structure-based sequence alignment is essential for the analysis of protein structural
and functional families. The comparison of protein structures can reveal distant evo-
lutionary relationships that would not be detected by sequence information alone.
This Chapter overviews the generation of MSAs from the alignment of protein struc-
ture domains organised in structural clusters (SCs) and functional families (Fun-
Fams) in CATH. MSAs are key to investigate genetic variation within and among
species and are used in this project for the analysis of missense variants in protein
interaction interfaces. To increase the structural coverage of the CATH domain clas-
sifications and enrich the analysis of genetic variants, new methods were developed
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so that reliable MSAs are generated by the STAMP (Structural Alignment of Mul-
tiple Proteins) (Russell and Barton, 1992) alignment program. A protocol that uses
profile Hidden Markov Model (HMM)-based methods (Eddy, 1998) was also devel-
oped so that similar protein sequences were annotated to extend the structure-based
alignments.
3.2 Introduction
Protein structure comparison is a crucial step in studying the relationships between
proteins, alluding to their functions and evolution. As protein structure often de-
termines function, similarity in structure implies similarity in function (Todd et al.,
1999). In fact, protein structure alignment has become an important technique
for protein structure classification, protein function prediction, evolutionary rela-
tionship determination, molecular modelling and protein engineering (Murzin and
Bateman, 1997; Abyzov and Ilyin, 2007; Launay and Simonson, 2008; Zhang et al.,
2012; Koga et al., 2012), among others. Accurate alignment of the three-dimensional
(3D) structure of proteins with near atomic-level resolution enables the detection
and analysis of key conserved sites associated with protein function, such as cat-
alytic sites (Valdar and Thornton, 2001; Halperin et al., 2004; Keskin et al., 2005).
Besides, it provides important insights into functional mechanisms and the potential
impact of genetic variation.
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3.2.1 Structure Alignment Programs
As summarised in Table 3.1, various methods for multiple structure alignment have
been developed over the last three decades (reviewed in Hasegawa and Holm, 2009).
Among the most comprehensive methods are: STAMP (Russell and Barton, 1992),
which is used throughout this work; DALI (Holm et al., 2008); TM-align (Zhang
and Skolnick, 2005); SSM (Krissinel and Henrick, 2004); and Mustang (Konagurthu
et al., 2006). Additionally, several methods originally developed for pairwise struc-
tural alignment: SSAP (Orengo and Taylor, 1996), CE (Shindyalov and Bourne,
2001); MAMMOTH (Lupyan et al., 2005); and FATCAT (Ye and Godzik, 2003);
have been extended to allow multiple structure alignment. Although presenting
important differences, all methods start by representing protein 3D structures in
some coordinate-independent manner to make them comparable. This is typically
achieved by constructing a series of matrices that encompass a variety of compar-
ative metrics. One of the most commonly used metric is to take the pairwise 3D
distances between some subset of the atoms (such as the Cα) in each structure
(e.g. STAMP, CE, MAMMOTH and FATCAT). In fact, reducing the protein to
a coarse metric such as structural fragments (SFs) (e.g. CE and SSAP) or sec-
ondary structure elements (SSEs) (e.g. SSM/PDBeFold), can also produce sensible
residue-level alignments, despite the loss of information. This reduction is computa-
tionally important as the dimensionality of the matrices increases when the number
of structures to be aligned increases. It is also common practice to apply dynamic
programming (DP) techniques to the generated matrices (e.g. STAMP and TM-
Align), and this allows a series of optimal local alignment paths to be determined,
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Table 3.1: Summary features of several protein structure alignment programs.
Alignment Program Type Class Flexible Year
SSAP (Orengo and Taylor, 1996) Multi SSE No 1989
STAMP (Russell and Barton, 1992) Multi Cα No 1992
DALI (Holm et al., 2008) Pair SF No 1993
CE (Shindyalov and Bourne, 2001) Multi Cα No 2000
SSM (Krissinel and Henrick, 2004) Multi SSE No 2003
FATCAT (Ye and Godzik, 2003) Pair Cα Yes 2003
TM-align (Zhang and Skolnick, 2005) Pair Cα No 2005
MAMMOTH (Lupyan et al., 2005) Multi Cα No 2005
POSA (Li et al., 2014) Multi Cα Yes 2005
Mustang (Konagurthu et al., 2006) Multi Cα No 2006
Matt (Menke et al., 2008) Multi Cα Yes 2008
FlexSnap (Salem et al., 2010) Multi SF Yes 2010
Multi - Multiple structure alignment; Pair - Pairwise structure alignment; Cα -
Backbone alpha-carbon; SSE - Secondary structure elements; SF - Structure frag-
ments.
that are then summed to form a summary matrix. In some instances, a second round
of DP is then performed on the summary matrix (e.g. SSAP). Although most meth-
ods are optimally tuned for rigid alignment of structures, methods such as FATCAT
(Ye and Godzik, 2003) and Matt (Menke et al., 2008) have been developed to ac-
count for flexibility and structural rearrangements/inversions. Structural alignment
techniques have allowed construction of all-to-all fold classification databases from
the known protein structures in the PDB. Some examples of such databases are
FSSP (Holm and Sander, 1996), CAMPASS (Sowdhamini et al., 1998), PDBeFold
(Krissinel and Henrick, 2005), and CATH (Sillitoe et al., 2015).
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3.2.2 Structural alignments by STAMP
STAMP (Russell and Barton, 1992) is a program that implements algorithms for
comparison and superimposition of protein structures. STAMP makes extensive
use of DP, least-squares fitting, and hierarchical cluster analysis techniques, as fully
described in Russell and Barton, 1992.
Dynamic programming is a general technique which allows fast determination of
the best path through a matrix containing a numerical comparison metric applied
to all possible pairs of structure positions to be aligned. STAMP relies on the
probability of residue structural equivalence measure (Pij) devised by Rossmann
and Argos, 1976. The probability function consisting of distance and conformation
terms (E1 and E2) is applied to the comparison of all pairs of residues and a DP
path routine (modified Smith-Waterman algorithm) is used to identify the best set
of equivalences between the pair. When aligning two domain structures A and B,
the least-squares fitting takes a set of n Cα atoms (x, y, z) from A and n equivalent
atoms from B and calculates the translation and rotation (transformation) that
minimises the root mean square deviation (RMSD). This transformation can be
applied to yield two new sets of coordinates for which calculation (and correction)
of Pij values, the DP path-finding and the least squares fitting can be repeated
iteratively until the two sets of residue coordinates, and the corresponding alignment,
converge on a single solution. Hierarchical cluster analysis takes N domains and
score measures calculated for the comparison of each of the N(N − 1)/2 possible
pairs of domains. Clustering returns a dendrogram that organises the domains
according to their structural similarity.
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STAMP provides two similarity measures to assess the quality of the structural
alignments. Sc quantifies the global structural similarity between pairs or groups
of domains, whereas Pij′ provides a normalised measure of the confidence in the
alignment of each domain’s residue. The final structural similarity Sc score reported
by STAMP results from a modified sum of Pij′ scores corrected for the length of
the pairwise alignments.
As illustrated in Figure 3.1, a good way to align a set of structure domains
in STAMP is to start with a pre-computed set of domain transformations, which
are selected from an initial all-against-all pairwise (Pairwise) domain scanning set
(STAMP Scan). This allows STAMP to start aligning the domains based on a pre-
superimposed set of 3D coordinates, instead of following a simple sequence-derived
MSA. Multiple structure alignment then follows a procedure similar to tree-based
multiple sequence alignment. Each possible pairwise comparison for the group of
proteins to be aligned is performed. Structural similarity scores are used to derive
a similarity matrix and corresponding dendrogram (Treewise). The dendrogram
is then followed from the branches to the root superimposing structures in order
of their similarity. MSAs are similarly generated by following the tree from the
branches to the root.
A major advantage of STAMP is that it not only provides multiple structure-
based MSAs and the corresponding superimpositions, but also provides a systematic
and reproducible method for assessing the quality of such alignments. STAMP
provides a series of alignments for domain structures thought to have a similar fold
by following the systematically derived hierarchy of structural similarity. All steps in
the alignment tree are preserved and can be individually assessed in order to improve
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Pairwise structure comparison
Hierarchical clustering
Structure-based 
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Initial set of 
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Structure 
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Figure 3.1: Schematic overview of the process performed by STAMP in order to
generate multiple sequence alignments from the alignment of protein structures. The
STAMP protocol works in five main stages: 1) all-against-all pairwise domain scan-
ning; 2) selection of a seed domain representative set of coordinate transformations,
which produce an overall higher scoring initial superimposition; 3) generation of a
new superimposition and structure-derived tree based on the selected seed trans-
formations; 4) further refinement of the superimposition found in 3) and creation
of multiple sequence alignments and structural trees derived from the structural
equivalences found; and 5) assignment of the reliability values to each region of the
alignment. Darker blue colour in the heatmap indicates a higher Sc score. The
example provided is for the Polo-box like domain (SPF:SC 3.30.1120.30:1).
the confidence of the final set of alignments. Additionally, STAMP assigns both the
overall quality of alignment (Sc score) at each stage of the hierarchy and provides
a confidence level for each aligned group of amino acid residues (Pij′ score) within
each alignment. This makes the quality metrics comparable among different protein
families containing different numbers of domains and different sequence lengths.
Structure-based MSAs have been used extensively to improve the quality of se-
quence alignments (Shatsky et al., 2006), and have helped to benchmark sequence
alignments derived without structure (Barton and Sternberg, 1987; Thompson et al.,
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1999; Raghava et al., 2003). Deriving MSA profile statistics was an important de-
velopment in computational biology that allowed the improvement of sequence sim-
ilarity detection as implemented in popular iterative sequence search programs such
as PSI-BLAST (Altschul et al., 1997). More recently, the SUPERFAMILY database
(Gough et al., 2001) used HMMs to represent each protein family MSA in the SCOP
database (Lo Conte et al., 2000). These profile HMMs were then used to identify se-
quence relatives to each SCOP family in a library of protein sequences. In a similar
fashion, Gene3D has been developed to provide protein domain assignments based
on the CATH hierarchy (Lees et al., 2012). Profile HMMs are similar to MSA pro-
files, but they contain position-specific probabilities for insertions and deletions, in
addition to the amino acid frequencies per aligned column of an MSA. Profile HMMs
have been shown to perform better than sequence profiles in detecting homologous
proteins and generating hit MSAs (Eddy, 1998, 2011).
3.3 Methods
3.3.1 Generating structural alignments with STAMP
As introduced in Section 2.3.9, structure-based MSAs were generated by STAMP
version 4.4.2 (Russell and Barton, 1992) for structure domains organised in SCs and
FunFams in CATH (Sillitoe et al., 2015). In order to align CATH domains based on
their structures, pre-processing of the generated biological assembly structures was
performed as described in Section 2.3.8. Simple redundancy removal was performed
by selecting only one copy of any domain which mapped to multiple chains in the bi-
ological assembly structures. Alignment of structures with STAMP (Pairwise and
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Treewise) was performed using default parameters for E1 and E2, with an extended
maximum domain length set to 1,000 amino acid residues. The two similarity mea-
sures provided by STAMP, Root Mean Square Deviation (RMSD) and Sc score,
were used as proxies for the reliability of the structural alignments.
Figure 3.2 illustrates how an initial all-against-all domain STAMP Scan is per-
formed (window size of 5 residues) to determine the best seed, i.e. the domain that
produces a higher overall Sc scoring initial set of superimposed structures. This
is performed since pairwise residue fitting with the Rossmann and Argos, 1976,
function is improved if the protein structures being compared are approximately
superimposed initially. For each pair of domains A and B, both A to B and B to A
STAMP scans are performed and the initial superimposition problem is solved by
attempting more than one initial fit between A and B. The best scoring domain
is selected if it can generate better initial superimpositions with as many other do-
mains in the family as possible. From the initial set of transformations obtained by
superimposition with the seed domain, a survey over the domain pairs that are not
optimally aligned is performed in order to test whether the reverse transformation
(i.e. B to A instead of A to B) should be selected instead (Figure 3.2). The STAMP
Pickframe program was used to reverse the set of transformations generated for
the seed domain by the initial STAMP scan, for those domain-domain pair scans
which the reverse transformation is preferred.
Percentage sequence identity (PID) reported throughout this Chapter is provided
by STAMP, and is defined from structure comparison as the percentage residue iden-
tity within structurally conserved (equivalent) regions (SCRs) (stretches of ≥3 po-
sitions with Pij′ ≥ 6.0). Root mean square deviation (RMSD) scores are iteratively
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Figure 3.2: Improving the reliability of structure-based STAMP MSAs by optimis-
ing the set of transformations obtained for the seed domain. After performing an
all-against-all domain STAMP scan, the higher Sc-scored seed domain is selected.
In order to further improve the quality of the superimpositions and MSAs generated
by STAMP alignment, the initial set of transformations is optimised by reversing
the coordinate transformations obtained for low scoring superimpositions. Darker
blue colour in the heatmap indicates higher Sc score.
calculated by the least-squares fitting only for the subset of structurally equivalent
Cα atom positions. RMSD scores are similarly provided by STAMP.
3.3.2 Extending STAMP structural alignments with HMMs
As summarised in Figure 3.3, profile HMMs were generated for each multiple struc-
ture alignment obtained for SCs and FunFams. MSAs were converted to Stockholm
file format and profile HMMs generated with the HMMER3 hmmbuild tool (Eddy,
2011). These profiles were then used to search a set of protein sequences from com-
plete proteomes (see Section 2.3.11). A profile HMM sequence search was performed
with the HMMER3 hmmsearch tool (Eddy, 2011) using inclusion/reporting signif-
icance thresholds E-value = 1 x 10−4. MSAs containing the hit sequences were
obtained with the same tool and merged with the full structure-based MSA (Figure
91
3. Analysis of protein domain families 3.4. Results and discussion
Domains in CATH SCs/FunFams STAMP structure-based  MSA
HMM-based extended MSA
Profile HMMs and 
sequence search
Sequence 
database
Structure domains
Sequence domains
Figure 3.3: General overview of the protocol developed to extend STAMP struc-
tural alignments with similar protein sequences. CATH SCs/FunFams are struc-
turally aligned with STAMP and MSAs generated. HMMER 3 tools (Eddy, 2011)
are used to generate profile HMMs from these MSAs and used to search a sequence
database containing protein sequences from complete reference proteomes. Finally,
the original structural alignments are extended with the search hit sequences (in yel-
low) that pass the E-value = 1 x 10−4 threshold. Structurally equivalent positions
(SCRs) are highlighted (blue square boxes) in the final extended MSA.
3.3). Whenever the hit sequences did not cover the entirety of the structure-based
alignment, these were extended with gaps in order to retain the length of the original
structure-based alignment.
3.4 Results and discussion
3.4.1 Improving the quality of the structural alignments
generated by STAMP
Structure-based multiple protein sequence alignments (MSAs) were generated for
both CATH SCs and FunFams. Although seed MSAs were available for both SC
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and FunFams from the CATH database, working with these proved extremely com-
plicated. This was mainly due to inconsistencies between the CATH domain defini-
tions and the domain sequences depicted in the final seed MSAs. Structure-based
MSAs were therefore generated by STAMP (Russell and Barton, 1992), due to our
extensive knowledge of its features and the recognised quality of the resulting align-
ments (Raghava et al., 2003). STAMP follows a similarity hierarchy, and the ob-
tained transformations and corresponding MSAs are output at each node of the
dendrogram so that each sub-alignment may be examined separately. This is a clear
advantage which allows for a fine structural analysis at increasing levels of structural
similarity or diversity. STAMP assumes overall topological similarity within the pro-
tein families to be aligned, and would not be able in principle to superimpose/align
structures with common secondary structures in similar orientations, but different
connectivity or topologies. This requirement was fulfilled since both SCs and Fun-
Fams are expected to be structurally similar as they are clustered under the same
Topology and Homologous Superfamily in CATH. Alternative structure alignment
programs (reviewed in Table 3.1), were also initially considered but unfortunately
were not suitable for generating the MSAs needed in this work. In addition to pro-
grams that only perform pairwise structural alignment (e.g. DALI (Holm et al.,
2008) and TM-align (Zhang and Skolnick, 2005)), some were no longer available for
use (e.g. SSAP (Orengo and Taylor, 1996)); others were only available through web-
servers which were not practical for aligning such a high number of domains (e.g.
FlexSnap (Salem et al., 2010) and POSA (Li et al., 2014)); or imposed limitations
on the number of domains to be aligned (e.g. MAMMOTH (Lupyan et al., 2005)
and Mustang (Konagurthu et al., 2006)).
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As described in Section 3.3.1, STAMP domain scanning was used to generate an
initial set of superimposed coordinates. This is achieved by scanning all-against-all
domains to be structurally aligned which belong to a particular SC or FunFam. A
seed domain is selected based on the overall Sc score. Transformations obtained for
the seed domain can be further optimised. Therefore these have been reversed in
order to generate the best-starting transformation set possible (Figure 3.2). Because
the difference in Sc scores can be small, only when at least a 0.25 Sc score difference
is observed, the reverse transformation is preferred. This approach was applied to
the entirety of CATH SCs and FunFams and led to a relative improvement of the
initial set of transformations, for 46% of those domain families.
As shown in Section 2.3.8, the number CATH FunFams is more than double the
number of CATH SCs (Table 2.6). This results in the number of domains clustered
into SCs to be higher than those classified into FunFams. Figure 3.4 overviews five
metrics used to compare the contents of STAMP MSAs generated for CATH SCs
and FunFams. The MSAs have on average 142 residues in length (AL) (21 ≤ AL
≤ 898). Although the distribution of MSA lengths is comparable, MSAs generated
for CATH SCs are slightly longer than those generated for CATH FunFams (Figure
3.4 A), which results from the higher diversity and number of domains aligned in
SCs, as well as the resulting insertion of gaps. The distribution of the length of the
shortest domain sequence (LSS) is similar for the 72% CATH domains, which are
simultaneously clustered into SCs and FunFams (Figure 3.4 B). The distribution
of the smallest percentage sequence identity (PID) scores observed for members of
the various CATH SCs and FunFams, as calculated by STAMP, is also provided in
Figure 3.4 C. PID scores range from 0 to 100 and a broader distribution of PID
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Figure 3.4: Overview of various STAMP alignment metrics for the comparison
between SCs and FunFams. Histograms are provided for comparing: A) alignment
length (AL); B) the length of the shortest domain sequence (LSS); C) the smallest
percentage sequence identity (PID) observed; D) the Root Mean Square Deviation
(RMSD); and E) STAMP Sc scores. Histogram binning was performed using nor-
malised counts. The number of SCs and FunFams is 2,371 and 5,777, respectively.
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scores is observed for the SCs, when compared to the FunFams, which distribute
closer to a higher PID. This suggests that clustering of domains on the basis of
function in CATH FunFams results in lower structural diversity.
Figure 3.4 D shows the distribution of RMSD scores obtained from STAMP by
the superimposition and alignment of the domains in CATH SCs and FunFams. A
Pij′ of 6.0 was used to define structurally conserved (equivalent) positions in the
structure superimpositions (and alignments). This threshold was found to yield
good superimpositions and alignments (Russell and Barton, 1992), where lower Pij′
scores generally result in poor fit. Higher Pij′ scores generally result in too few
structure equivalences. According to analysis of various protein families performed
with STAMP (Russell and Barton, 1992), stretches of three or more aligned posi-
tions with Pij′ values greater than 6.0 correspond to true topological equivalences,
values between 4.0 and 6.0 are equivalent >50% of the time, and values less than
4.0 are more often not equivalent. Stretches of residues having Pij′ ≥ 6.0 generally
correspond to regions of conserved secondary structure within a family of structures
being compared. RMSD scores are obtained for structurally equivalent positions
(Pij′ ≥ 6.0) and range from 0.0 to 2.0. A broader distribution of RMSD scores,
ranging from 0.0 to 3.5, is observed for SCs. Lastly, Figure 3.4 E shows a wider
dispersion of STAMP Sc quality scores for SCs when compared to those observed
for FunFams, which are generally highly scored. Again according to the original
STAMP analysis (Russell and Barton, 1992), alignments having a structural simi-
larity score Sc between 5.5 and 10.0 display a high degree of structural similarity,
which suggests a functional and/or evolutionary relationship. Scores between 2.5
and 5.5 correspond to more distantly related structures and do not always imply a
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functional or evolutionary relationship. Scores <2.0 generally indicate little overall
structural similarity.
3.4.2 Analysis of structurally conserved regions in the struc-
tural alignments
A complementary metric to analyse the reliability of the STAMP structure-based
MSAs is to calculate the number of structurally equivalent positions (NEP) divided
by the LSS. This corresponds to the number of residues that are considered to be
structurally conserved in STAMP (Pij′ ≥ 6.0) relative to the smallest number of
residue positions that could be equivalently aligned. Figure 3.5 shows the distri-
bution of STAMP structurally conserved residues (NEP / LSS) when comparing
CATH SCs and FunFams. An overall higher number of STAMP structurally con-
served positions is observed for MSAs generated for CATH FunFams than for SCs.
SCs FunFams
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Figure 3.5: Box-plot showing the distribution of structurally conserved positions
in the CATH SC- and FunFam-based STAMP MSAs. The number of STAMP
structurally equivalent positions (NEP) is divided by the length of the shortest
domain sequence (LSS). The distribution of NEP/LSS is provided for both CATH
SCs and FunFams.
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This results from the lower number of domains per protein family in FunFams, as
well as the fact that FunFams display overall lower PID and higher STAMP Sc
scores (Figure 3.4).
Figure 3.6 shows the correlation between the distribution of structurally con-
served positions and the STAMP RMSD, Sc scores and PID, obtained for the
STAMP structural alignments generate for SCs and FunFams. A high Pearson cor-
relation coefficient is observed for the comparison of both NEP / LSS and RMSD
(Figure 3.6 A) (r = -0.75 and r = -0.63, for SC and FunFam, respectively), as well
as NEP / LSS and Sc (Figure 3.6 B) (r = 0.90 and r = 0.86, for SC and FunFam,
respectively). Following the trend observed for the RMSD and Sc scores (Figure
3.4 D and E), the score distribution is tighter for FunFam-based alignments when
compared to those obtained for SCs. A weaker correlation is observed for the com-
parison of NEP / LSS and PID (Figure 3.6 C) (r = 0.73 and r = 0.59, for SC and
FunFam, respectively).
Figure 3.7 shows the trend of NEP / LSS, Sc and PID, for increasing num-
bers of domains per SC/FunFam family. The number of domains that compose
each SC/FunFam in the analysis shows that the larger the number of domains, the
lower the number of structurally equivalent positions in the resulting superimpo-
sitions/MSAs (Figure 3.7 A). The same profile is observed for both Sc and PID,
where a higher number of domains per SC/FunFam results in lower detection of
structural equivalence (Sc) (Figure 3.7 B) and lower PID (Figure 3.7 C). The effect
is observed more markedly for SC than to FunFams, since, as expected, the number
of domains and the structural diversity is higher for SCs than for FunFams.
Figure 3.8 shows three examples of SC/FunFam protein families superimposed
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Figure 3.6: Assessment of STAMP alignment reliability with RMSD, Sc and PID,
for SCs and FunFams. Pearson correlation coefficients A) of -0.76 and -0.63 were
obtained for the number of equivalent positions (NEP) divided by the length of the
shortest domain sequence (LSS) versus Root Mean Square Deviation (RMSD); B)
0.90 and 0.86 for NEP/LSS versus STAMP Sc score; and C) 0.73 and 0.59 for
NEP/LSS versus the smallest percentage identity (PID) for SCs and FunFams,
respectively. NDOM corresponds to the number of available domains per family.
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Figure 3.7: Assessment of STAMP alignment reliability comparing NEP/LSS,
Sc and PID, over the number of domains, for SCs and FunFams. A) Number of
equivalent positions (NEP) divided by the length of the shortest domain sequence
(LSS); B) STAMP Sc score; and C) the smallest percentage identity (PID) for SCs
and FunFams, respectively.
by STAMP, which despite having a low STAMP Sc score, show that the backbone
residues are overall well superimposed. Figure 3.8 A, shows the structure superim-
position of Actin-binding protein, T-fimbrin (CATH SPF:SC 1.10.418.10:1). This
example highlights the case where a high RMSD of 3.31 is obtained despite good
overall backbone superimposition (Sc of 3.07), as the result of relative low number
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of sites considered to be structurally equivalent (conserved) (NEP/ LSS = 0.47).
Regardless of good overall superimposition, the lowest PID observed within this SC
is 0%.
Figure 3.8 B shows the structure superimposition generated for the Putative
genome polyprotein (SPF:SC 2.60.120.20:5), which contains 45 domain members
and a low overall PID of 17%. Multiple structure alignment of this SC by STAMP
results in a Sc score of only 2.49. Despite this score, the RMSD score obtained
for the structurally equivalent positions is 0.53, indicating that many residues in
the backbone of the structure domains are well aligned. Nevertheless, the distri-
bution of NEP divided by the LSS shows that in fact only 35% of the sites to be
aligned are considered structurally equivalent (Pij′ ≥ 6.0, and hence used for RMSD
calculation) by STAMP.
Finally, Figure 3.8 C shows the superimposition of domains in the S-layer homol-
ogy domain ribonuclease family (CATH:FunFam 3.10.450.30:600). Despite showing
related protein function, domains belonging to this FunFam display structural di-
versity (and sequence diversity, lowest PID = 4%). The STAMP Sc obtained for
this FunFam was 2.41, which resulted in an RMSD of 2.54, for 38% of sites which
were defined as structurally conserved by STAMP.
3.4.3 Increasing the structural coverage of the STAMP align-
ments for CATH SCs and FunFams
STAMP structural alignments were expanded with similar protein sequences as de-
scribed in Section 3.3.2. Figure 3.9 shows the increase in the number of sequences
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Putative genome polyprotein
(CATH SPF:SC 2.60.120.20:5)
STAMP Sc = 2.49
RMSD = 0.53
NEP / LSS = 0.35
Number of domains = 45
Lowest PID = 17%
B
C
S-layer homology domain ribonuclease
(CATH:FunFam 3.10.450.30:600)
STAMP Sc = 2.41
RMSD = 2.54
NEP / LSS = 0.38
Number of domains = 66
Lowest PID = 4%
A
Actin-binding Protein, T-fimbrin
(CATH SPF:SC 1.10.418.10:1)
STAMP Sc = 3.07
RMSD = 3.31
NEP / LSS = 0.47
Number of domains = 61
Lowest PID = 0%
Figure 3.8: Example of low STAMP Sc scoring structure superimpositions ob-
tained for CATH SCs and FunFams. The superimposition and SC/FunFam sum-
mary information is shown for: A) Actin-binding protein, T-fimbrin (CATH SPF:SC
1.10.418.10:1), which contains 61 domains; B) Putative genome polyprotein (CATH
SPF:SC 2.60.120.20:5), which contains 45 protein domains; and finally C) for S-layer
homology domain ribonuclease (CATH:FunFam 3.10.450.30:600), which contains 66
domains.
(domains) that compose the extended MSAs, when compared to the number of
sequences that composed the STAMP structural MSAs. The distribution of the
number of domain sequences in the structure-based MSAs generated by STAMP
(Structural) was compared to that of the extended MSAs (Extended), for both
CATH SCs and FunFams. The increase in the number of domain sequences with
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Figure 3.9: Box-plot showing the distribution of the number of domain sequences
in the structure-based MSAs generated by STAMP (Structural) when compared to
that of the extended MSAs (Extended), for both SCs and FunFams. The increase
in the number of domains is statistically significant (p-value < 1 × 10−5 ).
the HMM-based protocol described in Section 3.3.2, is statistically significant for
both SCs and FunFams (p-value < 1 x 10−5). For CATH SCs a mean of 39 domain
sequences constitutes the structure-based MSAs. This number increases to a mean
of 312 sequences. Similarly, a mean of 16 domain sequences constitutes the MSAs
generated for CATH FunFams, which is raised to a mean of 384 sequences. Although
the number of domains in FunFams is on average lower than that of the SCs, the
extended MSAs are on average larger for FunFams than for SCs. This likely results
from the overall higher levels of sequence similarity observed among FunFam domain
members (Figure 3.4), which results in a stronger signal in the profile HMMs gen-
erated. Remarkably, there is 25-fold and 32-fold overall increase, on average, of the
number domains sequences that can be analysed for SCs and FunFams, respectively.
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3.5 Conclusions
In order to perform an enriched analysis of genetic variants under a structure and
evolutionary perspective (Chapter 4 and 5), structure-based MSAs were generated
for CATH structural and functional families. A central point of focus in this Chapter
was the careful assessment of the reliability of the structural MSAs generated by
STAMP. This Chapter focused on improving the quality of the generated MSAs
by: 1) developing methods that take advantage of the features of STAMP; and 2)
exploring the power of HMMs for extending the alignments and annotating them
with homologous protein sequences. Both these aspects are key for increasing the
scope and coverage of the structure/sequence data currently available for analysis.
The main conclusions of the work presented in this Chapter are:
• Selecting a seed domain from all-against-all domain STAMP scanning gen-
erates a good starting point for the alignment of multiple structures with
STAMP.
• Further optimisation of the set of transformations obtained for the seed domain
leads to an overall improvement of the Sc and RMSD alignment measures.
• Although STAMP produces overall reliable MSAs for CATH SCS and Fun-
Fams, the quality of the FunFam-based alignments is higher, which results
from a higher structural similarity between the family domain members.
• STAMP-based MSAs were extended with related protein sequences using a
new HMM-based protocol.
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Chapter 4
Overall analysis of genetic
variation
4.1 Summary
This Chapter focuses on the analysis of genetic variation in protein structural and
functional families. Missense variants are analysed in the context of the structure-
based MSAs generated for SCs and FunFams defined in CATH, as described in
Chapter 3. Variants were collected and grouped according to their annotation and
their attributes were compared. The distribution of nsSNPs regarding their struc-
tural locations was investigated. Missense variants were characterised across differ-
ent structural sites and environments. Amino acid exchanges were investigated, and
mutability matrices produced for germline, somatic and disease-associated variants.
Genetic variation exchanges by annotation and the potential consequence were in-
vestigated for SC and FunFam domains. Analysis of exchanges in terms of amino
acid change, physicochemical properties, as well as conservation was also performed.
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Finally, analysis of prediction scores from SIFT and Polyphen-2 on the effects of the
variants was performed.
4.2 Introduction
Missense mutations that gain clinical attention usually change the physicochemical
properties of the amino acid residue sufficiently to affect the function of the gene
product (Krawczak et al., 2000; Stone and Sidow, 2005), but the most severe mu-
tations are likely to result in lethal phenotypes that cannot be inherited (Steward
et al., 2003). At the same time, proteins are rather robust and can be quite tolerant
to alterations in amino acid sequence (Poussu, 2005; Pajunen et al., 2007). In prin-
ciple, an nsSNP can be deleterious either because it leads to disruption of a site that
is directly involved in the function of a protein (e.g. a catalytic residue, a residue
involved in ligand binding, or a residue that forms a critical interaction with another
protein), or because it causes destabilisation of protein structure, leading to protein
degradation, or the amino acid substitution abolishes protein function because of the
loss of the structural framework that enabled the functionality of the protein in the
first place. Pathogenic amino acid substitutions tend to have special characteristics
that distinguish them from those nsSNPs that cause no phenotypic effect (neutral
variations). In order to discriminate neutral variants from those causative of a dis-
ease phenotype, the prediction of the consequences of nsSNPs is a major research
challenge, accompanying the rapid growth of genomic tools which have produced
vast amounts of information about genetic variation within and among individuals
(Ng and Henikoff, 2003; Karchin, 2009; Steward et al., 2003; Mooney, 2005)
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4.2.1 Structural analysis of genetic variation
A general analysis of the effects of variation on the protein structures was performed
by Wang and Moult, 2001. The effects of nsSNPs were grouped into protein sta-
bility, catalytic binding, allosteric regulation, ligand binding and post-translational
modification. For protein stability, the factors investigated were the following: 1)
loss of hydrogen bonds; 2) reduced hydrophobic interaction; 3) loss of a salt bridge;
4) introduction of a buried charge; 5) over-packing; 6) formation of an internal cav-
ity (void space); 7) electrostatic repulsion; 8) causing the burial of a polar residue;
9) disruption of metal binding; 10) loss of disulphide bonds; 11) introduction of
backbone strain; and 12) the destabilization of a protein interaction. The SNP
dataset was separated into a disease subset, which contained variants known to be
involved in disease, and a neutral subset. For the disease subset, the nsSNPs af-
fected the protein stability of the protein more than the other factors. In contrast,
for the neutral subset, the majority of the nsSNPs were found to have no effect on
the structure. Furthermore, out of the six groups (protein stability, ligand binding,
catalytic binding, allosteric regulation and post-translational modification), protein
stability had the largest mutational effects (83%) for the disease subset. However,
in the neutral set, the majority of nsSNPs were classified as having no effects and
protein stability came second at 30%.
Following a similar approach, a global analysis of variation was also performed by
Martin et al., 2002. The effect of mutations in the core region of the p53 protein was
investigated. Seven effects of mutations on the p53 crystal structure were analysed:
1) mutations affecting a hydrogen bonding; 2) mutations to proline; 3) mutations
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from glycine; 4) residue clashes; 5) mutation at the DNA binding site; 6) mutation at
the zinc-binding site; and 7) mutation in conserved regions. An integrated pipeline
to map single amino acid polymorphisms to structure was developed (Cavallo and
Martin, 2005), which was later used in the development of SAAPdb (Hurst et al.,
2009).
In order to understand the structural characteristics of SNPs, Stitziel et al., 2003,
mapped a set of SNPs from OMIM and dbSNP to structures. Their objective was
to introduce a new geometric classification for characterising disease SNPs. A set of
SNPs from OMIM was classified as disease-causing while another set of SNPs from
dbSNP was used as a control set, and both sets were mapped to protein structures.
The majority of disease SNPs occurred in pocket or void regions (88%) and it was
less likely that disease SNPs occur in convex regions. Additionally, disease SNPs
tend to occur infrequently in completely buried regions. According to Stitziel et al.,
2003, a mutation is less likely to be observed in the protein core since the core plays
a critical role in protein stability; therefore, it is more likely that the mutation may
be eliminated early in the stages of biogenesis.
Another study by Yue et al., 2006, analysed the structural location of SNPs.
Homology modelling was used in this study to model human disease proteins before
comparing them with SNPs from the UniProt database. The distribution of both
disease and non-disease nsSNPs in protein 3D structures was analysed. A small
set of 369 experimentally determined domains from the PDB were used, and 1,484
domains from 874 proteins were modelled, covering 6,352 mutations. The result
showed a strong tendency for disease-associated variants to occur in the core region
in patches (spatial clusters). Yue et al., 2006, suggested that disease SNPs forming
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these patches could be involved in protein-protein interactions. In order to test
this hypothesis, eight experimentally determined disease proteins were examined.
In most of these experiments, disease mutations were observed to cluster at the
interaction sites.
Gong and Blundell, 2010, recently catalogued structural and functional features
of proteins that influence the substitution of amino acids. The motivation behind
this study was to discover if the factors that restrain the substitution of amino
acids in evolution also influence the occurrence of SNPs in coding regions. Although
previous studies (Steward et al., 2003; Ng and Henikoff, 2003; Ferrer-Costa et al.,
2005) look at the relationship between different factors (e.g., solvent accessible or
conserved residue) with SNPs, Gong and Blundell, 2010, argued that most of these
studies have not taken advantage of the rapidly growing information in structure
and function.
4.3 Methods
4.3.1 Organising genetic variants according to their anno-
tation
Genetic variants collected and organised in ProIntVar were separated into three main
classes: 1) germline variants from a variety of sources, which include: dbSNP (Sherry
et al., 2001); 1kGP (The 1000 Genomes Project Consortium, 2012); ExAC (Exome
Aggregation Consortium (ExAC), Cambridge, MA, 2016); ESP (NHLBI GO Exome
Sequencing Project (ESP), Seattle, WA, 2016); HGMD-public (Stenson et al., 2014);
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HapMap (The International HapMap Consortium, 2007); and PhenCode (Giardine
et al., 2007); 2) somatic variants from COSMIC (Forbes et al., 2015); and 3) disease-
associated (a subset of germline variants), obtained from: Humsavar (Wu et al.,
2006; Famiglietti et al., 2014); OMIM (Amberger et al., 2015); and ClinVar (Lan-
drum et al., 2016). Section 2.3.13 overviews the source and set of annotations col-
lected for each variant. The variation types covered are: missense (non-synonymous
single nucleotide polymorphisms (nsSNPs)), frameshift-variant, stop-gained, start-
lost, inframe-deletion, inframe-insertion, splice-region-variant. Synonymous SNPs
were not considered in this study, since the mutational outcome results in the same
amino acid.
The consequences of genetic variation were investigated using prediction scores
and categorical classification from Polyphen-2 (Adzhubei et al., 2010) and SIFT
(Kumar et al., 2009). Only these two methods were used, since prediction scores
were readily available for each variant from the Ensembl database (Chen et al.,
2010; Flicek et al., 2013; Cunningham et al., 2015), through the Ensembl REST
API (Rios et al., 2010; Yates et al., 2014), as well as from the UniProt Variation
endpoint (The UniProt Consortium, 2015). Qualitative categorical prediction states
are defined from the prediction scores (P ) provided by SIFT as: deleterious (P ≤
0.05); or tolerated (P > 0.05). Similarly, categorical states generated for Polyphen-2
(HumVar) are classified as: benign (P < 0.446); probably damaging (0.446 ≤ P <
0.909); or possibly damaging (P ≥ 0.909).
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4.3.2 Characterising genetic variants across structural re-
gions and environments
Genetic variants were mapped to protein 3D structure as described in Section 2.3.3
and Section 2.3.12. Protein domains were grouped into SCs and FunFams in CATH
(Sillitoe et al., 2015) and MSAs generated by the structural alignment of the domains
(Section 3.3.1). MSAs were further extended with similar protein sequences (Section
3.3.2). The analysis of genetic variants focused on three protein sequence/structure
datasets including: protein domains classified in CATH that are mapped to protein
chains; protein domains that are mapped to protein chains in the PDB and are
not covered by CATH; and finally protein sequence domains that were found to
extend the STAMP structural alignments (Section 2.3.13). Mutated residues and
their position in 3D space was investigated in the context of the SC/FunFam protein
families.
Figure 4.1 illustrates the process of mapping genetic variants and structure-
annotated residues onto the STAMP extended MSAs. Residues were annotated
according to their location within the protein structural regions (environments) as
described in Section 2.3.7. The occurrence of genetic variants was compared across
secondary structure elements (SSEs): α-helix ; β-sheet/strand ; and Turns or coil ;
across structural spatial environments: solvent inaccessible (Core), partially exposed
to solvent (Part. Exposed), accessible to the solvent (Surface), and interaction
interface (Interface): interaction with domains (Inter. Domain), interaction with
ligands (Inter. Ligand, ligand definition is provided in Section 2.3.5), and interaction
with other protein residues which are not part of CATH domains (Inter. Protein);
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STAMP structure-based extended MSA
Structure domains
Sequence domains
i j
Mapping of genetic variants 
and other structure features 
(e.g. interaction interfaces)
Interacting residues
Genetic variants
Structure 
superimposition
i
j
Figure 4.1: Mapping of genetic variants and structure-annotated residues in
structure-based MSAs. MSAs are generated by STAMP and extended with similar
sequences of proteins with unknown structure as described in Section 3.3. Struc-
turally conserved columns/positions in the structure-based domain MSA are defined
by STAMP. Conserved regions as well as individual MSA columns, i and j, are
highlighted. The mapping of genetic variants and structure-annotated residues is
illustrated for both MSA and the structure superimposition.
as well as across STAMP-defined structurally equivalent (Conserved) regions (or
positions) (SCRs), and Variable regions, as described in Section 3.3.1.
4.3.3 Mapping and analysis of variants in the MSAs
As shown in Figure 4.1, multiple genetic variants and structure features are mapped
onto aligned positions (or columns) in the MSA. The characterisation of genetic
variants that map onto particular structure domains was performed considering the
structural annotations of that particular domain alone. This is particularly impor-
tant for interaction interfaces, which were treated differently so that only domains
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which are found to interact are annotated as such. As an example, the majority of
domain residues that are aligned in column i are classified to be part of an α-helix,
nevertheless, a variant position is classified as turns/coil if the secondary structure
state of the domain to which the variant is mapped to is structurally annotated
with that state. In addition to secondary structure classification, variant positions
in column i are also annotated with regard to the spatial location, accessibility to
solvent, as well as to the STAMP conservation status of the domains to which the
variation maps to.
STAMP-defined structurally conserved regions (SCRs) (columns), as well as vari-
able regions were analysed as structural environments. SCRs were used to infer
conserved regions in the similar protein sequences found to extend the structure-
based MSAs (Figure 4.1). Characterisation of genetic variants was conducted so
that every unique variant was only considered once in the analysis (Section 2.3.13).
This prevents redundancy arising from multiple structure-sequence mapping being
propagated or considered multiple times.
Variants were compared across the structural regions and environments using
the odds ratio (OR) measure described in David et al., 2012. The preference for a
variant to be in region i rather than region j was calculated as:
ORij =
pi/(1 − pi)
pj/(1 − pj)
(4.1)
where the probability of observing variants in region i is pi =
ni
Ni
(ni corresponds
to the number of observed variants, whereas Ni corresponds to the total number
of available residues in region i). To compare two structural environments, log OR
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scores are calculated as the ratio between the odds (relative likelihood) pi/(1 − pi)
and pj/(1 − pj). When the total number of variants and residues in analysis are
identified within multiple regions (e.g. α-helix, β-sheet, and Turns or coil), variants
and residues in a region i (e.g. α-helix ) are compared to all other variants/residues
that compose the remaining regions, aside from the region under analysis.
The mutability score for each amino acid residue was calculated by taking the
total number of mutations observed in the dataset divided by its frequency of oc-
currence in the human proteome. Background relative amino acid frequencies for
the human proteome were obtained from de Beer et al., 2013, and are summarised
in Table 2.5. Inspired by the Point Accepted Mutation (PAM) matrices generated
by Dayhoff and Schwartz, 1978, as well as the Block Substitution Matrices (BLO-
SUM) generated by Henikoff and Henikoff, 1992, log-odds mutability matrices were
calculated for the genetic variants as:
Rij =
(
1
λ
)
log
(
P (ij)
P (i)P (j)
)
(4.2)
where P (ij) is the probability of two amino acids i and j replacing each other in a
similar sequence, and P (i) and P (j) are the background probabilities of finding the
amino acids i and j in any protein sequence. An arbitrary scaling factor of λ = 2
was set such that the matrix contains easily comparable values.
The Shannon’s entropy (H) (Shannon, 1948) conservation measure was calculated
for each alignment column position as:
H = −
20∑
i
pC(i)log(pC(i)) (4.3)
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where pC is the distribution of a set of 20 amino acids in column C. H is subsequently
calculated using the frequency of each amino acid i observed in column C as pC(i),
and is the smallest for a column with complete conservation (H = 0.0).
4.3.4 Analysis of variation exchanges for amino acids and
their physicochemical properties
Figure 4.2 shows a summary Venn diagram with the physicochemical properties of
amino acids as defined by Taylor, 1986, and Livingstone and Barton, 1993. Two
alphabets that group amino acids according to physicochemical properties were ex-
plored. In the first alphabet, ‘Chemical A’, amino acids were divided into the fol-
lowing six groups according to their physicochemical properties as: polar (Gln, Asn,
His, Ser, Thr, Tyr, Cys, Met and Trp); hydrophobic (Ala, Ile, Leu, Phe, Val); basic
(Arg and Lys); acidic (Asp and Glu); proline (pro); and glycine (Gly). Pro and
Figure 4.2: Summary of the physicochemical properties of amino acids. Amino
acids are grouped according to overlapping properties which include: size, charge,
polarity and hydrophobicity. Figure adapted from Taylor, 1986, and Livingstone
and Barton, 1993.
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Gly amino acids were analysed as separated classes in this alphabet as their partic-
ular importance in disease-association has been reported (Martin et al., 2002). The
second alphabet, ‘Chemical B’, grouped amino acids as: aliphatic (Leu, Ala, Gly,
Val, Ile, Pro); acidic (Glu, Asp); basic (Arg, Lys, His); small hydroxy (Ser, Thr);
aromatic (Phe, Tyr, Trp); amide (Gln, Asn); and sulphur (Met, Cys). Although
other amino acid classifications could have been used (e.g. according to size), these
simple classifications were used as they allow to classify all amino acids without
resulting in amino acid overlap between classes.
Standard amino acid properties summarised in Table 2.5, were used in the vari-
ous analyses performed in this work. Amino acid properties include: monoisotopic
atomic mass (Knapp, 1996); average volume of buried residues, calculated from the
surface area of the side chain (Zamyatnin, 1972); hydrophobicity (Fauchère et al.,
1988); total accessible surface area (Ahmad et al., 2004); and frequency of occurrence
(abundance) in the human proteome (de Beer et al., 2013).
4.4 Results and discussion
4.4.1 Mapping genetic variation to SCs and FunFam do-
mains
Genetic variants were grouped by annotation into three main classes: germline vari-
ants, somatic variants and disease-associated variants. Table 4.1 summarises the
number of SCs and FunFams for which genetic variants could be obtained, as well
as the mean number of variants per variation group. Genetic variation was mapped
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to domain members of 663 CATH SCs and 1,231 FunFams, from a total of 2,371
SCs and 5,777 FunFams, respectively. The resulting mean number of variants is
210 and 124, for SCs and FunFams, respectively. Taking all unique genetic variants
together results in a total of 139,516 for SCs and 152,926 for FunFams. The highest
number of unique variants mapped across SC/FunFam families is 7,511. Figure 4.3
shows a positive Pearson correlation (r = 0.41 and r = 0.20, for SCs and FunFams,
respectively) between the number of human missense variants mapped to domain
members of SCs and FunFams and the number of domains per SC/FunFam family.
This result indicates that a higher number of domain residues per family increases
the likelihood of observing a higher number of variant positions. Some protein fam-
ilies seem to be particularly enriched for variants, whereas others show only a small
number of variants mapped to them (Figure 4.3). These outlier protein families re-
sult from the fact that not all SC/FunFam families are composed of human proteins,
for which variation is obtained. The total number of domains per family also affects
the correlation, despite the fact that only uniquely mapped variants are considered
and the fact that, on average, only 2% of the domains per family have variants
mapped to them.
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Table 4.1: Overview of SCs and FunFams for which genetic variation could be mapped to their domain members. Genetic variants
were grouped as germline variants, somatic mutations and disease-associated variants. The mean (x̄) [minimum; median; maximum]
and the total number of genetic variants that were mapped to domains in SCs and FunFams is shown.
SCs FunFams
Class of
variants
Numb. of
SCs
Variants per
SC (x̄)
Total numb.
of variants
Numb. of
FunFams
Variants per
FunFam (x̄)
Total numb.
of variants
Alla 663 210 [1; 114; 7,511] 139,516 1,231 124 [1; 76; 7,511] 152,926
Germlinea 662 133 [2; 75; 2,784] 87,769 1,230 78 [1; 49; 2,784] 96,096
Somatica 658 66 [1; 27; 3,499] 43,325 1,217 39 [1; 20; 3,499] 47,756
Diseasea 336 26 [1; 7; 1,228] 8,422 495 18 [1; 5; 1,228] 9,074
Allb 728 408 [1; 127; 57,220] 296,887 1,822 365 [1; 117; 22,870] 664,175
Germlineb 728 284 [1; 90; 39,580] 206,358 1,814 256 [1; 84; 16,020] 464,508
Somaticb 703 117 [1; 31; 17,340] 82,470 1,744 103 [1; 29; 6,678] 179,827
Diseaseb 388 21 [1; 6; 535] 8,059 901 22 [1; 7; 537] 19,840
Allc 662 187 [1; 101; 5,680] 123,729 1,231 111 [1; 70; 5,693] 137,060
Germlinec 662 120 [2; 69; 2,185] 79,157 1,230 71 [1; 45; 2,193] 87,268
Somaticc 661 56 [1; 24; 2,284] 37,050 1,215 34 [1; 18; 2,285] 41,505
Diseasec 325 23 [1; 6; 1,211] 7,522 477 17 [1; 5; 1,215] 8,287
aAll variation types mapped onto protein structure domains; bAll variant types mapped onto similar protein sequences with
unknown structure; cFinal subset (as described in the text) of human missense mutations mapped onto protein structure
domains.
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Figure 4.3: Correlation between the number of genetic variants mapped to SCs and
FunFams domains and the number of domains per SC/FunFam for which variation
could be obtained. The binned total number of domains in each SC/FunFam was
also compared to the number of mapped variants.
The breakdown of the number of variants in SCs and FunFams by the class of
variation is also provided in Table 4.1. The mean number of variants per class drops
to 133 and 78 for germline variants, 66 and 39 for somatic variants, and 26 and 18 for
disease-associated variants, for SCs and FunFams, respectively. Germline variants
account for 63% of the total variants analysed in both SCs and FunFams. Somatic
variants account for 31%, whereas known disease-associated variants account for
only 6%. CATH Superfamily 2.60.40.720 (SC 2 and FunFam 7) accounts for the
highest number of somatic and disease-associated variants, mapped to the structure
domains (Figure 4.3). This Superfamily comprises the Cellular tumour antigen p53,
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which is the most frequent target for mutation in human cancer (Freed-Pastor and
Prives, 2012), among other proteins. p53 corresponds to the most widely studied
protein (Prives and Hall, 1999), so observational bias is expected for this protein
family.
Table 4.1 also summarises the number of variants that were mapped to simi-
lar protein sequences in the extended MSAs. The number of SCs and FunFams
for which variants could be mapped increased from 663 to 728 and 1,231 to 1,822,
resulting in a mean number of variants of 408 and 365, for SCs and FunFams, re-
spectively. This result was expected since the number of sequences found in the
MSAs was extended by the HMM-based protocol (Section 3.4.3). The increase
in the availability of genetic variants introduced by extending the MSAs enables a
much higher number of genetic variants to be analysed in the context of the SCs and
FunFams. In fact, an additional 296,887 and 664,175 human genetic variants were
identified for SCs and FunFams, respectively. A higher proportion of these addi-
tional variants corresponds to germline variants (69% compared to 63% in structure
domains), with 28% somatic and 3% disease-associated variants. Although pre-
liminary analysis of the STAMP MSAs indicate that STAMP-defined structurally
conserved positions/regions (Section 3.4.2) could be used to infer structure domain
features onto similar protein sequences with unknown structure, additional analysis
need to be performed in order to extrapolate information between the structures
and sequences within measurable levels of confidence. Therefore, only variants that
were mapped to protein structure domains in the SCs and FunFams were considered
in the remaining analysis performed here.
From the human genetic variants mapped onto SCs and FunFams, 89% are of
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the missense type (nsSNPs). The remaining variants correspond to a combina-
tion of frameshift variants, stop-gained, stop-lost, in-frame deletion, in-frame inser-
tion, and splice-region variants. Table 4.2 overviews the total number of frameshift,
stop-gained and stop-lost mutations mapped onto structure domains in SCs and
FunFams. Although these variation types are among those that are regarded as
potentially producing more dramatic protein phenotypes (Stankiewicz and Lupski,
2010; Gonzaga-Jauregui et al., 2012), only between 3 to 6% of these variants are
currently annotated as disease-associated. These variant types were not included in
the remaining analysis, since only ‘from’ and ‘to’ exchanges where a single amino
acid is mutated were considered. Nevertheless, these variants are kept in ProIntVar
for analysis. In fact, some examples of frameshift and stop-gaining mutations are
further explored in Section 5.4.8.
The final subset of missense variants from human mapped onto protein structure
domains corresponds to a total of 123,729 variants, with a mean of 187 variants per
SC across 662 SCs (Table 4.1). This corresponds to a total of 137,060 unique variants
and 1,231 FunFam protein families, and a mean of 111 variants per FunFam (Table
Table 4.2: Total number of frameshift and stop-gained/lost variants in SCs and
FunFams across the three main classes of variants.
SCs FunFams
Class of
variants
Frameshift
Stop
gained
Stop
lost
Frameshift
Stop
gained
Stop
lost
All 5,738 6,004 29 6,200 6,559 27
Germline 3,293 2,455 25 3,732 2,770 23
Somatic 2,177 3,162 3 2,197 3,363 3
Disease 268 387 1 271 426 1
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4.1). The relative proportion of variants by class is identical to the initial dataset
with 64% germline nsSNPs, 30% somatic mutations, and 6% disease-associated vari-
ants (a part of germline or somatic variants), for both SCs and FunFams. Table 4.3
highlights the top-10 most mutated SC/FunFam families. The top protein fami-
lies include protein domains from all three main classes in CATH, mainly α-helix
(Class 1), mainly β-sheet (Class 2), and mixed secondary structure content (Class
3). Five of the top-10 families comprise domains that interact with nucleic acids
(e.g. Winged-helix DNA binding domain family).
Figure 4.4 shows an example of a STAMP structure-based MSA and structure
superimposition where mapping of variants is performed with the aid of ProIntVar.
The example is for the CATH Superfamily 1.10.540.10 (Butyryl-CoA dehydrogenase,
subunit A, domain 1, SC ID 1 and FunFam ID 15764). This family is composed of
Medium-chain-specific acyl-CoA dehydrogenases (EC 1.3.99.3).
Table 4.3: Top-ranking SC and FunFam protein families for which genetic variants
could be mapped to its domain members.
Rank SPF ID SC ID FunFam ID Descriptiona
1 2.40.50.100 3 50450 Sulfate ABC transporter
2 1.10.10.10 24 266362 Winged-helix DNA binding domain
3 3.10.100.10 3 11954 Mannose-binding protein
4 1.10.10.10 9 123911 Winged-helix DNA binding domain
5 3.30.160.70 1 2113 Protein-cysteine DNA methyltransferase
6 3.30.40.10 12 40330 Zinc/RING finger domain (C3HC4)
7 2.30.18.10 1 280 Transcription factor IIA β-barrel
8 1.10.287.1010 1 31 Ataxin 3
9 2.10.25.10 4 45504 Laminin
10 1.10.10.60 7 124109 Homeodomain-like
aCATH Superfamily (SPF) description or representative domain name.
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Figure 4.4: Example of a STAMP structure-based MSA, dendrogram and struc-
ture superimposition highlighting variant positions. The example is for Medium-
chain-specific acyl-CoA dehydrogenase (CATH Superfamily 1.10.540.10, FunFam ID
15764). Germline (orange), somatic (red) and disease-associated (dark red) variants
are highlighted in both the MSA and domain superimposition. Structure superim-
position is provided for the domains highlighted in bold text. MSA colouring is
based on BLOSUM62 scores as implemented in Jalview (Waterhouse et al., 2009).
Dendrogram was calculated by Jalview using Neighbour Joining PID.
4.4.2 Analysis of genetic variation across different struc-
tural environments
In section 4.3.2 various structural sites/regions were defined for the analysis of vari-
ants. These include secondary structure elements (SSEs): α-helix, β-sheet (or
strand), and turns/coils; residue spatial subsets according to the solvent accessi-
bility and interaction: core, partially exposed surface, surface, and interface; as well
as structurally equivalent (conserved) or variable residues, as defined by STAMP
(Section 3.3.1).
Table 4.4 summarises the number of amino acid residues that compose each of
these structure regions. Residue counting is only cumulative within each of the sub-
sets defined, i.e. within secondary structure elements, spatial location, and STAMP
structure conservation. Additionally, residues that are located at interaction inter-
faces are organised according to three types of interaction: interaction with domains
(domain-domain interaction); interaction with ligands (domain-ligand); and inter-
action with other protein residue partners which are not part of domain themselves
(domain-protein). The mean number of residues and distributions across the dif-
ferent regions/environments is identical for both SCs and FunFams. Core, partially
exposed and surface spatial locations account for 15%, 14% and 40% of the residues
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Table 4.4: Residue composition of SC and FunFam domains across different struc-
tural environments. The mean (x̄) [minimum; median; maximum] and the total
number of residues mapped to SCs and FunFams is provided.
SCs FunFams
Region
Residues
per SC (x̄)
Total
residues
Residues
per FunFam (x̄)
Total
residues
Conserved 108 [14; 88; 452] 70,747 133 [28; 114; 457] 163,880
Variable 137 [0; 100; 697] 90,686 39 [0; 18; 551] 48,234
Core 36 [0; 26; 212] 24,064 33 [0; 24; 189] 40,906
Exposed 34 [0; 27; 166] 22,359 30 [0; 24; 170] 36,720
Surface 98 [7; 81; 442] 64,765 69 [8; 59; 339] 84,972
Interface 76 [0; 63; 411] 50,245 40 [0; 29; 411] 49,516
Inter. Domaina 48 [0; 40; 287] 31,745 27 [0; 21; 289] 32,868
Inter. Liganda 12 [0; 6; 110] 7,936 6 [0; 3; 108] 7,726
Inter. Proteina 16 [0; 7; 190] 10,564 7 [0; 1; 190] 8,922
α-helix 88 [0; 72; 344] 58,023 62 [0; 50; 572] 75,954
β-sheet/strand 41 [0; 36; 263] 27,022 37 [0; 38; 226] 45,438
Turns or coil 115 [1; 92; 533] 76,388 77 [1; 58; 453] 90,722
aInterface residues which result from the interaction with: domains, ligands,
and other proteins (not domain); are a subset of the interface.
in SCs. For FunFams, 19% core, 17% partially exposed and 40% surface residues are
observed. A mean of 76 and 40 residues in SCs and FunFams, respectively, partici-
pate in interactions. Although the number of alignment positions (columns) where
interaction residues are found is higher for SCs than for FunFams, the proportion
across different types of interaction is relatively similar. Domain-domain interactions
account for 63% and 67% of the interface residues for SCs and FunFams, respectively.
Domain-ligand and domain-protein interactions account for 15% and 18-21% of the
residues, respectively. Regarding secondary structure elements, 35-36% residues in
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SCs and FunFams are annotated as α-helix, whereas 17-21% and 44-47% are anno-
tated as β-sheet and turns/coils, respectively. These SSE proportions broadly agree
with previous analysis (Sreerama et al., 1999). A bigger difference is observed for
the mean number of residues in STAMP conserved/variable regions and in inter-
action interfaces. As discussed in Chapter 3.4.1, the number of FunFams is triple
the number of SCs in CATH. This means that the number of domains clustered
into SCs is higher than those classified into FunFams. As a result of this, longer
alignments are produced for SCs due to a higher number of domains and resulting
insertion of gaps, when compared to FunFam MSAs (Figure 3.4 A). Accordingly,
the mean number of residues in STAMP variable regions is 137 for SC and only 39
for FunFam. In contrast, the number of conserved residues is 133 for SCs and 108
for FunFams. This results from the fact that less structural diversity is observed
for FunFams than for SCs, as a result of grouping together domains on the basis
of functional similarity in addition to structural similarity. This leads to a higher
number of structurally conserved positions being identified for FunFams than for
SCs (Figure 3.6).
Figure 4.5 summarises the distribution of unique genetic variants mapped to
domains within SCs and FunFams across the various structural environments. The
distribution profile is overall similar for variants in all three classes, as well as be-
tween SCs and FunFams. The number of residues that compose each structure
environment and the number of variants that are mapped to them is positively cor-
related for both SCs and FunFams (r = 0.93 and r = 0.95, respectively). This result
is expected since a bigger region is expected to accommodate a higher number of
mapped variants.
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Figure 4.5: Distribution of genetic variants mapped to domain members of SCs and
FunFams across different structural environments. Genetic variants were grouped
as germline variants, somatic mutations and disease-associated variants. The ag-
gregation of all variants in the three classes is also provided. n corresponds to the
total number of genetic variants in each class that fall into that particular structure
environment. Structural environments/regions were defined as described in Section
4.3.2.
Some substantial differences can be still be seen particularly for the frequency
of disease-associated variants located in the protein core, in the interface regions,
as well as in the STAMP structurally conserved and variable regions. The full
analysis of how different variants in the different classes map to the different re-
gions/environments and whether there is any enrichment of a particular variant
type in a particular region is explored in the next Section 4.4.3.
4.4.3 Variation odds ratio across different structural envi-
ronments
In order to identify structural regions/environments that are enriched or depleted in
genetic variants, a measure of the odds ratio (OR) was used to compare the propor-
tion of variants that are mapped onto a variety of structure regions/environments
(Section 4.3.2). Figure 4.6 summarises the log OR obtained when comparing vari-
ation in the three classes mapped onto different structure environments, for both
CATH SC and FunFam domain families. Log OR scores are calculated for each
environment and take into account both the observed number of variants and the
total number of residues that compose each region. Log OR scores above 0.0 corre-
spond to enrichment of a particular variation class in a particular environment (e.g.
structurally conserved regions in the MSA), when comparing to the same class in a
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different environment (e.g. variable regions).
The overall analysis of the log OR indicates that although there are differences
in the log OR profiles obtained for germline and somatic variants, more dramatic
differences are observed for disease-associated variants. This is true for the log OR
calculated for both SCs and FunFams, but is less pronounced for the interface envi-
ronments, where germline variants and somatic variants are significantly differently
distributed (p-value < 1 x 10−5), for both SCs and FunFams. Taking the log OR
profiles of SCs and FunFams together, variants in the three classes are significantly
enriched (p-value < 0.01) in the STAMP structurally conserved regions (SCRs) of
the domain structures when compared to variable positions. Likewise, a significant
enrichment of genetic variants is observed for the Core, partially-exposed Surface,
and β-sheet regions (p-value < 0.001). Germline and somatic variants are also sig-
nificantly enriched at the surface, whereas disease-associated variants are depleted
(p-value < 0.001).
The analysis of the log OR profiles comparing the different variation classes
within each structural environment indicates that substantial differences are ob-
served for SCs and FunFams. Considering the composition of different structure
regions/environments (Figure 4.5) and the reliability assessment of the MSAs per-
formed in Section 3.4.2, the overall results indicate that a more reliable characterisa-
tion of variants can be performed within FunFams. Additionally, there is a slightly
higher number of variants in the three classes mapped to FunFams when compared
to SCs (Table 4.1 and Figure 4.5). The remaining variation analysis performed
in this Chapter, as well as the analyses performed in Chapter 5, were therefore
performed in the context of CATH FunFam domain families.
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Figure 4.6: Log Odds Ratio (OR) scores obtained for the comparison of genetic
variants mapped to domain members of SCs and FunFams across different structural
environments. Genetic variants were grouped as germline variants (green), somatic
mutations (blue) and disease-associated variants (red). The error-bars provided
correspond to 95% C.I.
The comparison of the log OR between variation classes for FunFams (Figure
4.6), shows a strong enrichment of disease-associated variants at STAMP SCRs, at
the protein Core, Interfaces (domain-domain and domain-ligand), and β-sheet re-
gions (p-value < 1 × 10−5 ). This result is consistent with work reported by others,
which identified a strong correlation between disease-associated nsSNPs and solvent
inaccessible area and interacting interfaces (Wang and Moult, 2001; Burke et al.,
2007; Sunyaev et al., 2001; de Beer et al., 2013; David and Sternberg, 2015; David
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et al., 2012). The breakdown analysis of log OR scores in interaction interfaces shows
that disease-associated residues are comparatively enriched in interactions with do-
mains and ligands, when compared to domain-protein interactions. Germline and
somatic variants are differently distributed at all interface environments. Somatic
variants are less depleted at interfaces when compared to germline variants, which
potentially accounts for the fact that some somatic variants are driver mutations in
cancer (Gulati et al., 2013; Nishi et al., 2013; Alexandrov et al., 2013; Berliner et al.,
2014; Cancer Genome Atlas Research Network et al., 2013; Supek et al., 2014).
4.4.4 Analysis of genetic variation amino acid exchanges
Figure 4.7 highlights how ‘from’ and ‘to’ amino acid exchanges obtained for the
three variation classes compare to the frequency of each amino acid in the human
proteome. Overall, some differences are observed for the frequency of amino acid
mutations. Mutation ‘from’ Arg is significantly enriched (p-value < 0.001) for all
variation classes. Minor enrichment is also observed for Asp and Gly, for somatic and
disease-associated variants, respectively. Regarding mutation ‘to’, charged residues
Asp and Glu, as well as neutral Ala and Gly, are significantly depleted (p-value <
0.01), across all variation classes.
Figure 4.8 shows the frequency in which all of the ‘from’ and ‘to’ amino acid
exchanges are observed in the variation dataset. The overall trend in amino acid
exchange frequencies is similar when comparing different variation classes. Aromatic
amino acids (Phe, Tyr and Trp) are among the least mutated, whereas charged
residues (Arg, Asp and Glu) are among the most mutated residues.
For disease-associated variants, the most mutated residues are Arg, Leu and
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Figure 4.7: Comparison of the human proteome abundance of amino acids and
mutation frequencies for all classes of genetic variants. The frequency of the observed
mutations is provided for germline variants (green), somatic mutations in (blue), and
disease-associated variants (red). These frequencies were compared to the frequency
of each amino acid in the proteome (dark-grey line). Amino acids are arranged by
1-letter code according to decreasing abundance in the human proteome (de Beer
et al., 2013).
Gly. In fact, the biggest frequency difference for ‘from’ mutations is observed for
Gly which is found mutated more often in disease-associated variants (p-value <
0.01). This likely results from the fact that Gly is the smallest amino acid and
structurally dissimilar to larger aromatic and charged amino acids, adopting many
angle conformations inaccessible to other amino acids (Martin et al., 2002; Bradshaw
et al., 2011; David and Sternberg, 2015). The side chain of Gly is constituted by
a single hydrogen atom, which can adopt a much larger range of conformations
than other residues, providing structural flexibility that is lost upon mutation. Any
changes from this amino acid are likely to lead to important structural changes.
Cys and Arg are enriched for mutation in disease-associated variants. Ile and Val
are enriched for mutation in germline variants, whereas for somatic mutations both
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Figure 4.8: Amino acid exchanges observed for the three classes of genetic variants
mapped onto FunFams. Genetic variants were grouped as germline variants (green),
somatic mutations (blue) and disease-associated variants (red). Amino acids are
arranged by 1-letter code according to increasing hydrophobicity (least hydrophobic
is left and most hydrophobic is right) according to the Fauchère et al., 1988, scale.
acidic residues, Asp and Glu, are similarly enriched. Considering the nature of the
amino acids, disease-associated exchanges enrichment for Gly and Cys (p-value <
0.01) is in agreement with the fact that these amino acids are structurally dissimilar
and any changes from these are likely to lead to important structural changes. In
terms of amino acids whose exchanges are depleted, only Lys and Ala are marginally
less mutated (p-value > 0.05) for disease-associated variants. The depletion of Ala
in the disease-associated variants agrees with the fact that Ala is a neutral amino
acid in terms of its size and physicochemical properties.
For ‘to’ amino acid exchanges, some frequency differences can also be identified.
Among the most dramatic differences are the enrichment of mutations to Pro and
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Arg found for disease-associated variants (p-value < 0.01). Enrichment in mutations
that result in Val, Thr and Ser for germline variants, as well as mutation to Asn,
Lys and Leu, for somatic variants, are also observed (p-value < 0.05). The differ-
ence in the profiles obtained for the ‘to’ exchanges, between germline and somatic
variants, indicates that the mutational profile of somatic variants is different from
that of the neutral germline variants. Mutations to Met and Ile seem to be depleted
for disease-associated variants which are frequent for both germline and somatic
variants. Considering the nature of the amino acids, disease-associated exchanges
enrichment to Arg, Pro and Cys, are in line with the expected outcome of mutation
to these residues. Mutation to Arg is likely to affect the protein because of the in-
troduction of a large charged amino acid. Similarly, mutation to Pro is known to be
problematic since the introduction of Pro is likely to impose angle constraints to the
protein backbone chain conformation. Pro side-chain locks its backbone dihedral
angle, causing it to be exceptionally rigid conformationally. The introduction of a
Pro residue is known to have the potential to disrupt secondary structure elements
(Martin et al., 2002; Wang and Moult, 2001).
Figure 4.9 shows the breakdown of all amino acid exchanges observed in the
different genetic variation subsets. Each subplot shows the results of mutation from a
specific amino acid (e.g. Arg at top left) to every other amino acid. Interestingly, all
possible variant exchanges, in terms of codon changes, were found for all amino acids.
Among the more dramatic changes in the frequency of mutation are mutations from
Arg, Gln, Ser, Ala and Leu to Pro, found for disease-associated variants. Smaller
frequency differences are observed for the mutational profile of germline and somatic
variants, when compared to those from disease-associated variants.
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Figure 4.9: Comparison of the mutations frequencies for all classes of genetic variants. The frequency of observed mutations is
provided for germline variants (green), somatic mutations in (blue), and disease-associated variants (red). Each plot shows the results
of mutation from a specific amino acid (e.g. Arg at top left) to every other amino acid. Amino acids are arranged by 1-letter code
according to increasing hydrophobicity (least hydrophobic is left and most hydrophobic is right) according to the Fauchère et al., 1988,
scale.
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Amino acid exchanges from Tyr to Cys and from Cys to Tyr are common among
germline and somatic variants, while entirely depleted for disease-associated variants
(Figure 4.9). These results are in agreement with those obtained for the analysis of
germline variants in the 1kGP (The 1000 Genomes Project Consortium, 2012), and
disease-associated variants from OMIM (Amberger et al., 2015), which are both a
part of the variant datasets studied here, as performed by de Beer et al., 2013.
In order to obtain a summary view of the entire mutational space and to calculate
the rate of exchange for genetic variants in the three variant classes, log-odds mu-
tability matrices were generated by calculating the log-odds scores of the observed
mutation frequencies divided by the expected mutation frequencies (Equation 4.2).
Figure 4.10 shows the log-odds mutability matrices for all amino exchanges in the
three variation classes, as well as difference matrices which highlight the differences
between the variation datasets. Unlike other substitution matrices such as BLO-
SUM62 (Henikoff and Henikoff, 1992), which assume that the mutation direction is
unknown and produce symmetric matrices, here the depth of the variation data al-
lows matrices to be generated with embedded directionality. The relevance of these
matrices is three-fold: 1) they capture the rate and exchangeability of missense
variants, cancer mutations and disease-associated mutations separately; 2) which
can be used to model the probability of fixation of different mutation classes in
protein evolution; 3) as well as to aid the prediction of the effects of amino acid
exchanges. The analysis of the extreme differences observed for the mutation ma-
trices of germline, somatic and disease-associated variants, highlights the differences
observed and discussed previously (Figure 4.10 D-F).
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Figure 4.10: Log-odds mutability matrices for amino acid exchanges observed for
the three genetic variation classes. Exchange matrices are provided for: A) germline
variants; B) somatic variants; C) and disease-associated variants. The compari-
son (difference) matrices are provided for: D) germline and somatic variants; E)
germline and disease-associated variants; and F) somatic and disease-associated
variants. Amino acids are arranged by 1-letter code according to increasing hy-
drophobicity (least hydrophobic is left/top and most hydrophobic is right/bottom)
according to the Fauchère et al., 1988, scale.
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4.4.5 Analysis of genetic variation exchanges according to
physicochemical properties
In order to further investigate the amino acid exchanges observed within the vari-
ation dataset, amino acids were grouped according to their physicochemical prop-
erties. Two single state alphabets, ‘Chemical A’ and ‘Chemical B’, which organise
each amino acid according to their unique physicochemical properties, were investi-
gated. Figure 4.11 shows the frequency in which all of the ‘from’ and ‘to’ physic-
ochemical group exchanges are observed in the variation dataset. The analysis of
exchanges for both physicochemical alphabets reveals that only minor frequency dif-
ferences (not significant) are observed for variants in different variation classes. In
agreement with the amino acid exchange profiles (Figure 4.9), Gly and Pro seem to
be enriched for mutation in disease-associated variants. There is also a small enrich-
ment of mutations occurring at hydrophobic and acidic residues (p-value < 0.05),
for germline and somatic variants, respectively. A minor enrichment of mutation
to hydroxy-group containing residues (Ser and Thr) is also observed for germline
variants (p-value > 0.05).
Figure 4.12 shows the breakdown distribution of physicochemical changes in-
troduced by genetic variants according to the two alphabets defined. Regarding
Chemical A, the most dramatic transition is observed for exchanges between hy-
drophobic residues and Pro for disease-associated variants. Smaller changes in the
frequency of exchanges between acidic residues and both hydrophobic and basic
residues are also observed for somatic variants (Figure 4.12 A). Since these residues
are often involved in interaction, this might affect the propensity to interact and
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Figure 4.11: Physicochemical exchanges observed for the three classes of genetic
variants. Genetic variants were grouped as germline variants (green), somatic mu-
tations (blue) and disease-associated variants (red). Amino acids were grouped into
two alphabets: A) ‘Chemical A’ and B) ‘Chemical B’.
lead to changes in binding partners with regulatory implications. The analysis of
physicochemical transitions shown for the Chemical B alphabet indicates that mu-
tation of aliphatic residues such as Leu, Ala, and Val, to either acidic and basic
residues, are enriched for disease-associated variants. This is expected since the in-
troduction of charged groups is likely to affect intermolecular interactions between
amino acids. Interestingly, mutation of residues containing sulphur (Met and Cys)
also show some enrichment (p-value < 0.05) in exchanges to basic and aromatic
residues, for disease-associated variants (Figure 4.12 B). Cys often participates in
disulphide bonds which are disrupted when these residues are mutated.
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Figure 4.12: Comparison of the physicochemical exchange frequencies for all classes of genetic variants. Genetic variants were
grouped as germline variants (green), somatic mutations (blue) and disease-associated variants (red). Amino acids were grouped into
two alphabets: A) ‘Chemical A’ and B) ‘Chemical B’.
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The biggest frequency differences observed between somatic variants and germline
variants are observed for exchanges from Met and Cys residues (sulphur group) to
chemically complex aliphatic residues, as well as for exchanges from hydroxy-group
containing residues (Ser and Thr) to aromatic residues (Figure 4.12). Mutation from
Ser and Thr is likely to have consequences, especially since these residues are often
post-translationally modified (e.g. phosphorylation and O-linked glycosylation).
Figure 4.13 explores the overall variant transitions in terms of amino acid prop-
erties including: residue’s atomic mass (Knapp, 1996); average volume (Zamyatnin,
1972); and hydrophobicity (Fauchère et al., 1988). The differences between the stan-
dard amino acid values for mass, volume and hydrophobicity for the ‘from’ and ‘to’
amino acids were calculated and plotted as the density of differences. The compar-
ison of the hydrophobicity exchange profiles obtained for the three variant classes
reveals that, for disease-associated variants, transitions are spread slightly more
widely, to the extremes of the scale. This means that disease-associated transitions
lead to bigger changes in hydrophobicity. Only minor differences are observed be-
tween the profiles of germline and somatic variants. Nevertheless, germline variant
transitions are likely result more frequently in hydrophobic-equivalent amino acids.
A similar trend is observed for the amino acid transition profiles which are related
to amino acid size (atomic mass and average volume). Germline variants and so-
matic variants are often mutated to identically sized amino acids when compared to
disease-associated variants, which lead to more extreme amino acid size exchanges.
In agreement with previous observations (de Beer et al., 2013), these results indicate
that drastic amino acid transitions are likely to disrupt stability/activity of proteins
and lead to disease states (Miller and Kumar, 2001; Tang et al., 2004; Stone and
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Sidow, 2005; Khan and Vihinen, 2007; Briscoe et al., 2004).
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Figure 4.13: Genetic variation transitions in terms of amino acid hydrophobicity,
volume, and atomic mass. Amino acid transitions were calculated as the differ-
ence between the property (i.e. hydrophobicity, volume or mass) value of the orig-
inal (mutated) amino acid and that of the resulting amino acid. Genetic variants
were grouped as germline variants (green), somatic mutations (blue) and disease-
associated variants (red)
4.4.6 Analysis of conservation
Various methods to measure conservation in MSAs have been developed (Valdar,
2002; Johansson and Toh, 2010). Some of these methods take evolution models and
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residue background distribution into account, but often result in complicated inter-
pretation of the conservation scores. Here a simple measure of conservation was used
to compare the degree of conservation among MSA positions (columns) to which ge-
netic variation could be mapped (Figure 4.1). Shannon’s Entropy (H) is one of the
simplest conservation measures, that only takes into account the amino acid fre-
quencies in the MSA columns (Shannon, 1948). Figure 4.14 shows the distribution
of Shannon’s entropy conservation scores across the three different classes of vari-
ation. Previous work has shown that disease-associated variants are often located
within conserved regions of proteins (Hu et al., 2000; Guharoy and Chakrabarti,
2010; Fiser et al., 1996). Interfaces have been shown to be more conserved than
the rest of the surface (Nooren and Thornton, 2003b; Bordner and Abagyan, 2005).
In agreement, there is a substantial proportion of disease-associated variants that
are found in highly conserved regions (low H score). In fact, both germline and
somatic variants follow the same trend of being located in conserved positions of the
alignment for FunFam domain families.
All genetic transitions in the variation dataset were investigated within the full
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Figure 4.14: Distribution of Shannon’s entropy conservation scores obtained from
the alignment columns to which genetic variants could be mapped. Genetic variants
were grouped as germline variants (green), somatic mutations (blue) and disease-
associated variants (red).
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MSAs to assess whether the amino acids resulting from mutation ‘to’ are already
found in the aligned positions. Table 4.5 shows the number of variant exchanges
present in the alignment column where they map to. Interestingly, although 31% of
the resulting germline and somatic variant amino acids are observed in the alignment
column to which the variant in analysis is mapped to, this number drops to 24%
for disease-associated variants. This decrease is expected since disease-variants are
preferentially found in conserved positions (Figure 4.6). This result is in agreement
with the observation that mutation of conserved positions is likely to affect protein
function. Interestingly, the disease-associated variants which are observed might
result from misalignment of the structures/sequences, but most likely from particular
features of the domain for which the disease variant is observed and that confer
functional uniqueness. These include unique domain or ligand interaction partners
as well as unique structural/functional features that might be disrupted in this
particular family domain member. Additionally, an event such as the co-evolution
of interface residues in homologous proteins is also a possibility (Halperin et al.,
2006; Marks et al., 2012; Pazos and Valencia, 2008).
Table 4.5: Summary of the number of variant exchanges for which the resulting
amino acid is already present in the aligned position in the MSA.
Class of variants Observed exchange Total variants
All variants 42,243 (0.31) 137,060
Germline variants 27,273 (0.31) 87,268
Somatic variants 12,976 (0.31) 41,505
Disease variants 1,994 (0.24) 8,287
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4.4.7 Predicting the consequences of genetic variation
Prediction scores from Polyphen-2 (Adzhubei et al., 2010) and SIFT (Kumar et al.,
2009) were collected for each variant. Polyphen-2 predicts the effect of an amino
acid substitution on the structure and function of a protein using sequence homology,
Pfam (Finn et al., 2014a) annotations, protein structures, secondary structure states,
and several other databases and tools. The Polyphen score represents the probability
that a substitution is damaging, so prediction scores (P ) values nearer one are
more confidently predicted to be deleterious. SIFT predicts whether an amino acid
substitution is likely to affect protein function based on sequence homology and the
physicochemical similarity between the alternating amino acids. The SIFT score is
the normalised probability that the amino acid change is tolerated so that scores
nearer 0 are more likely to be deleterious (note that this is the opposite to Polyphen-
2). Categorical classification states are derived from P resulting in three states for
Polyphen-2: benign, possibly-damaging, and probably-damaging; as well as two
states for SIFT: benign and tolerated. SIFT and Polyphen2 were chosen because
prediction scores were provided by the Ensembl and UniProt Variant APIs.
Figure 4.15 shows the distribution of Polyphen-2 and SIFT categorical states
observed across the three variant classes. The distribution of Polyphen-2 scores
indicates that there is a high number of germline and somatic variants classified as
deleterious. Interestingly, according to the Polyphen-2 categorical states, a higher
proportion (68%) of disease-associated variants is classified as probably-damaging,
when compared to germline and somatic variants. This result is expected since
the methods have been trained to classify variants by considering physicochemical
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Figure 4.15: Bar-plot showing the categorical SIFT and Polyphen-2 predictions
observed across the three variation classes. Bar-plot showing the: A) Polyphen-2
(Adzhubei et al., 2010), and B) SIFT (Kumar et al., 2009) categorical transitions
observed across the classes of variants. Qualitative categorical prediction states
are defined from the prediction scores (P ) provided by SIFT as: deleterious (P ≤
0.05); or tolerated (P > 0.05). Similarly, categorical states generated for Polyphen-2
(HumVar) are classified as: benign (P < 0.446); probably damaging (0.446 ≤ P <
0.909); or possibly damaging (P ≥ 0.909).
transitions and conservation. Besides, some of the disease-associated variants might
be included in the training sets used to train Polyphen-2. Germline and somatic
variants are enriched within benign classification states from Polyphen-2 (44% and
33%, respectively). Figure 4.16 shows the distribution of Polyphen-2 and SIFT
prediction scores across the different genetic variation classes. In agreement with the
distribution of Polyphen-2 scores observed, an overall lower proportion of variants
across the three classes is classified as possibly-damaging (16-17%) (Figure 4.15).
The profiles obtained for Polyphen-2 indicate that the method is biased towards the
extreme scores, where a variant is either classified as benign or probably-damaging.
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SIFT categorical classification seems to be in agreement with Polyphen-2 predic-
tions, classifying 83% of disease-associated variants as deleterious. Since SIFT also
predicts a high proportion of germline and somatic variants to be deleterious (38%
and 50%, respectively), it is likely that the number of false positive predictions is
high and biased towards predicting deleterious (low P ) mutations (Figure 4.16).
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Figure 4.16: Distribution of Polyphen-2 and SIFT prediction scores for genetic
variants stratified by variation class. Genetic variants were grouped as germline
variants (green), somatic mutations (blue) and disease-associated variants (red).
4.5 Conclusions
This Chapter focused on the overall analysis of genetic variants in protein families
and in the context of various structural environments. The approach of characteris-
ing in depth the variants across different environments by type of substitutions and
annotation is important as it enables finding transitions that might be implicated
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in disease, and that can potentially affect protein stability, activity and function.
The global trends identified are also important for selecting priority variants and
protein families for further analysis. Analysis of the genetic variation that maps
onto domain-domain and domain-ligand interaction interfaces is further explored in
Chapter 5.
The main conclusions of the work presented here are:
• Genetic variants were obtained from multiple sources and organised according
to their annotations.
• A large number of genetic variants were mapped to protein domains in SCs
and FunFams.
• 64% of the variants analysed are germline variants, which are thought to be
neutral, but may contain variants unknown to cause disease.
• 30% of the variants were identified in cancer samples and were annotated as
somatic variants.
• 6% of the variants are organised in OMIM, Humsavar and ClinVar, and have
been annotated as disease-associated.
• Only between 3-6% of frameshift, stop-lost and stop-gained variants are anno-
tated as disease-associated.
• Domain-domain interaction interfaces account for 63-67% of all interactions.
• 15% of interface residues participate in domain-ligand interactions.
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• There is a positive correlation between the number of residues that compose
different structural environments/regions and the number of genetic variants
mapped to those regions.
• The bigger differences in the odds ratio are observed for disease-associated
variants that map onto the protein core, surface and interface regions, when
compared to neutral and somatic variants.
• Disease-associated variants are enriched on domain-domain and domain-ligand
interaction interfaces, as well as in STAMP structurally conserved regions, for
FunFam domain families.
• A slight enrichment of disease-associated variants is also observed within β-
sheets.
• Mutability matrices were generated for all amino acid exchanges in the variant
classes.
• Amino acid exchanges were analysed according to physicochemical properties.
• The more drastic physicochemical transitions are observed for mutation from
and to Gly and Pro residues.
• The extremer size and hydrophobicity amino acid transitions are observed for
disease-associated variants.
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Chapter 5
Exploring variation at domain
interfaces
5.1 Summary
This Chapter focuses on the analysis of genetic variants at interfaces. To identify sig-
nificant genetic variation trend differences, variants at the interfaces were compared
to variants mapped to other structural environments/regions. Variant analysis was
performed at structurally conserved interface positions in the context of CATH Fun-
Fams. Analysis of domain-domain interactions by interface orientation type was also
performed. The overall variation analysis follows the same general trends observed
when investigating genetic variants across all domain sites. The comparison of the
variation profiles in terms of amino acid exchanges and physicochemical properties
obtained for different classes of variants was performed. The most important fea-
tures were identified to help prioritise the analysis of the potential consequences of
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variants. In particular, trends observed for disease-associated variants at the inter-
faces and across all structure environments were used to help investigate unclassified
variants thought to be neutral. A set of protein families and domains were selected
and further investigated regarding their potential effects and involvement in dis-
ease. The mechanisms in which neutral germline and somatic variants mapped to
these domain interfaces might lead to stability/activity functional disruption were
investigated.
5.2 Introduction
Proteins have evolved in a way that fine-tunes interactions, forming specific molec-
ular complexes and participating in concerted interaction networks (Russell et al.,
2004; Codoñer and Fares, 2008; Pazos and Valencia, 2008). Disruption of protein
interactions as the result of genetic variation at the single amino acid level prompts
immediate functional consequences, which may result in disease. Understanding
how genetic differences affect protein-protein and protein-ligand interactions is es-
sential to understand their effects in susceptibility to particular diseases and drug
response (Giacomini et al., 2007; Lahti et al., 2012; Ma and Lu, 2011).
Park et al., 2001, found that there is a difference between domain-domain in-
teractions that occur between two domains on the same polypeptide chain (intra-
molecular interactions) and those seen between domains on different chains (inter-
molecular), the main difference being functional. Proteins encoded on separate
genes tend to be involved in modulating the flow through a metabolic pathway as
they can be independently regulated. However, domains that are part of the same
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enzyme, oligomer or protein tended to be involved in intra-molecular interactions
as co-regulation and co-expression are necessary. The small percentage of domains
(∼20% of the overall domain interactions observed) which were seen to interact in
both an intra-molecular and inter-molecular manner were mainly domains of en-
zymes involved in small-molecule or macromolecular metabolism.
The geometry of domain combinations, specifically the order in which domain
combinations occur in nature was investigated by Bashton and Chothia, 2002. They
found that if domains from Superfamily A and Superfamily B were observed fused
together on a single protein chain, then they could either occur in either order, e.g.
AB or BA. However, only 2% of the time did both variations occur leading them to
conclude that domain order is likely to be conserved because recombination of the
domains has only occurred once during evolution.
Littler and Hubbard, 2005, investigated the promiscuity of intra-chain domain-
domain interactions, focusing on the surface area used to form these interactions, and
the relative orientations of their domain partners. The authors found that different
Superfamilies show a range of promiscuity using either the same interacting surface
region or by utilising several areas of their accessible surface and that interactions
between two Superfamilies tended to be in the same orientation. They also found
that domain interfaces are more conserved in sequence than the rest of the accessible
surface of the protein domain.
5.2.1 Genetic variation at interaction interfaces
Protein-protein interactions have been combined with SNP datasets in various stud-
ies to predict the effects of mutations on protein-protein interactions and to identify
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novel disease genes and correlations between diseases. Many studies on variation
at interfaces have focused on the features of interaction networks rather than the
structural effects of variation. Jonsson and Bates, 2006, investigated the network
features of genes using a human cancer genes dataset from COSMIC (Forbes et al.,
2015) and interactome data. Cancer proteins tended to have twice as many inter-
action partners as non-cancer proteins. In addition, the authors also found that
cancer-related proteins tend to reside in large clusters, unlike non-cancerous pro-
teins. Later, Nishi et al., 2013, showed that cancer-associated missense mutations
alter binding properties of proteins ultimately affecting their interaction networks
(Nishi et al., 2013). Accordingly, genes with mutations directly affecting protein-
binding properties are preferentially located in central network positions, which may
influence critical nodes and edges in signal transduction networks.
Goh and Choi, 2012, created a network of disease-to-gene associations, where
each genetic disease is connected to the genes known to cause it, using the OMIM
database. The disease-associated genes were shown to have high tendencies to in-
teract with one another, and they were often co-expressed. In addition, the au-
thors found that the disease-associated genes often have a similar classification in
all three domains (the biological process, the molecular function, and the cellular
components) regarding their GO term annotation (Harris et al., 2004). However,
the study found evidence for links between high numbers of protein-protein inter-
actions and disease-associated genes. Schuster-Böckler and Bateman, 2008, used a
combination of SNPs, interactome and structural data to create a method for im-
proving the identification of disease genes. Using the structural interactome data
from iPfam (Finn et al., 2014b), Schuster-Böckler and Bateman identified residues
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that made contacts between distinct polypeptide chains. The authors developed
an algorithm based on conservation score and the OMIM dataset to identify which
residues had disease-causing effects. From 264 proteins, 1,428 SNPs were predicted
to affect protein-protein interactions.
Teng et al., 2009, used dbSNP, BLAST (Altschul et al., 1990) and the MMDB
(Madej et al., 2014) to construct 3D models of protein-protein complexes with known
nsSNPs in their interfaces. They argued that any mutation that occurs at the
protein interface could affect the binding affinity by perturbing a normal interaction.
The CHARMM program was used to examine if the binding energy of the PPIs
was affected by the substitution. The nsSNPs were grouped into categories based
on how they affected the energetics of PPIs. According to Teng et al., 2009, the
physicochemical properties of nsSNPs alone were not enough to predict their effect
on PPIs, because changes in physicochemical properties had minimal effects on
binding energy. Similarly, substitutions at non-conserved regions resulted in minimal
effects on binding affinity compared to those in highly conserved regions.
A recent report suggested that protein-protein interaction sites are hot-spots
for disease-associated variants (David et al., 2012). By sub-grouping variants into
neutral and pathogenic classes and performing enrichment analysis, the authors
showed that disease-causing nsSNPs that do not occur in the protein core are more
likely to be located at the interface region rather than on the surface non-interface
region. The enrichment analysis also showed that there were more neutral nsSNPs
at the interface region than the buried region or the surface non-interface region
of the protein structures. Further analysis of the neutral nsSNPs revealed that the
majority of them came from cancerous samples. Later, David and Sternberg, 2015,
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further characterised interface residues as ‘core’ and ‘rim’. The authors argued that
within interfaces, only a small subset of residues (hot-spots) is critical for the binding
free energy of the protein-protein complex. They demonstrated that disease-causing
mutations are preferentially located within the interface core, as opposed to the rim.
In contrast, the interface rim was significantly enriched in neutral nsSNPs, similar
to the remaining non-interacting surface. Additionally, David and Sternberg, 2015,
found that energetic hot-spots tend to be enriched in disease-causing mutations,
regardless of their occurrence in core or rim residues.
5.3 Methods
5.3.1 Analysis of CATH domain interactions
Protein domain interactions were analysed in the context of the CATH hierarchy
for SCs and FunFams. Domain-domain interaction interfaces were defined as de-
scribed in Section 2.3.5. In order to be able to analyse domain-domain interactions
by interface type (or orientation) and within the structural perspective of the CATH
hierarchy, the next sub-section describes the implementation of the iRMSD (inter-
action Root Mean Squared Deviation) method (Aloy et al., 2003; Jefferson et al.,
2007b).
5.3.2 Analysis of domain-domain interactions by iRMSD
In order to classify interactions by their interaction interface, the relative orientation
of the interacting pair was determined using the iRMSD method developed by Aloy
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et al., 2003, and further developed by Jefferson et al., 2007b. This method deter-
mines if a pair of interacting domains bind in a similar orientation as another pair
of interacting domains and thus if they are interacting using the same interfaces.
The iRMSD method uses the sequence alignments generated by STAMP (described
in Section 2.3.9), to match equivalent positions from each separate partner of the
interaction pairs to determine the transformation of one structure to another.
As illustrated in Figure 2.3, comparing one pair of interacting domains AB to
another pair A′B′, the transform of A′ on to A and B′ on to B is calculated by
structure superimposition. The transform of A′ to A is then used to transform A′
to A and B′ to B. Then for each domain of each pair, 7 representative coordinates
are selected using the centre of gravity (centre of mass) as the middle point and
then ±5 Å in each axis from the centre of gravity to generate 6 further points. The
RMSD of the seven representative points of A′ (7A′) on to the 7 points of A (7A)
and 7B′ onto 7B is then calculated. The transform of B′ on to B is then also used to
transform A′ on to A and the RMSDs of 7A′ on to 7A and 7B′ onto 7B calculated.
The iRMSD for the A transform is the highest RMSD of the 7A′ to 7A and 7B′ to
7B using the A transform. The iRMSD for the B transform is the highest RMSD of
the 7A′ to 7A and 7B′ to 7B using the B transform. The overall iRMSD is the lowest
of the iRMSD using the A transform or the iRMSD using the B transform. In this
work, the iRMSD method was modified so that the centre of gravity is determined
based on the domain residues classified as structurally equivalent by STAMP (as
defined in Section 3.3.1).
Aloy et al., 2003, suggested that interacting pairs with an iRMSD ≤5 Å should be
considered similar whereas an iRMSD value as high as 5-10 Å could indicate similar
158
5. Exploring variation at domain interfaces 5.3. Methods
Superposition based on 
reference domain A /domain B
A
B
Calculate domain’s center 
of mass and iRMSD
Clustering by interface 
(iRMSD < 5Å) 
Similar orientation 
(low iRMSD) Different orientation
(high iRMSD)
B
A
A B
A’
B’
A’
B’
CATH domain-domain pairs (e.g. SPF:SCG 1.10.135.10:2)
1QK1 chain A-G and
1QK1 chain D-E
1QK1 chain A-G and 
1U6R  chain A-B
Cluster 1 Cluster 2 Cluster 3
Figure 5.1: Schematic overview of the method for analysis of CATH domain-
domain interactions by orientation. Domain-domain interactions are clustered by
orientation based on a protocol that computes interaction RMSD (iRMSD) scores for
related interacting domain-domain pairs. The example shown in the highlighted box
illustrates the iRMSD analysis of inter-chain domain-domain pairs for PDB 1QK1
chain A-G (in green and blue) compared to PDB 1QK1 chain D-E and PDB 1U6R
chain A-B (in light blue and light green), all belonging to CATH SPF 1.10.135.10
SC 2.
positioning of domains but with a rotation of one domain relative to another. In this
work, the definition of a similar interaction is that two pairs of interacting domains
are interacting with an iRMSD of <5 Å. Structure clustering based on the iRMSD
score was performed by OC (Barton, G. J. University of Dundee, UK, 2004) using
complete linkage. Percentage sequence identity (PID) was calculated according to
the Doolittle method (Doolittle, 1981; Raghava and Barton, 2006), where PID =
(identical positions / (aligned positions + internal gaps)), and ranges from 0 to 100.
159
5. Exploring variation at domain interfaces 5.3. Methods
5.3.3 Domain-domain contact propensities
Domain-domain interaction propensities were calculated based on a modified method
by Glaser et al., 2001. The contact propensity for an interacting pair of residues i
and j is given by:
CPij = ε+
(
1
λ
)
log
(
Qij
(Wi/Ai)(Wj/Aj)
)
(5.1)
where Wi =
Fi
Nr
corresponds to the normalised frequency of residue i. Fi is the
number of residues i that have at least one contact with any residue across the
interaction interface in the total number of interacting residues Nr. Similarly, the
normalised frequency of contacts is Qij =
Cij
Nc
, where Cij is the number of contacts
between residues i and j in the total number of observed contacts Nc. The expected
number of contacts between residue i and j, is the value that would have been
obtained if there were no preferences between residues of different types, i.e. Wi x
Wj. This method was modified to account for the abundance of the amino acids
in the human proteome by normalising the expected frequency of residue i (Wi)
with the background abundance of residue Ai. Background relative amino acid
frequencies for the human proteome were obtained from de Beer et al., 2013, and
are summarised in Table 2.5. Arbitrary scaling factors ε = −1.5 and λ = 2 were set
such that the matrix contains easily comparable values.
As an illustrative example, the contact propensity for the interaction of Arg (i)
and Glu (j) is obtained when considering: Fi = 73,490, Fj = 49,325 and Nr =
520,765, Cij = 11,431 and Nc = Nr/2 = 260,383, which results in Wi = 0.025, Wj =
0.013 and Qij = 0.044. Wi is divided by 5.63%, which corresponds to the abundance
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of Arg (Ai). Likewise, Wj is divided by 7.13% (Aj). The final contact propensity
CPij = 0.94 (Figure 5.5) is obtained by applying Equation 5.1.
5.3.4 Domain-domain intermolecular bonding
Protein interactions were defined as described in Section 2.3.5. The types of inter-
molecular interactions analysed in this work include: hydrogen bonds; disulphide
bonds; salt-bridges; aromatic-aromatic bonds; and non-covalent Van der Waals (hy-
drophobic) contacts. Intermolecular interaction types were calculated as defined in
Section 2.3.5. Table 5.1 overviews which residue types participate in the various in-
termolecular bonds, noting that some only participate as donors or acceptors in the
bounding. It is important to notice that the various interaction types defined were
only probed on the basis of both residue-residue distance and residue-pairings (i.e.
based on the identification of known residue/molecular-group acceptors and donors).
The results of the analysis of domain-domain intermolecular interactions therefore
used atomic distance and residue-pairing as proxies for intermolecular bonding clas-
sification.
5.3.5 Characterising genetic variants at domain interfaces
Genetic variants collected and organised in ProIntVar were separated into three main
classes: germline variants; somatic variants; and disease-associated. Section 2.3.13
overviews the source and set of annotations collected for each variant. As described
in Section 2.3.3 and Section 2.3.12, genetic variants were mapped to protein 3D
structure, and domains were investigated in the context of functional families (Fun-
Fams) in CATH (Sillitoe et al., 2015). The analysis of genetic variants performed
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Table 5.1: Summary of amino acid residues that participate in intermolecular
interactions.
Bonding type Contacting residues
Van der Waalsa Gly, Ala, Val, Leu, Ile, Pro, Phe, Tyr, Trp
Hydrogen bondsb
Arg, Asn, Asp, Cys, Gln, Glu, His, Lys, Met, Set, Thr,
Trp, Tyr
Salt-bridgec Asp, Glu, Lys, Arg, His
Aromatic-aromaticd Phe, Tyr, Trp
Disulphide bondse Cys
Intermolecular interaction types were calculated as defined in: aVan der
Waals/Hydrophobic (Voet and Voet, 2010); bHydrogen bonds (McDonald and
Thornton, 1994); cSalt-bridges (ionic interactions) (Kumar and Nussinov, 2002);
dAromatic-aromatic (Burley and Petsko, 1985); and eDisulphide bonds (Schmidt
et al., 2006).
in this Chapter focused on the subset of human missense variants described in Sec-
tion 4.4.1 that map to STAMP-defined structurally conserved interaction interface
residues (Section 2.3.7 and Section 4.3.2). Interaction interfaces were defined as:
interaction with domains (Inter. Domain), interaction with ligands (Inter. Ligand,
ligand definition is provided in Section 2.3.5), and interaction with other protein
residues which are not part of CATH domains (Inter. Protein). The process of
analysis of multiple genetic variants and interface residues, which mapped onto the
same aligned positions (columns in the MSA), was performed as described in Section
4.3.2. Analyses of variation exchanges for amino acids and their physicochemical
properties were performed as described in Section 4.3.4.
The terminology used to report nsSNPs is as follows: Cys34Phe represents an
exchange from Cys residue in position 34 to Phe; Cys241* represents a mutation of
Cys 241 to a stop codon (stop-gained mutation); and His661fs represents a frameshift
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(fs) mutation, where His in position 661 is mutated in a way that leads to a change
in the reading frame and the resulting translated product.
5.4 Results and discussion
5.4.1 Domain-domain interactions
The iRMSD measure is a useful solution to compare interacting domain pairs as
it is independent of the size of the domains or interaction surface (Figure 5.1).
The iRMSD method is also a purely geometric measure of interaction similarity.
This is a useful property when the pair of interactions being compared are only
remote homologs where equivalent residues can be difficult to define. In addition,
an alternative measure, such as interface overlap, would not capture variations such
as domain rotations and would not measure different degrees of identity. A potential
problem with the iRMSD method for classifying interactions is that just because two
pairs of domains are interacting at the same orientation does not necessarily mean
that the interaction sites are the same.
Following the CATH hierarchy for SC and FunFam families under the Superfam-
ily level (SPF), domain-domain interaction types can be classified as hetero-SPF or
homo-SPF, based on the whether the two domains are grouped in different or the
same CATH SPFs. Similarly, domain-domain interaction pairs can be classified
as Hetero-SC/FunFam or Homo-SC/FunFam, for when the domains are grouped
under the same or different families (SCs or FunFams in this case). Because SCs
and FunFams are a family grouping that is defined under the Superfamily level in
the CATH hierarchy, Hetero-SC/FunFam domain-domain pairs can arise from both
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Hetero-SPF or Homo-SPF interaction types.
According to the CATH domain definitions and hierarchy, the structural dataset
contains 90,132 unique domain-domain interaction pairs. Domain-domain interac-
tions can be analysed by the context where the interaction occurs as: intra-chain,
inter-chain or ‘fusion’; if the domains are found in the same protein chain, in separate
chains, or a mixture of both, respectively. Domain interactions were analysed for
the CATH levels of SC and FunFam separately. As described in Section 2.3.5, two
domains are considered to be interacting according to the distance between residues
and if there are ≥10 interacting residue pairs between the domains. Results on the
unique domain-domain interaction types are summarised in Table 5.2.
Domain-domain interactions were further classified by orientation based on an
improved interaction RMSD (iRMSD) method (Aloy et al., 2003; Jefferson et al.,
2007b). The iRMSD protocol requires at least two domain-domain entries of the
same domain-domain interaction type (each domain belonging to a particular SPF-
SC/FunFam), because a single entry would result in no possible comparisons. A
minimum of two entries results in only one possible interaction iRMSD cluster (or
interaction orientation). Since the iRMSD protocol relies on the multiple structure
alignment of the involved domains, SCs and FunFams containing a single domain
member were not considered. The domain-domain interaction analysis was per-
formed for the three main types of interaction: inter-chain, intra-chain and fusion
as shown in Table 5.2.
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Table 5.2: Overview of CATH domain-domain interaction analysis by iRMSD. Re-
sults are shown for both structural clusters (SCs) and functional families (FunFams).
The number of unique domain-domain interaction types for inter-chain, intra-chain
and fusion, as well as comparing the CATH hierarchy classification (for Superfamily
and SC/FunFam) of each domain-domain pair is shown.
SC domain-domain types Inter-chain Intra-chain Fusion
All 1,837 1,029 2,604
Homo-SPF 826 140 905
Hetero-SPF 372 594 873
Homo-SC 795 52 808
Hetero-SC 403 682 970
Hetero-SC (Homo-SPF) 31 88 97
Hetero-SC (Hetero-SPF) 372 594 873
SPF-SPF 893 585 1,331
SC-SC 1,198 734 1,778
FunFam domain-domain types Inter-chain Intra-chain Fusion
All 3,345 1,778 4,748
Homo-SPF 1,338 300 1,583
Hetero-SPF 522 992 1,373
Homo-FunFam 1,201 13 1,208
Hetero-FunFam 659 1,279 1,748
Hetero-FunFam (Homo-SPF) 137 287 375
Hetero-FunFam (Hetero-SPF) 522 992 1,373
SPF-SPF 892 594 1,335
FunFam-FunFam 1,860 1,292 2,956
5.4.2 Classifying domain-domain interactions by orientation
The next step in the analysis of domain-domain interactions is the classification of
the type of interaction by orientation with the iRMSD clustering protocol. Domain-
domain interaction pairs were compared all-against-all where the domain-domain
interaction was of the same type (i.e. both interacting domain sets sharing the
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same CATH classification) and an iRMSD score computed for each pair. Complete
linkage hierarchical clustering based on the iRMSD score was then performed using
an inclusion threshold of ≤5 Å.
The distribution of the number of clusters (or modes of interaction) resulting
from the domain-domain classification by iRMSD is shown in Figure 5.2. The trend
in the distribution of the number of clusters is similar for SCs and FunFams. Never-
theless, the overall number of clusters inclusion is lower for FunFams when compared
to SCs. The difference between FunFams and SCs results from the fact that although
the total number of CATH FunFams is higher than that of SCs, the number of do-
mains per FunFam group is lower than the observed for SCs. In this way, more
structural diversity is expected for SCs. The number of clusters is lower for intra-
chain domain-domain interaction types when compared with both inter-chain and
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Figure 5.2: Box-plots showing the distribution of the number of iRMSD clusters
for SCs and FunFams. The iRMSD scores were obtained for both SC and FunFam
groups under Superfamily level in CATH, and the various domain-domain interac-
tion types: inter-chain, intra-chain and fusion.
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fusion interaction modes, for both SCs and FunFams. This result is in agreement
with the observation that multi-domain proteins share a more structural constrained
fold/topology (Bhaskara and Srinivasan, 2011; Vogel et al., 2004).
Figure 5.3 shows the relationship between iRMSD score and protein sequence
identity (PID), as originally plotted by Aloy et al., 2003. The original analysis
was performed using a much smaller and non-redundant set of interacting protein
domains up to the Fold level as classified in SCOP (Lo Conte et al., 2000), where only
the best iRMSD scoring domain-domain entry for each domain-domain interaction
type was plotted. In contrast, here the iRMSD classification was performed for
SCs and FunFams under Superfamily level in CATH, which groups together very
structurally similar domains, thus an inherently high level of sequence redundancy
was kept. Although not fully comparable, the results shown here seem to be in overall
agreement with the original study. Interestingly, as suggested by the high density of
points on the right-hand side of the plots (Figure 5.3 A and B), a higher number of
domain-domain pairs interact using distinct interfaces, although sharing a high PID.
There are also some differences in the SCs and FunFams profiles, which result from
the different domain composition observed for these two CATH Superfamily sub-
groups. An additional aspect expected to introduce some confounding interference is
related to the way in which PID is calculated (Raghava and Barton, 2006). Aloy and
colleagues calculated PID as the number of identical residues divided by the number
of structurally equivalent residues, whereas here the Doolittle method (Doolittle,
1981), which also considers internal gap positions, was used. PID ranges from 1.8%
to 100% with the mean PID being 63%.
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Figure 5.3: Scatter plot showing the correlation between interaction RMSD
(iRMSD) versus percentage sequence identity (PID). The iRMSD PID scores were
obtained for both: A) structural clusters (SCs) and B) functional families (Fun-
Fams) under Superfamily level in CATH. Accompanying histograms highlighting
the binned counts per PID and iRMSD are also shown.
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5.4.3 Mapping genetic variants to conserved sites at the in-
terfaces
Initial analysis of genetic variants mapped to protein domain interfaces was per-
formed in Chapter 4. In order to extend the analysis of variation at domain inter-
faces, CATH FunFam protein domain families were explored by considering STAMP-
defined structurally conserved regions/positions (SCRs) that are found to partici-
pate in interactions with: domains (domain-domain interaction); ligands (domain-
ligand interaction); and protein (domain-protein, where protein correspond to pro-
tein residues not classified to any CATH domain). Variation analysis was performed
for the subset of human missense variants described in Section 4.4.1.
Structurally and functionally important residues are often well conserved (Hu
et al., 2000; Guharoy and Chakrabarti, 2010; Fiser et al., 1996; Thusberg et al.,
2011). It is reasonable to assume that key residues of a vital protein-protein in-
teraction are spared from mutations, as the loss of an interaction either has fatal
consequences for the organism or confers an evolutionary disadvantage. Conse-
quently, functional interfaces are commonly associated with a lower mutability than
other, non-functional parts of the protein surface.
Table 5.3 shows the total number of FunFams for which variants could be mapped
to their conserved sites within the domain interaction interfaces. The number of
FunFam families drops to 1,080, 915, 202 when considering germline, somatic and
disease-associated variants only, respectively, when compared to the 1,127 families
when accounting for all variants (Table 4.1). The total number of unique germline
variants that map onto interfaces is 9,574. This accounts for a mean of 11 variants
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Table 5.3: Overview of FunFams for which genetic variation could be mapped to
structurally conserved residues at domain interaction interfaces. Genetic variants
were grouped as germline variants, somatic mutations and disease-associated vari-
ants. The mean (x̄) [minimum; median; maximum] and the total number of genetic
variants that were mapped to domains in FunFams is shown.
FunFams
Variants Total FunFams Variants per FunFam (x̄) Total variants
All 1,127 17 [1; 10; 1053] 16,005
Germlinea 1,080 11 [1; 6; 395] 9,574
Somatica 915 7 [1; 4; 481] 4,934
Diseasea 262 7 [1; 3; 177] 1,497
aFinal subset of human missense mutations mapped onto STAMP structurally
conserved positions within interaction interfaces.
per FunFam. The total number and mean of variants is lower for the somatic and
disease-associated classes, with a total 4,934 and 1,497 variants (mean of 7 residues),
respectively. This is expected since only 15% of all variants map to interface posi-
tions in FunFams (Figure 4.5), and a decreasing number of germline (64%), somatic
(30%) and disease-associated (6%) variants in each class are analysed (Table 4.1).
Figure 5.4 summarises the total number of variants mapped to STAMP conserved
sites across the interaction interfaces. The breakdown of the number of variants
that map onto interfaces by interface type reveals that a majority of variants (73-
78%) is involved in domain-domain interactions. The remaining 13-18% and 0.9-
1.1% of the variants are mapped to domain-ligand and domain-protein interactions,
respectively. These results are in line with the proportions shown in Figure 4.5,
which were calculated taking into account both conserved and variable positions
within interaction interfaces. This results from the fact that a high number of
interface sites with mapped variants correspond to conserved positions. In fact, the
number of STAMP-defined structurally conserved regions account for the mapping
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of 82-86% of all variants (Figure 5.4).
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Figure 5.4: Distribution of genetic variants mapped to structurally conserved re-
gions within interaction interfaces in FunFam domain families. Genetic variants were
grouped as germline variants, somatic mutations and disease-associated variants.
The aggregation of all variants in the three classes is also provided. n corresponds
to the total number of genetic variants in each class that fall into that particular
structure environment. Structural environments/regions were defined as described
in Section 4.3.2. The number of variants in variable regions is shown for comparison
purposes.
171
5. Exploring variation at domain interfaces 5.4. Results and discussion
5.4.4 Domain-domain interaction propensities
In order to investigate whether some amino acid residues are preferentially mutated
at interfaces, domain-domain contact propensities were derived from the residue
pairings observed for the interaction interfaces of the subset of 1,127 FunFam fam-
ilies, to which variation could be mapped (Table 5.3). Figure 5.5 shows the log
contact propensity matrix for all amino interaction pairs that compose the domain-
domain interfaces. The contact propensity matrix is symmetric since the amino acid
pairing frequencies are non-directional.
Among the most frequent amino acid pairs are Arg-Glu, Arg-Asp, Lys-Glu, and
Lys-Asp, which correspond to favourable opposite-charge ionic interactions (salt-
bridges). Leu-Leu interaction is also enriched and results in favourable hydrophobic
(aliphatic-aliphatic) interactions. Other hydrophobic (Van der Waals) interactions,
as well as hydrogen bonding, are favourable including Leu-Val, Val-Val, Ser-Ser
and Ile-Ile. Aromatic-aromatic interactions between Phe-Phe and polar interactions
between Ser-Asp are also observed. The contribution of Asp to the maintenance of
interaction interfaces might be related to its special conservation status (Fiser et al.,
1996). Cys-Cys interactions are also enriched, which might result from favourable
disulphide bonds. Among the less likely interactions are interactions between large
aromatic and hydrophobic residues (Trp, Tyr, Ile) and sulphur-containing residues
(Cys and Met). These correspond to chemically complex amino acids which are
less favourable at domain-domain interfaces. Interactions with Trp are expectedly
less likely since Trp is the least abundant amino acid in the proteomes (Table 2.5).
The interaction between Trp-Cys is also very unfavourable, given the nature of
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Figure 5.5: Log contact propensities for variant-mapping FunFam protein families.
The amino acid pairings are provided for domain-domain interactions observed for
FunFam protein families for which variants could be mapped to conserved positions.
Amino acids are arranged by one letter code according to increasing hydrophobicity
(least hydrophobic is left/top and most hydrophobic is right/bottom) according to
the Fauchère et al., 1988, scale.
the physicochemical properties of these residues and their abundance. The least
favourable interactions are observed between some of the biggest amino acid residues
including Arg, Lys, Asp and Glu to aromatic residues, Trp and Phe. Accordingly,
charged-aromatic interactions including: Trp-Arg, Trp-Lys, Trp-Glu, Trp-Asp and
Phe-Asp; are depleted. This is expected since aromatic residues share constrained
side-chain geometries that impose limitations on the angles which would allow for
electrostatic interactions to be made with these residues. Overall, these results are
in agreement with work by Glaser et al., 2001, which calculated protein-protein
contact propensities using a non-redundant set of protein complexes.
Figure 5.6 shows the comparison of the abundance of amino acids in the human
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Figure 5.6: Comparison of the abundance of amino acids in the human proteome
and in the domain-domain interaction dataset. Amino acid frequencies are provided
for the human proteome (line) and the domain-domain interface subset (dashed-
line). Amino acids are arranged by 1-letter code according to decreasing abundance
in the human proteome (de Beer et al., 2013).
proteome (de Beer et al., 2013) and the abundance of amino acids in the domain-
domain interfaces dataset. The frequency of each amino acid in the domain-domain
interface dataset follows a similar overall trend to the frequency of each amino acid
in the human proteome. A significant depletion of charged residues (Lys, Arg and
Asp), as well as aromatic Thr, is observed. In contrast, an enrichment of Tyr, His
and Cys is observed at the domain-domain interfaces. This result indicates that
despite the natural abundance of each amino acid, particular residues are preferred
at interfaces. It also agrees with the contact propensities observed in Figure 5.5 and
those reported by Glaser et al., 2001.
Table 5.4 overviews the occurrence of particular intermolecular bonding types
observed in the domain-domain interaction interfaces dataset. Non-covalent Van der
Waals (hydrophobic) intermolecular interactions account for 68% of all interactions
in the dataset. Hydrogen bonds are formed for 15% of the amino acid pairs, followed
by salt-bridge (ionic) interactions. The least common interaction types are aromatic-
aromatic (1%) and disulphide bonds (0.001%).
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Table 5.4: Overview of the domain-domain interaction bonding types in the Fun-
Fam protein families.
Bonding type Total number of contacts
Van der Waals 541,727 (0.68)
Hydrogen bonds 122,959 (0.15)
Salt-bridge 57,962 (0.07)
Aromatic-aromatic 11,655 (0.01)
Disulphide bonds 962 (0.00)
5.4.5 Analysis of genetic variation amino acid exchanges at
interfaces
With the growing amount of protein-protein interaction information that exists to-
day, studying the effects of variation on interfaces is essential to understanding the
molecular mechanisms of disease. In a similar fashion to the analysis performed in
Chapter 4, genetic variation amino acid exchanges were investigated for structurally
conserved positions at the interfaces. The overall trend in amino acid exchange
frequencies is similar when comparing different variation classes as well as when
comparing the interface subset with the entire variation dataset, as performed in
Section 4.4.4.
Figure 5.7 shows the frequency difference obtained for ‘from’ and ‘to’ amino acid
exchanges by comparing the relative frequencies of the entire variation dataset and
those of the interface subset. The frequency difference is calculated as the frequency
of amino acid exchange at the interface, minus the frequency of exchange in the entire
variation dataset. Frequency differences bigger than zero correspond to enrichment
of a particular amino acid exchange at the interfaces, whereas frequency differences
lower than zero correspond to interface depleted variation exchanges. Only minor
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frequency differences are observed overall. Nevertheless, the difference is bigger for
‘from’ amino acid exchanges, than for ‘to’ exchanges.
Regarding ‘from’ exchanges, Arg mutation is enriched at interfaces (p-value <
0.01), whereas Ser and Gly are depleted, for all three variation classes (Figure 5.7).
Mutation from these to small size amino acids is likely to introduce steric clashes.
Likewise, mutation from Arg is likely to affect binding by introducing a void space
in the structure, which might affect interaction (Martin et al., 2002; Stefl et al.,
2013). There is an enrichment of mutation of Asp at interfaces for disease-associated
variants, which potentially results from the disruption of hydrogen bond networks.
Mutation from Cys is enriched for somatic variants. This mutation is likely to affect
protein binding, particularly to ligands, since Cys participates in disulphide bonds
and is often found coordinating binding to metal ions.
For ‘to’ amino acid exchanges minor frequency differences are observed for amide-
containing Asn and Gln residues (Figure 5.7), which are found enriched (p-value <
0.05) at interfaces and are major contributors as donors and acceptors in hydrogen
bonds. In contrast, neutral residues (Ser and Leu) are depleted at interfaces, par-
ticularly for known disease-associated variants. Overall, mutations are expected to
affect the interaction interfaces to some extend, through several mechanisms such as
by introducing constrained geometries to the protein backbone (Pro), introducing
steric clashes (Arg) or void spaces (Gly), and disrupting interaction networks (Asn
and Phe).
Similarly to the breakdown of amino acid exchanges obtained for the entire
variation dataset (Figure 4.9), the breakdown of all amino acid exchanges observed
in the different genetic variation subsets that map onto STAMP-defined structurally
176
5. Exploring variation at domain interfaces 5.4. Results and discussion
−0.050
−0.025
0.000
0.025
0.050
R K D E N Q S G H T A P Y V M C L F I W
−0.050
−0.025
0.000
0.025
0.050
R K D E N Q S G H T A P Y V M C L F I W
Mutation 'from' amino acid
Fr
eq
ue
nc
y 
D
i
.
Mutation 'to' amino acid
Fr
eq
ue
nc
y 
D
i
.
Germline variants Somatic variants Disease-associated variants
Figure 5.7: Comparison of the mutation frequency differences for all classes of
genetic variants. The frequency difference of observed mutations is provided for
germline variants (green), somatic mutations in (blue), and disease-associated vari-
ants (red). Amino acids are arranged by 1-letter code according to increasing hy-
drophobicity (least hydrophobic is left and most hydrophobic is right) according to
the Fauchère et al., 1988, scale.
conserved interface residues is provided. An identical amino acid exchange profile is
observed when comparing the two variation datasets. Figure 5.8 shows the frequency
difference obtained between the interface variation subset and the overall variation
dataset. Bigger frequency differences are observed for disease-associated amino acid
exchanges mutating from hydrophobic and polar residues (Asp, Gln, Ser, Ala, Pro,
Tyr, Val, Leu, Phe and Ile). Mutations to Pro are not particularly enriched (p-value
> 0.05) at interfaces, despite being among the most frequent mutation found for
disease-associated variants (Figure 5.7).
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Figure 5.8: Comparison of the mutation frequency differences obtained for all classes of genetic variants, when comparing conserved
interface residues and against the whole database. The frequency difference of observed mutations is provided for germline variants
(green), somatic mutations in (blue), and disease-associated variants (red). Each plot shows the frequency difference of mutation
from a specific amino acid (e.g. Arg at top left) to every other amino acid. Amino acids are arranged by 1-letter code according to
increasing hydrophobicity (least hydrophobic is left and most hydrophobic is right) according to the Fauchère et al., 1988, scale.
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Amino acid exchanges involving residues that participate in favourable domain-
domain interfaces (Figure 5.5) are enriched for disease-associated variants, since
they lead to drastic changes (loss of interaction), based on the properties of the
amino acids. An example of such transitions would be for opposite charge muta-
tions from Lys to Glu and Asp to His (depleted outside interfaces). These lead
to opposite charge transitions and potentially disrupt ionic interactions as well as
hydrogen-bond networks. The scenario in which amino acid exchanges involving
residues that participate in unfavourable (gain of interaction) interactions lead to
a more favourable interaction is also observed. Mutations from Val to Met, Tyr to
His, Met to Leu, and Ile to Tyr, are among those transitions which are depleted
for disease-associated variants and might lead to improvement of the interaction.
Disease-associated variant exchanges from Ala to Thr are highly enriched (p-value
< 0.001) at interfaces, despite both amino acids sharing similar properties. Only
minor frequency differences are observed for the mutational profiles obtained for
germline and somatic variants, when compared to those from disease-associated
variants. Mutation of Gly to Glu is depleted at interfaces for somatic variants.
5.4.6 Analysis of genetic variation exchanges at interfaces
according to physicochemical properties
In order to further investigate specific differences observed for amino acid exchanges
at interfaces, amino acids were grouped according to their physicochemical proper-
ties. Similarly to the analysis performed in Section 4.4.5, two single state alphabets
were investigated.
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Figure 5.9 shows the frequency difference obtained between the interface vari-
ation subset and the entire variation dataset, when considering the physicochem-
ical alphabets. Again, only minor differences are observed for the ‘from’ and ‘to’
physicochemical group exchanges across the three variation classes. The analysis of
exchanges for both physicochemical alphabets reveals that only minor frequency dif-
ferences are observed when comparing variants in different variation classes, as well
as when comparing to the frequency profiles obtained for the full variation dataset
(Figure 4.11).
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Figure 5.9: Frequency differences for physicochemical exchanges observed for
the three classes of genetic variants obtained when comparing conserved interface
residues and all domain residues. Genetic variants were grouped as germline vari-
ants (green), somatic mutations (blue) and disease-associated variants (red). Amino
acids were grouped into two alphabets: A) ‘Chemical A’, and B) ‘Chemical B’.
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In agreement with the amino acid exchange profiles (Figure 5.8), mutations from
Gly and mutations to Pro are slightly enriched (p-value> 0.05) for disease-associated
variants. A slight enrichment (p-value < 0.05) in the frequency of mutation from
both acidic (Arg, Lys and His) as well as basic (Asp and Glu) residues is observed at
interfaces, which is accompanied by a depletion of hydrophobic residues (Figure 5.9
A). This is particularly noted for disease-associated variants. Mutation to amide-
group containing residues (Asn and Gln) also are slightly enriched at interfaces for
disease-associated variants, although this enrichment is not significant (p-value >
0.05) (Figure 5.9 B).
Figure 5.10 shows the breakdown of the frequency differences for physicochemical
changes introduced by genetic variants at interfaces according to the two alphabets
defined. To help to identify particular physicochemical trends at the interfaces,
Figure 5.10 shows the frequency difference obtained between the interface variation
subset and the entire variation dataset. Regarding the Chemical A alphabet, the
most dramatic transition is observed for exchanges between hydrophobic and polar
residues, as well as Pro and Gly, for disease-associated variants. Smaller changes in
the frequency of exchanges between basic residues is observed for somatic variants
(Figure 5.10 A). Mutations of hydrophobic residues to Pro residues observed for
disease-associated variants are statistically significant (p-value < 0.01). Enrichment
of exchanges from basic and Cys/Met residues to aliphatic is accompanied by a
depletion of basic and hydrophobic residues, for disease-associated variants (Figure
5.10).
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Figure 5.10: Comparison of the physicochemical exchange frequency differences for all classes of genetic variants. Genetic variants
were grouped as germline variants (green), somatic mutations (blue) and disease-associated variants (red). Amino acids were grouped
into two alphabets: A) ‘Chemical A’, and B) ‘Chemical B’.
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Similarly to what was observed for the entire variation dataset (Figure 4.12), the
analysis of physicochemical transitions shown for the Chemical B alphabet indicate
that mutation of hydroxy-containing residues to aromatic for both somatic and
disease-associated variants is enriched at interfaces. Similarly, mutation of residues
containing sulphur (Met and Cys) also show depletion in exchanges to aliphatic and
basic residues, for somatic and disease-associated variants, respectively (Figure 5.10
B). In fact, the bigger frequency differences observed between somatic variants and
germline variants are observed for exchanges from Met and Cys residues (sulphur
group) to chemically complex aliphatic residues, as well as aromatic residues in the
case of somatic variants. Transitions from residues that contain hydroxy-groups (Ser,
Thr) to aromatic residues is depleted for somatic and disease-associated variants at
the interfaces (Figure 5.10). Amide-group containing residues (Asn and Gln) display
an enrichment (p-value < 0.05) of exchanges to basic residues, which is accompanied
by a depletion of acidic residues, for disease-associated variants. Among the biggest
frequency differences observed at the interfaces for somatic variants when comparing
to germline variants are also observed for Gly to hydrophobic (enrichment) and
from Gly to acidic (depletion). Enrichment of aromatic to aliphatic residues is
observed for somatic variants at the interface (p-value < 0.05). Among the more
dramatic depletions of somatic variants are the observed depletion of Met/Cys to
aliphatic, and Ser/Thr to aromatic residues. The frequency differences obtained for
germline variants are the smallest overall, which results from the neutral nature of
this variation.
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5.4.7 Prioritising the analysis of genetic variants at inter-
faces within FunFam families
The residue variation at key sites within a protein may result in a series of changes
impacting protein stability, the conformation or folding kinetics, the disruption of
salt bridges and hydrogen bonds, and the perturbation of the energy landscape,
ultimately affecting protein function (Wang and Moult, 2001; Yue and Moult, 2006;
Teng et al., 2010; Stefl et al., 2013). The comparison of the variation profiles in
terms of amino acid exchanges and physicochemical properties obtained for different
classes of variants enhances features that can be used to help prioritise the analysis
of the potential consequences of variants. In particular, trends observed for disease-
associated variants at the interfaces and across all structural environments can be
used to help investigate germline variants thought to be neutral.
Table 5.5 summarises the general features used to select FunFam protein fam-
ilies and domains for further analysis. Variation consequences have been grouped
according to the main consequence or behaviour they can have an effect on (Wang
and Moult, 2001; Martin et al., 2002; Tang et al., 2004; Stone and Sidow, 2005;
Khan and Vihinen, 2007). Variation can lead to: disruption of intermolecular bonds
(e.g. hydrogen and disulphide bonds); substantial size changes (e.g. introduction
of steric clashes or void spaces); change in ionisation state (e.g. change to opposite
charge); change in hydrophobicity; and mutation from/to Pro and Gly. Another
level of filtering can be performed by focusing on variants predicted to be deleteri-
ous/damaging (Figure 4.15).
A set of FunFam protein families were selected as proof-of-concept examples to
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Table 5.5: Summary of the most important variation consequences used to help to
prioritise the analysis of genetic variation.
Feature Evidence
Disruption of intermolecular
bonds
Enrichment of mutations that lead to drastic physico-
chemical transitions found for disease-associated vari-
ants (e.g. Figure 5.8 and Figure 5.10).
Substantial size changes Broader distribution of volume and atomic mass tran-
sitions for disease-associated variants, as well as enrich-
ment of mutations that lead to size changes (e.g. Figure
4.13 and Figure 5.8).
Change in ionisation state Enrichment of opposite charge exchanges found for
disease-associated variants (e.g. Figure 5.8 and Figure
5.10).
Change in hydrophobicity Broader distribution of hydrophobicity transitions for
disease-associated variants (e.g. Figure 4.13 and Figure
5.8)
Mutation from/to Pro and
Gly
Enrichment of exchanges to Pro and mutations from
Gly, for disease-associated variants (e.g. Figure 5.8 and
Figure 5.10).
showcase the power of performing structure-based analysis of genetic variation in the
context of feature-rich annotations and within protein families. Protein families were
selected if variants were mapped to structurally conserved domain-domain and/or
domain-ligand interfaces and at least one of the variants displays some of the features
defined in Table 5.5. Structurally conserved MSA positions at the interface where
the variation exchange outcome is observed in that particular column (Table 4.5)
were excluded, as they are less likely to impair activity/stability of the interface.
Variation types other than missense variants (i.e. frameshift-variant, stop-gained,
and others described in Section 4.3.1), were also included in the proof-of-concept
analysis. Each potential consequence shown in Table 5.5 was scored according to a
decreasing scale, from 6 to 1, and every FunFam family showing mapping of genetic
variants at interfaces was ranked. The score of each potential consequence was added
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to a particular FunFam, when at least one instance of that consequence is observed
for that FunFam. Figure 5.11 shows the clustering analysis results performed on the
40 highest ranked FunFam families.
Table 5.6 lists a set of 20 highly-ranked FunFam protein families and domain
examples. The examples include a variety of enzyme families: proteinases; dehydro-
genases; esterases; reductases; and isomerases; as well as regulatory protein families;
1.10.510.10_78758
3.40.390.10_13247
3.30.500.10_3472
1.20.140.10_16374
3.40.50.720_284952
2.40.10.10_46567
3.10.129.10_29582
1.10.510.10_79008
1.10.510.10_79007
1.10.510.10_78989
1.10.1540.10_596
1.10.510.10_21492
1.10.510.10_78743
1.10.1040.10_17579
1.10.40.40_45
1.10.510.10_78730
1.10.1300.10_1262
1.10.220.10_3807
3.90.70.10_17146
3.50.50.60_112428
3.40.50.720_285713
3.40.50.720_284423
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Figure 5.11: Clustering analysis of the top 40 FunFam families mapping potentially
disruptive genetic variants at interfaces. The potential consequences of variation
summarised in Table 5.5 were used to score each FunFam family (severity weight).
Clustering was performed with hclust method in R (R Core Development Team,
2016) using Euclidean distance and complete linkage.
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signalling receptors and immunity proteins.
Table 5.6: Top 20 FunFam families showing potentially disruptive genetic variants
at the interfaces.
SPF ID FunFam ID FunFam Descritption/Representative domain
1.10.510.10 78758 Ephrin type-A receptor 2 (ephrin-A2)
3.40.390.10 13247 Matrix metalloproteinase-3 (MMP-3)
3.30.500.10 3472 T-cell surface glycoprotein CD1e (CD1e)
1.20.140.10 16374 Acyl-Coenzyme A dehydrogenase family, member 9
3.40.50.720 284952 Estradiol 17-β-dehydrogenase 1
2.40.10.10 46567 Coagulation factor XI (FXI)
3.10.129.10 29582 Acyl-coenzyme A thioesterase 12
2.60.20.10 2537 β-crystallin A3
3.30.200.20 267 Fibroblast growth factor receptor 1 (FGFR-1)
3.30.497.10 4990 α-1-antitrypsin 1-3
3.50.50.60 112428 Thioredoxin reductase 1
3.90.226.10 34066 Enoyl-CoA delta isomerase 2, mitochondrial
3.90.70.10 17146 Cathepsin B
1.10.1040.10 17579 Glyoxylate/succinic semialdehyde reductase 1
1.10.1300.10 1262 Phosphodiesterase 8, isoform A
1.10.1540.10 596 CDNA FLJ16600 fis, clone TESTI4006704
1.10.220.10 3807 Annexin A5 (Anchorin CII)
1.10.287.130 38277 Methylmalonic aciduria type A protein, mitochondrial
1.10.40.40 45 5’(3’)-deoxyribonucleotidase
1.10.540.10 15764 Medium-chain-specific acyl-CoA dehydrogenase, mitocon-
drial
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5.4.8 Analysis of variants at selected domain interfaces
The analysis of variants mapped to interface residues of domain members of three
FunFam families from Table 5.6 showing the highest severity weight: Ephrin type-
A receptor 2 (ephrin-A2); Matrix metalloproteinase-3 (MMP-3); and T-cell surface
glycoprotein CD1e (CD1e); are explored in the next Sub-sections. It is important to
notice here that none of the germline and somatic variants identified that cluster into
domain interaction interfaces are currently annotated as having disease-association.
Since disease-association annotation is likely to lag behind current research in the
field, additional queries to the appropriate literature need to be performed to confirm
this is the case.
5.4.8.1 Ephrin type-A receptor 2 (ephrin-A2)
Figure 5.12 shows the spatial location of germline and somatic variants mapped to
domain 3pix A 02 (PDB ID 3pix (Kuglstatter et al., 2011), through UniProtKB ID
Q06187), which is a member of the Ephrin type-A receptor 2 (ephrin-A2) FunFam
family (CATH Superfamily 1.10.510.10, FunFam ID 78758). Domain members of
this FunFam include proteins which are involved in cell-signalling and act as receptor
kinases. 3pix A 02 is an epithelial cell receptor tyrosine-kinase domain which was
co-crystallised with Bruton’s tyrosine kinase (BTK) inhibitor ligand (PDB ligand
ID 027) but also participates in a domain-domain interaction with a phosphorylase
kinase domain (Figure 5.12 A).
The overview of the variants that are mapped to this domain is shown in Figure
5.12 B. Several of these variants are mapped to the domain-domain and domain-
ligand interface and are highlighted in Figure 5.12 C. Among the variants most likely
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Leu542Pro
Ser538Pro
Tyr511*
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Met477Arg
Ala508Thr
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Cys481Ser
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C
Figure 5.12: Overview of the spatial location of variants mapped to ephrin-A2
interface residues. Variants were mapped to Ephrin type-A receptor 2 (ephrin-A2)
(CATH Superfamily 1.10.510.10, FunFam ID 78758), domain 3pix A 02. Highlight
of: A) interface residues and any ligands bound to the domain; B) mapped germline
and somatic variants; and C) variants that mapped to structurally conserved inter-
faces positions. Germline (orange) and somatic (purple) are highlighted. Ligands
and the side-chain of interface residues are represented as ball-and-stick, whereas
variants that are mapped to interface residues are represented as spheres.
to lead to disruption of the domain-domain interface are Leu542Pro (PhenCode:
BTKbase U78027.1:g.66839T>C) and Ser538Pro (PhenCode: BTKbase U78027.1:
g.66826T>C), which result in Pro residues, as well as the Tyr511* (PhenCode: BTK-
base U78027.1:g.65390C>A) that leads to a truncated protein by encoding a pre-
mature stop-codon. Met477Arg (PhenCode: KinMutBase U78027.1:g.65287T>G)
might also be important to help to maintain the domain-domain interaction. The
analysis of the interaction with the inhibitor ligand indicates that this variation
might affect the interaction. Various disease-associated mutations have been identi-
fied for domain members of this FunFam. The most severe trait reported for these
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mutations is X-linked agammaglobulinemia (XLA, also known as Fleisher syndrome
- MIM:307200), which is a humoral immunodeficiency disease that leads to develop-
mental defects in the maturation pathway of B-cells (Conley et al., 1991).
5.4.8.2 Matrix metalloproteinase-3 (MMP-3)
Figure 5.13 shows the spatial location of variants mapped to domain 1hy7 B 00
(PDB ID 1hy7 (Natchus et al., 2001), through UniProtKB ID P08254), which is a
member of the Matrix metalloproteinase-3 (MMP-3) FunFam family (CATH Super-
family 3.40.390.10, FunFam ID 13247). This FunFam family is comprised of many
metalloproteinase proteins which have proteinase activity (EC. 3.4.24.17) acting as
a collagen-activation protein. Figure 5.13 A highlights the various residues involved
in the interaction with Ca2+ and Zn2+ ions, as well as the MMP inhibitor (PDB
ligand ID MBS). Figure 5.13 B overviews the spatial location of germline and so-
matic variants mapped to the domain. Figure 5.13 C highlights those variants that
affect domain-ligand interface residues. Among the germline and somatic variants
that most likely affect both the coordination of the ions are Gly661Arg (dbSNP:
rs782745338), which corresponds to the mutation of a Gly to Arg. This is likely
to affect binding to Ca2+ as Gly is substituted by a much larger basic amino acid.
Gly673Val (COSMIC: COSM1492416) also results in a mutation from Gly, but since
Val is a small hydrophobic amino acid, the exchange might not affect the binding
to Ca2+. Glu684Lys (COSMIC: COSM3868291) corresponds to a somatic mutation
from an acidic amino acid to basic and is likely to affect binding to Ca2+. His666fs*
(dbSNP: rs782137879) leads to a frameshift mutation, which is likely to disrupt the
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Figure 5.13: Analysis of germline and somatic variants mapped to MMP-3 in-
terface residues. Variants were mapped to Matrix metalloproteinase-3 (MMP-3)
(CATH Superfamily 3.40.390.10, FunFam ID 13247), domain 1hy7 B 00. Highlight
of: A) interface residues and any ligands bound to the domain; B) mapped germline
and somatic variants; and C) variants that mapped to structurally conserved inter-
faces positions. Germline (orange) and somatic (purple) are highlighted. Ligands
and the side-chain of interface residues are represented as ball-and-stick, whereas
variants that are mapped to interface residues are represented as spheres.
stability of the entire protein leading to total or partial impairment of its func-
tion. Likewise, Leu664* (dbSNP: rs782500546) results in a premature stop and the
truncation of the domain.
5.4.8.3 T-cell surface glycoprotein CD1e (CD1e)
Figure 5.14 shows the spatial location of germline and somatic variants mapped to
domain 1onq A 01 (PDB ID 1onq (Zajonc et al., 2003), through UniProtKB ID
P06126). This domain is a member of the T-cell surface glycoprotein CD1e (CD1e)
FunFam family (CATH Superfamily 3.30.500.10, FunFam ID 3472), which presents
191
5. Exploring variation at domain interfaces 5.4. Results and discussion
Ser77*
Leu148Pro
Arg76Pro
Arg73Pro
Leu114Phe
Ile81Asn
A
B
C
Trp14*
Figure 5.14: Overview of the spatial location of variants mapped to CD1e interface
residues. Variants were mapped to T-cell surface glycoprotein CD1e (CD1e) (CATH
Superfamily 3.30.500.10, FunFam ID 3472), domain 1onq A 01. Highlight of: A)
interface residues and any ligands bound to the domain; B) mapped germline and
somatic variants; and C) variants that mapped to structurally conserved interfaces
positions. Germline (orange) and somatic (purple) are highlighted. Ligands and the
side-chain of interface residues are represented as ball-and-stick, whereas variants
that are mapped to interface residues are represented as spheres.
a Murine Class I Major Histocompatibility Complex, H2-DB, subunit A, domain.
Domain members of this FunFam include membrane proteins CD1 antigens involved
in the presentation of peptide antigens to the immune system. These bind a variety
of self and foreign lipid and glycolipid antigens for presentation to CD1-restricted T
cell receptors (TCRs). Figure 5.14 A highlights the CD1e binding pocket with bond
sulfatide self-antigen (PDB ID SLF), whereas Figure 5.14 B overviews the variants
that are mapped to this domain. Figure 5.14 C highlights those variants that poten-
tially affect domain-ligand binding. Among the variants that likely affect the domain
as a whole are Ser77* (dbSNP: rs538916791) and Trp14* (dbSNP: rs149019370) that
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lead to a premature truncation of the protein. A total of three variants lead to mu-
tations to Pro, and likely affect binding of the sulfatide self-antigen. These include
the germline variant Arg76Pro (dbSNP: rs146048507), and two somatic variants
Arg73Pro (COSMIC: COSM1498715) and Leu148Pro (COSMIC: COSM1661050).
5.5 Conclusions
In depth characterisation of variants across different environments by type of substi-
tutions and annotation is important as it enables finding transitions that might be
implicated in disease, and that can potentially affect protein stability, activity and
function. Therefore, this Chapter focused on the overall analysis of genetic variants
at structurally conserved interface positions. The overall analysis of genetic variants
at structurally conserved interface positions follows the same general trends observed
when investigating genetic variants across all domain sites. The trends of variation
were used to help prioritise variants and protein families for further analysis.
The main conclusions of the work presented in this Chapter are:
• Domain-domain interaction types were analysed in the context of CATH SC
and FunFams.
• Domain-domain interactions were classified by orientation as a measure of
iRMSD clustering.
• A high number of genetic variants were mapped to protein interfaces for Fun-
Fam protein families.
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• 73-78% of the variants in the three classes mapped to domain-domain inter-
faces, whereas 13-18% of the variants mapped to domain-ligand interfaces.
• Domain-domain contact propensity matrices were generated and showed that
favourable interactions are performed by charged (ionic), hydrophobic and
aliphatic residues.
• The frequency of amino acids in the domain-domain interaction dataset follows
the same overall trend observed for the abundance of each amino acid in the
human proteome.
• Hydrophobic interactions account for 68% of all interactions, followed by
hydrogen-bond (15%) and salt-bridge (7%) interactions.
• Mutations to Pro and Arg are frequently observed for disease-associated vari-
ants. This is accompanied by mutation of Gly and Cys residues.
• Overall, small differences are observed when comparing both the variation
at interfaces and variation at all structural environments, for germline and
somatic variants.
• Mutations from charged residues are more frequently observed for somatic
variants, whereas mutations from Ile and Val are enriched for somatic variants.
• Regarding the physicochemical properties of the amino acids, disruptive tran-
sitions are more consistently observed for disease-associated variants.
• The bigger frequency differences observed between germline and somatic vari-
ants are observed for exchanges from sulphur-containing residues to chemically
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complex aliphatic and aromatic residues.
• The most problematic amino acid exchanges are those that: disrupt inter-
molecular bonds; lead to substantial size changes; lead to changes in ionisation
state; lead to changes in hydrophobicity; or mutate from/to Pro and Gly.
• Preliminary analysis of some proof-of-concept examples indicates that many
variants currently annotated and thought to be neutral might affect protein
binding and in that way disrupt important functional interactions.
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Chapter 6
Conclusions and future work
6.1 Summary
The work presented in this Thesis focused on the analysis of genetic variation in
protein domain families and interaction interfaces. This has been approached by:
1) developing integrative methods for the analysis of structural protein-protein and
protein-ligand interactions; 2) combining structural and sequence data to enable the
study of genetic variants on protein interfaces; 3) improving the current methods
for comprehensive analysis of protein structural and functional families; 4) increas-
ing the availability and understanding of genetic variation at domain interaction
interfaces. This chapter summarises the contributions made in each Chapter and
provides suggestions of possible future work.
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6.2 Development and contents of ProIntVar
Chapter 2 described the development of ProIntVar and overviewed the tools and
methods necessary for the analysis of genetic variants in the context of feature-rich
protein structural data. Chapter 2 also overviewed the datasets collected and or-
ganised in ProIntVar. The main features of ProIntVar are that: 1) it implements
routines for generating biological assemblies, defining protein interactions, annotat-
ing additional structural features in sites and regions; 2) it allows protein structure,
protein sequence and genomic DNA sequence to be cross-mapped; 3) it incorporates
generated structure-based MSAs for CATH structural clusters and functional fam-
ilies, which were further extended with similar protein sequences; 4) it allows the
comprehensive analysis of protein domain families and exploring protein interfaces
across different protein families within a structural perspective; and finally 5) it pro-
vides an integrative environment for the analysis of large genetic variation datasets
in the context of proteins structure and protein domain families.
The availability of structural data and genetic variation is likely to increase at
a steady pace over the next years. Additionally, one of the biggest problems cur-
rently in bioinformatics is that many tools stop being updated very shortly after
development and release. With both of these points in mind, ProIntVar has been
developed in a way that enables updates to the raw structure and sequence datasets
which ProIntVar is built on. Several scripts have also been developed to enable the
update of such datasets and to perform all the computations needed for populating
the database. These cover all the steps necessary from pre-processing the data to
generating the analysis results provided in the ProIntVar web-server, which will be
197
6. Conclusions and future work 6.3. Structural alignment of domain families
made available at a later stage. This process could in principle be further improved
so that an updating ‘job’ could be scheduled to run on a regular basis. Further
improvements to the web-interface could also be made in order to give a wider
community of biologists and bioinformatics tools developers access to the computa-
tional results. For this, a RESTful API could be developed in a way that flexible
web-server endpoints would return a variety of results. Some of the most basic and
frequently queried results are already provided in such an API, but the improvement
and extensibility of the current methods would be very useful.
6.3 Structural alignment of domain families
In order to perform an enriched analysis of genetic variants under a structural and
evolutionary perspective (Chapter 4 and 5), structure-based MSAs were generated
for CATH structural and functional families by STAMP. Chapter 3 focused on im-
proving the quality of the generated MSAs by: 1) developing methods that take
advantage of the features of STAMP; and 2) exploring the power of HMMs for ex-
tending the alignments and annotating them with homologous protein sequences.
Both these aspects are key for increasing the scope and reliability of the struc-
ture/sequence data currently available for analysis. A new approach for selecting
seed domains from a pool of all-against-all domain STAMP scanning superimposi-
tions was developed. This optimisation of the set of transformations obtained for the
seed domain led to an overall improvement of the Sc and RMSD alignment measures
for 46% of the CATH domain families. Although STAMP produces overall reliable
MSAs for CATH SCs and FunFams, the quality of the FunFam-based alignments is
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generally higher, which results from a higher structural similarity between the family
domain members. Regarding the reliability of the structural alignments, alternative
quality assessment measures could be used (Edgar, 2010; Raghava et al., 2003).
This would improve the scope of the variation analysis by increasing the confidence
with which key functional sites can be inferred across the MSAs. Additionally, it
would be useful to investigate the reliability and quality of MSAs generated by new
multiple structure alignment programs that have been recently developed, among
which: MICAN (Minami et al., 2013), POSA (Li et al., 2014), and UniAlign (Zhao
and Sacan, 2015).
Another key related aspect is the aim of increasing the coverage of the structural
data available, in order to be able to map/infer potential interaction or variant sites
in homologous sequences. It has been predicted that only about half of the human
genome is structurally covered (Xie and Bourns, 2005; Marsden et al., 2007; Khafizov
et al., 2014). Additionally, both the number of known folds and types of domain-
domain interactions that have been identified is believed to be far from complete
(Garma et al., 2012). Trying to address this issue, HMM-based approaches have
been developed so that CATH domain predictions are provided for many proteomes
(Lees et al., 2012). Gene3D (Lees et al., 2012) provides predicted domains that could
be mapped to available protein structures not currently covered in CATH. These
could be used to extend the STAMP structure-based MSAs or as an alternative
to the HMM-based method implemented in this work (Section 3.4.3). Importantly,
HMM profiles built from FunFams seed alignments were also recently made available
for function prediction and protein annotation in a new protocol called FunFHM-
Mer (Das et al., 2015b). FunFHMMer provides functional family (FunFam)-based
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domain assignments and constitutes an alternative to Gene3D. Both structure and
(predicted) sequence domains are now included in FunFHMMer, which enables the
analysis of domains and particularly domain interactions in the context of a larger
protein universe. This helps in increasing the CATH coverage of the current set of
protein structures in the PDB, as well as in the prediction/classification of domains
in newly solved structures or entire proteomes. As a result of these developments,
FunFHMMer could be used in addition to Gene3D, and as an alternative way to
extend the STAMP generated MSAs.
The structural data has powered new advances in computational prediction of
protein-protein interactions on a genome-wide scale (Zhang et al., 2012; Tuncbag
et al., 2011). Owing to the explosive growth in available sequences, novel methods
were also developed to predict the 3D structure of proteins (Marks et al., 2012; Hopf
et al., 2012, 2014). Experimental methods are also in active continuous development
towards better determination of the structure of proteins (Shi et al., 2013; Nannenga
and Gonen, 2014) and better identification of native protein complexes (Ewing et al.,
2007; Gingras et al., 2007; Kirkwood et al., 2013). The current combination of
detailed domain classification and sophisticated HMM domain assignment provides a
good source of homology relevant information. Nevertheless, alternative approaches
that explore structural homology by using comparative protein structure models
exist and their use could be further investigated. Such methods include ModBase
(Pieper et al., 2011), IBIS (Inferred Biomolecular Interaction Server) (Shoemaker
et al., 2012), Phyre2 (Kelley et al., 2015), and SwissModel (Biasini et al., 2014).
New approaches that combine these developments could be valuable for increasing
the structural coverage of the current variation analysis.
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6.4 Variation across protein domain families
Chapter 4 focused on the overall analysis of genetic variants in protein families, in
the context of various structure regions. The in-depth characterisation of variants
across different environments is key for finding transitions that might be implicated
in disease, and that can potentially affect protein stability, activity and function.
The global trends identified are also important to select priority variants and pro-
tein families for further analysis. The reason for classifying structure domains into
Families and Superfamilies is to be able to compare similar domains within a spe-
cific Superfamily/Family to discover the properties of each group. This leads to
an inherently high level of redundancy, which which is kept by working with all
the domain members of the CATH SCs and FunFams. A domain belonging to a
particular Superfamily/Family could thus in principle be chosen to represent the
group if the majority of the domains within the group are essentially the same. Re-
dundancy removal approaches for the analysis of nsSNPs in protein structures have
been performed by others (David et al., 2012; Yates and Sternberg, 2013b; David
and Sternberg, 2015). This process is useful for removing data duplication, for re-
moving duplicated data, but presents a new problem in the form of loss of depth in
the analysis of genetic variation within species. For example, in David et al., 2012,
the analysis of SNPs using non-redundant structure datasets led to a total of 4,532
nsSNPs in 537 protein structures.
A good future development for ProIntVar would be the analysis of variation
at key sites in proteins, such as protein post-translational modified (PTM) sites
201
6. Conclusions and future work 6.4. Variation across protein domain families
(Craveur et al., 2014; Gray et al., 2014; Beltrao et al., 2012). PTMs such as phos-
phorylation, glycosylation, methylation, acetylation, lipid modifications and ubiqui-
tylation, have wide-ranging effects on protein function and interactions with other
molecules and are thereby central to cellular behaviour and responses. PTMs have
no effect on protein fold, but have a role in protein function or localisation within
the cell, on the cell membrane or in the extracellular matrix. A missense mutation
may abolish a PTM site by introducing an amino acid that cannot be modified,
or altering the neighbouring residues so that the PTM site cannot be recognised,
thereby leading to abnormal protein function. A missense mutation-induced gain
of PTM is another possible disease mechanism, leading to protein destabilisation,
changes in protein interactions, catalytic properties or other protein functions.
With the amount of genetic variation data growing exponentially, several groups
have started performing comparative functional analysis of the distribution of vari-
ants between and within protein families and started analysing the specific load
of variants at various frequencies in particular biological pathways. Accordingly,
it has been found recently that particular members of 2R-ohnologue protein fami-
lies show some mutation-load skew to a particular member, which is hypothesised
to be particularly relevant in cancer (Tinti et al., 2014). Preferential distribution
skew has also been identified for mutations in certain protein families of the hu-
man kinome (Izarzugaza et al., 2011). This approach would enable finding protein
families that are significantly over-mutated or mutation-free (Yates and Sternberg,
2013a; Petrovski et al., 2015). Following these recent developments in the functional
characterisation of genetic variation data, it would be interesting to look for both
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hot-spots and cold-spots for genetic variation in protein families or specific mem-
bers of such families. This would enable finding protein families that are significantly
over-mutated (polymorphic) or mutation-depleted (protected).
6.5 Variation at conserved interfaces
Chapter 5 focused on the overall analysis of genetic variants at structurally conserved
interface positions. Domain-domain interactions were classified by orientation as a
measure of iRMSD clustering. The overall analysis of genetic variants at structurally
conserved interface positions follows the same general trends observed when inves-
tigating genetic variants across all domain sites. The trends of variation were used
to help prioritise variants and protein families for further analysis.
Analysis of variation at interaction interfaces could be further explored by mea-
suring the change in binding energetics through the use of modelling and molecular
dynamics (Schymkowitz et al., 2005; Kumar and Purohit, 2014; Frappier and Na-
jmanovich, 2014). This would enable cross-checking of transitions that can poten-
tially affect protein stability, activity and function, as a result of either increased or
decreased binding affinity. Similarly, the use of newer predictors such as PredicSNP2
(Bendl et al., 2016) could be used to help prioritise the analysis of variants.
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González-Pérez, A., and López-Bigas, N. 2011. Improving the Assessment of the Out-
come of Nonsynonymous SNVs with a Consensus Deleteriousness Score, Condel. The
American Journal of Human Genetics 88(4):440–449.
Gore, S., Velankar, S., and Kleywegt, G. J. 2012. Implementing an X-ray validation
pipeline for the Protein Data Bank. Acta Crystallographica Section D 68(Pt 4):478–
483.
Gough, J., Karplus, K., Hughey, R., and Chothia, C. 2001. Assignment of homology to
genome sequences using a library of hidden Markov models that represent all proteins
of known structure. Journal Molecular Biology 313(4):903–919.
Gray, V. E., Liu, L., Nirankari, R., Hornbeck, P. V., and Kumar, S. 2014. Signatures of
natural selection on mutations of residues with multiple posttranslational modifications.
Molecular Biology and Evolution 31(7):1641–1645.
Gribenko, A. V., Patel, M. M., Liu, J., McCallum, S. A., Wang, C., and Makhatadze, G. I.
2009. Rational stabilization of enzymes by computational redesign of surface charge-
charge interactions. Proceedings of the National Academy of Sciences U.S.A. 106(8):
2601–2606.
Guharoy, M., and Chakrabarti, P. 2010. Conserved residue clusters at protein-protein
interfaces and their use in binding site identification. BMC Bioinformatics 11(1):286.
Gulati, S., Cheng, T. M. K., and Bates, P. A. 2013. Cancer networks and beyond: In-
terpreting mutations using the human interactome and protein structure. Seminars in
Cancer Biology 23(4):219–226.
Gutmanas, A., Alhroub, Y., Battle, G. M., Berrisford, J. M., Bochet, E., Conroy, M. J.,
Dana, J. M., Fernandez Montecelo, M. A., van Ginkel, G., Gore, S. P., Haslam, P.,
Hatherley, R., Hendrickx, P. M. S., Hirshberg, M., Lagerstedt, I., et al. 2014. PDBe:
Protein Data Bank in Europe. Nucleic Acids Research 42(Database issue):D285–D291.
Gutteridge, A., and Thornton, J. M. 2005. Understanding nature’s catalytic toolkit.
Trends in Biochemical Sciences 30(11):622–629.
Hadley, C., and Jones, D. T. 1999. A systematic comparison of protein structure classifi-
cations: SCOP, CATH and FSSP. Structure 7(9):1099–1112.
Hall, S. R. 1991. The STAR file: a new format for electronic data transfer and archiving.
Journal of Chemical Information and Modeling 31(2):326–333.
Halperin, I., Wolfson, H., and Nussinov, R. 2004. Protein-protein interactions; coupling
of structurally conserved residues and of hot spots across interfaces. Implications for
docking. Structure 12(6):1027–1038.
Halperin, I., Wolfson, H., and Nussinov, R. 2006. Correlated mutations: Advances and
limitations. A study on fusion proteins and on the Cohesin-Dockerin families. Proteins
63(4):832–845.
Hamelryck, T. 2009. Probabilistic models and machine learning in structural bioinformat-
ics. Statistical Methods in Medical Research 18(5):505–526.
213
Bibliography
Hamelryck, T., and Manderick, B. 2003. PDB file parser and structure class implemented
in Python. Bioinformatics 19(17):2308–2310.
Hamosh, A. 2004. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of
human genes and genetic disorders. Nucleic Acids Research 33(Database issue):D514–
D517.
Han, J.-H., Batey, S., Nickson, A. A., Teichmann, S. A., and Clarke, J. 2007. The folding
and evolution of multidomain proteins. Nature Reviews Molecular Cell Biology 8(4):
319–330.
Harris, M. A., Clark, J., Ireland, A., Lomax, J., Ashburner, M., Foulger, R., Eilbeck, K.,
Lewis, S., Marshall, B., Mungall, C., Richter, J., Rubin, G. M., Blake, J. A., Bult, C.,
Dolan, M., et al. 2004. The Gene Ontology (GO) database and informatics resource.
Nucleic Acids Research 32(Database issue):D258–D261.
Hasegawa, H., and Holm, L. 2009. Advances and pitfalls of protein structural alignment.
Current Opinion Structural Biology 19(3):341–348.
Hashem, Y., des Georges, A., Dhote, V., Langlois, R., Liao, H. Y., Grassucci, R. A.,
Pestova, T. V., Hellen, C. U. T., and Frank, J. 2013. Hepatitis-C-virus-like internal
ribosome entry sites displace eIF3 to gain access to the 40S subunit. Nature 503(7477):
539–543.
Heinzen, E. L., Swoboda, K. J., Hitomi, Y., Gurrieri, F., Nicole, S., de Vries, B., Tiziano,
F. D., Fontaine, B., Walley, N. M., Heavin, S., Panagiotakaki, E., European Alternating
Hemiplegia of Childhood (AHC) Genetics Consortium, Biobanca e Registro Clinico
per l’Emiplegia Alternante (I.B.AHC) Consortium, European Network for Research
on Alternating Hemiplegia (ENRAH) for Small and Medium-sized Enterpriese (SMEs)
Consortium, Fiori, S., et al. 2012. De novo mutations in ATP1A3 cause alternating
hemiplegia of childhood. Nature Genetics 44(9):1030–1034.
Henikoff, S., and Henikoff, J. G. 1992. Amino acid substitution matrices from protein
blocks. Proceedings of the National Academy of Sciences U.S.A. 89(22):10915–10919.
Henrick, K., Feng, Z., Bluhm, W. F., Dimitropoulos, D., Doreleijers, J. F., Dutta, S.,
Flippen-Anderson, J. L., Ionides, J., Kamada, C., Krissinel, E., Lawson, C. L., Markley,
J. L., Nakamura, H., Newman, R., Shimizu, Y., et al. 2007. Remediation of the protein
data bank archive. Nucleic Acids Research 36(Database):D426–D433.
Henrick, K., and Thornton, J. M. 1998. PQS: a protein quaternary structure file server.
Trends in Biochemical Sciences 23(9):358–361.
Hermjakob, H., Montecchi-Palazzi, L., Lewington, C., Mudali, S., Kerrien, S., Orchard,
S., Vingron, M., Roechert, B., Roepstorff, P., Valencia, A., Margalit, H., Armstrong, J.,
Bairoch, A., Cesareni, G., Sherman, D., et al. 2004. IntAct: an open source molecular
interaction database. Nucleic Acids Research 32(Database issue):D452–D455.
Herrero, J., Muffato, M., Beal, K., Fitzgerald, S., Gordon, L., Pignatelli, M., Vilella, A. J.,
Searle, S. M. J., Amode, R., Brent, S., Spooner, W., Kulesha, E., Yates, A., and Flicek,
P. 2016. Ensembl comparative genomics resources. Database 2016:bav096.
214
Bibliography
Hintze, B. J., Lewis, S. M., Richardson, J. S., and Richardson, D. C. 2016. MolProbity’s
Ultimate Rotamer-Library Distributions for Model Validation. Proteins 84(9):1177–
1189.
Holm, L., Kaariainen, S., Rosenstrom, P., and Schenkel, A. 2008. Searching protein
structure databases with DaliLite v.3. Bioinformatics 24(23):2780–2781.
Holm, L., and Sander, C. 1996. The FSSP database: Fold classification based on structure-
structure alignment of proteins. Nucleic Acids Research 24(1):206–209.
Holm, L., and Sander, C. 1999. Protein folds and families: Sequence and structure align-
ments. Nucleic Acids Research 27(1):244–247.
Hopf, T. A., Colwell, L. J., Sheridan, R., Rost, B., Sander, C., and Marks, D. S. 2012.
Three-Dimensional Structures of Membrane Proteins from Genomic Sequencing. Cell
149(7):1607–1621.
Hopf, T. A., Schärfe, C. P. I., Rodrigues, J. P. G. L. M., Green, A. G., Sander, C.,
Bonvin, A. M. J. J., and Marks, D. S. 2014. Sequence co-evolution gives 3D contacts
and structures of protein complexes. eLife 3:65.
Hu, Z., Ma, B., Wolfson, H., and Nussinov, R. 2000. Conservation of polar residues as hot
spots at protein interfaces. Proteins: Structure, Function, and Genetics 39(4):331–342.
Hubbard, S. J., and Argos, P. 1994. Cavities and packing at protein interfaces. Protein
Science 3(12):2194–2206.
Hubbard, T. J., Murzin, A. G., Brenner, S. E., and Chothia, C. 1997. SCOP: a Structural
Classification Of Proteins database. Nucleic Acids Research 25(1):236–239.
Huminiecki, L., and Conant, G. C. 2012. Polyploidy and the evolution of complex traits.
International Journal of Evolutionary Biology 2012(4):292068–292112.
Hurst, J. M., McMillan, L. E. M., Porter, C. T., Allen, J., Fakorede, A., and Martin,
A. C. R. 2009. The SAAPdb web resource: a large-scale structural analysis of mutant
proteins. Human Mutation 30(4):616–624.
Ito, T., Chiba, T., Ozawa, R., Yoshida, M., Hattori, M., and Sakaki, Y. 2001. A compre-
hensive two-hybrid analysis to explore the yeast protein interactome. Proceedings of the
National Academy of Sciences U.S.A. 98(8):4569–4574.
Ivanov, A. A., Khuri, F. R., and Fu, H. 2013. Targeting protein–protein interactions as
an anticancer strategy. Trends in Pharmacological Sciences 34(7):393–400.
Izarzugaza, J. M. G., Hopcroft, L. E. M., Baresic, A., Orengo, C. A., Martin, A. C. R.,
and Valencia, A. 2011. Characterization of pathogenic germline mutations in human
protein kinases. BMC Bioinformatics 12 Suppl 4:S1.
Jackson, R. N., McCoy, A. J., Terwilliger, T. C., Read, R. J., and Wiedenheft, B. 2015. X-
ray structure determination using low-resolution electron microscopy maps for molecular
replacement. Nature Protocols 10(9):1275–1284.
Janin, J., and Chothia, C. 1990. The structure of protein-protein recognition sites. Journal
Biological Chemistry 265(27):16027–16030.
215
Bibliography
Janin, J. l., Henrick, K., Moult, J., Eyck, L. T., Sternberg, M. J. E., Vajda, S., Vakser,
I., and Wodak, S. J. 2003. CAPRI: A critical assessment of PRedicted interactions.
Proteins: Structure, Function, and Genetics 52(1):2–9.
Jefferson, E. R., Walsh, T. P., and Barton, G. J. 2006. Biological units and their effect
upon the properties and prediction of protein-protein interactions. Journal Molecular
Biology 364(5):1118–1129.
Jefferson, E. R., Walsh, T. P., and Barton, G. J. 2007a. A comparison of SCOP and
CATH with respect to domain-domain interactions. Proteins 70(1):54–62.
Jefferson, E. R., Walsh, T. P., Roberts, T. J., and Barton, G. J. 2007b. SNAPPI-DB: A
database and API of structures, iNterfaces and Alignments for Protein-Protein Inter-
actions. Nucleic Acids Research 35(Database issue):D580–D589.
Johansson, F., and Toh, H. 2010. A comparative study of conservation and variation
scores. BMC Bioinformatics 11(1):388.
Jones, S., Marin, A., and Thornton, J. M. 2000. Protein domain interfaces: characteri-
zation and comparison with oligomeric protein interfaces. Protein Engineering, Design
and Selection 13(2):77–82.
Jones, S., and Thornton, J. M. 1997. Analysis of protein-protein interaction sites using
surface patches. Journal Molecular Biology 272(1):121–132.
Jones, S., and Thornton, J. M. 1996. Principles of protein-protein interactions. Proceedings
of the National Academy of Sciences U.S.A. 93(1):13–20.
Jones, T. A., Zou, J. Y., Cowan, S. W., and Kjeldgaard, M. 1991. Improved methods
for building protein models in electron density maps and the location of errors in these
models. Acta Crystallographica Section A 47 (Pt 2):110–119.
Jonic, S., and Vénien-Bryan, C. 2009. Protein structure determination by electron cryo-
microscopy. Current Opinion in Pharmacology 9(5):636–642.
Jonsson, P. F., and Bates, P. A. 2006. Global topological features of cancer proteins in
the human interactome. Bioinformatics 22(18):2291–2297.
Kabsch, W., and Sander, C. 1983. Dictionary of protein secondary structure: pattern
recognition of hydrogen-bonded and geometrical features. Biopolymers 22(12):2577–
2637.
Kamburov, A., Lawrence, M. S., Polak, P., Leshchiner, I., Lage, K., Golub, T. R., Lander,
E. S., and Getz, G. 2015. Comprehensive assessment of cancer missense mutation
clustering in protein structures. Proceedings of the National Academy of Sciences U.S.A.
112(40):E5486–5495.
Kanehisa, M., and Goto, S. 2000. KEGG: kyoto encyclopedia of genes and genomes.
Nucleic Acids Research 28(1):27–30.
Karchin, R. 2009. Next generation tools for the annotation of human SNPs. Briefings in
Bioinformatics 10(1):35–52.
216
Bibliography
Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N., and Sternberg, M. J. E. 2015.
The Phyre2 web portal for protein modeling, prediction and analysis. Nature Protocols
10(6):845–858.
Kenworthy, A. K. 2001. Imaging Protein-Protein Interactions Using Fluorescence Reso-
nance Energy Transfer Microscopy. Methods 24(3):289–296.
Keskin, O., Gursoy, A., Ma, B., and Nussinov, R. 2008. Principles of protein-protein
interactions: what are the preferred ways for proteins to interact? Chemical Reviews
108(4):1225–1244.
Keskin, O., Ma, B., and Nussinov, R. 2005. Hot regions in protein–protein interactions:
the organization and contribution of structurally conserved hot spot residues. Journal
Molecular Biology 345(5):1281–1294.
Khafizov, K., Madrid-Aliste, C., Almo, S. C., and Fiser, A. 2014. Trends in structural
coverage of the protein universe and the impact of the Protein Structure Initiative.
Proceedings of the National Academy of Sciences U.S.A. 111(10):3733–3738.
Khan, S. H., Ahmad, F., Ahmad, N., Flynn, D. C., and Kumar, R. 2011. Protein-protein
interactions: principles, techniques, and their potential role in new drug development.
Journal of Biomolecular Structure and Dynamics 28(6):929–938.
Khan, S., and Vihinen, M. 2007. Spectrum of disease-causing mutations in protein sec-
ondary structures. BMC Structural Biology 7(1):56.
Kirkwood, K. J., Ahmad, Y., Larance, M., and Lamond, A. I. 2013. Characterization of
native protein complexes and protein isoform variation using size-fractionation-based
quantitative proteomics. Molecular and Cellular Proteomics 12(12):3851–3873.
Knapp, D. R. 1996. Mass Spectrometry in the Biological Sciences A. L. Burlingame and
S. A. Carr, Editors . Journal of the American Society for Mass Spectrometry 7(7):
692–692.
Koga, N., Tatsumi-Koga, R., Liu, G., Xiao, R., Acton, T. B., Montelione, G. T., and
Baker, D. 2012. Principles for designing ideal protein structures. Nature 491(7423):
222–227.
Konagurthu, A. S., Whisstock, J. C., Stuckey, P. J., and Lesk, A. M. 2006. MUSTANG:
a multiple structural alignment algorithm. Proteins 64(3):559–574.
Kono, H., Yuasa, T., Nishiue, S., and Yura, K. 2007. coliSNP database server mapping
nsSNPs on protein structures. Nucleic Acids Research 36(Database):D409–D413.
Koshland, D. E. 1958. Application of a Theory of Enzyme Specificity to Protein Synthesis.
Proceedings of the National Academy of Sciences U.S.A. 44(2):98–104.
Krawczak, M., Ball, E. V., Fenton, I., Stenson, P. D., Abeysinghe, S., Thomas, N., and
Cooper, D. N. 2000. Human Gene Mutation Database: a biomedical information and
research resource. Human Mutation 15(1):45–51.
Krissinel, E., and Henrick, K. 2004. Secondary-structure matching (SSM), a new tool for
fast protein structure alignment in three dimensions. Acta Crystallographica Section D
60(Pt 12 Pt 1):2256–2268.
217
Bibliography
Krissinel, E. 2011. Macromolecular complexes in crystals and solutions. Acta Crystallo-
graphica Section D 67(4):376–385.
Krissinel, E., and Henrick, K. 2005. Multiple alignment of protein structures in three
dimensions. In Lecture notes in computer science (including subseries lecture notes in
artificial intelligence and lecture notes in bioinformatics), 67–78. European Bioinfor-
matics Institute, Cambridge, United Kingdom.
Krissinel, E., and Henrick, K. 2007. Inference of macromolecular assemblies from crys-
talline state. Journal Molecular Biology 372(3):774–797.
Kudla, G., Murray, A. W., Tollervey, D., and Plotkin, J. B. 2009. Coding-sequence
determinants of gene expression in Escherichia coli. Science 324(5924):255–258.
Kuglstatter, A., Wong, A., Tsing, S., Lee, S. W., Lou, Y., Villase or, A. G., Bradshaw,
J. M., Shaw, D., Barnett, J. W., and Browner, M. F. 2011. Insights into the conforma-
tional flexibility of Bruton’s tyrosine kinase from multiple ligand complex structures.
Protein Science 20(2):428–436.
Kumar, A., and Purohit, R. 2014. Use of Long Term Molecular Dynamics Simulation in
Predicting Cancer Associated SNPs. PLoS Computational Biology 10(4):e1003318.
Kumar, P., Henikoff, S., and Ng, P. C. 2009. Predicting the effects of coding non-
synonymous variants on protein function using the SIFT algorithm. Nature Protocols
4(7):1073–1081.
Kumar, S., and Nussinov, R. 2002. Close-range electrostatic interactions in proteins.
ChemBioChem 3(7):604–617.
Kummerfeld, S. K., and Teichmann, S. A. 2009. Protein domain organisation: adding
order. BMC Bioinformatics 10(1):39.
Kwan, A. H., Mobli, M., Gooley, P. R., King, G. F., and Mackay, J. P. 2011. Macro-
molecular NMR spectroscopy for the non-spectroscopist. The FEBS Journal 278(5):
687–703.
Kwok, P.-Y., and Duan, S. 2003. SNP discovery by direct DNA sequencing. Methods in
Molecular Biology 212:71–84.
Lahti, J. L., Tang, G. W., Capriotti, E., Liu, T., and Altman, R. B. 2012. Bioinformatics
and variability in drug response: a protein structural perspective. Journal of The Royal
Society Interface 9(72):1409–1437.
Lander, G. C., Saibil, H. R., and Nogales, E. 2012. Go hybrid: EM, crystallography, and
beyond. Current Opinion Structural Biology 22(5):627–635.
Landrum, M. J., Lee, J. M., Benson, M., Brown, G., Chao, C., Chitipiralla, S., Gu, B.,
Hart, J., Hoffman, D., Hoover, J., Jang, W., Katz, K., Ovetsky, M., Riley, G., Sethi,
A., et al. 2016. ClinVar: public archive of interpretations of clinically relevant variants.
Nucleic Acids Research 44(Database issue):D862–D868.
Larranaga, P. 2006. Machine learning in bioinformatics. Briefings in Bioinformatics 7(1):
86–112.
218
Bibliography
Launay, G., and Simonson, T. 2008. Homology modelling of protein-protein complexes: a
simple method and its possibilities and limitations. BMC Bioinformatics 9(1):427.
Lawson, C. L., Baker, M. L., Best, C., Bi, C., Dougherty, M., Feng, P., van Ginkel, G.,
Devkota, B., Lagerstedt, I., Ludtke, S. J., Newman, R. H., Oldfield, T. J., Rees, I.,
Sahni, G., Sala, R., et al. 2011. EMDataBank.org: Unified data resource for CryoEM.
Nucleic Acids Research 39(Database issue):D456–D464.
Lees, J., Yeats, C., Perkins, J., Sillitoe, I., Rentzsch, R., Dessailly, B. H., and Orengo,
C. 2012. Gene3D: A domain-based resource for comparative genomics, functional an-
notation and protein network analysis. Nucleic Acids Research 40(Database issue):
D465–D471.
Lengyel, J., Hnath, E., Storms, M., and Wohlfarth, T. 2014. Towards an integrative
structural biology approach: combining Cryo-TEM, X-ray crystallography, and NMR.
Journal of Structural and Functional Genomics 15(3):117–124.
Li, X., Keskin, O., Ma, B., Nussinov, R., and Liang, J. 2004. Protein-protein interactions:
hot spots and structurally conserved residues often locate in complemented pockets
that pre-organized in the unbound states: implications for docking. Journal Molecular
Biology 344(3):781–795.
Li, Z., Natarajan, P., Ye, Y., Hrabe, T., and Godzik, A. 2014. POSA: A user-driven,
interactive multiple protein structure alignment server. Nucleic Acids Research 42(Web
Server issue):W240–W245.
Lilley, D. M., and Wilson, T. J. 2000. Fluorescence resonance energy transfer as a struc-
tural tool for nucleic acids. Current Opinion in Chemical Biology 4(5):507–517.
Littler, S. J., and Hubbard, S. J. 2005. Conservation of Orientation and Sequence in
Protein Domain-Domain Interactions. Journal Molecular Biology 345(5):1265–1279.
Liu, R., Baase, W. A., and Matthews, B. W. 2000. The introduction of strain and its
effects on the structure and stability of T4 lysozyme. Journal Molecular Biology 295(1):
127–145.
Livingstone, C. D., and Barton, G. J. 1993. Protein sequence alignments: a strategy for the
hierarchical analysis of residue conservation. Computer Applications in the Biosciences
9(6):745–756.
Lo Conte, L., Chothia, C., and Janin, J. 1999. The atomic structure of protein-protein
recognition sites. Journal Molecular Biology 285(5):2177–2198.
Lo Conte, L., Ailey, B., Hubbard, T. J. P., Brenner, S. E., Murzin, A. G., and Chothia, C.
2000. SCOP: A structural classification of proteins database. Nucleic Acids Research
28(1):257–259.
Loladze, V. V., Ermolenko, D. N., and Makhatadze, G. I. 2002. Thermodynamic Conse-
quences of Burial of Polar and Non-polar Amino Acid Residues in the Protein Interior.
Journal Molecular Biology 320(2):343–357.
Luca, S., Heise, H., and Baldus, M. 2004. High-Resolution Solid-State NMR Applied to
Polypeptides and Membrane Proteins. ChemInform 35(6).
219
Bibliography
Lupyan, D., Leo-Macias, A., and Ortiz, A. R. 2005. A new progressive-iterative algorithm
for multiple structure alignment. Bioinformatics 21(15):3255–3263.
Luu, T.-D., Rusu, A.-M., Walter, V., Ripp, R., Moulinier, L., Muller, J., Toursel, T.,
Thompson, J. D., Poch, O., and Nguyen, H. 2012. MSV3d: database of human MisSense
Variants mapped to 3D protein structure. Database 2012:bas018.
Ma, B., Elkayam, T., Wolfson, H., and Nussinov, R. 2003. Protein-protein interactions:
Structurally conserved residues distinguish between binding sites and exposed protein
surfaces. Proceedings of the National Academy of Sciences U.S.A. 100(10):5772–5777.
Ma, Q., and Lu, A. Y. H. 2011. Pharmacogenetics, pharmacogenomics, and individualized
medicine. Pharmacological Reviews 63(2):437–459.
Madej, T., Lanczycki, C. J., Zhang, D., Thiessen, P. A., Geer, R. C., Marchler-Bauer, A.,
and Bryant, S. H. 2014. MMDB and VAST+: Tracking structural similarities between
macromolecular complexes. Nucleic Acids Research 42(Database issue):D297–D303.
Maglott, D., Ostell, J., Pruitt, K. D., and Tatusova, T. 2011. Entrez gene: Gene-centered
information at NCBI. Nucleic Acids Research 39(Database issue):D52–D57.
Maleki, M., Hall, M., and Rueda, L. 2013. Using desolvation energies of structural do-
mains to predict stability of protein complexes. Network modeling analysis in health
informatics and bioinformatics 2(4):267–275.
Mao, B., Tejero, R., Baker, D., and Montelione, G. T. 2014. Protein NMR structures
refined with Rosetta have higher accuracy relative to corresponding X-ray crystal struc-
tures. Journal of the American Chemical Society 136(5):1893–1906.
Marks, D. S., Hopf, T. A., and Sander, C. 2012. Protein structure prediction from sequence
variation. Nature Biotechnology 30(11):1072–1080.
Marsden, R. L., Lewis, T. A., and Orengo, C. A. 2007. Towards a comprehensive structural
coverage of completed genomes: a structural genomics viewpoint. BMC Bioinformatics
8(1):86.
Marsh, J. A., and Teichmann, S. A. 2015. Structure, dynamics, assembly, and evolution
of protein complexes. Annual Review of Biochemistry 84(1):551–575.
Martin, A. C. R., Facchiano, A. M., Cuff, A. L., Hernandez-Boussard, T., Olivier, M.,
Hainaut, P., and Thornton, J. M. 2002. Integrating mutation data and structural
analysis of the TP53 tumor-suppressor protein. Human Mutation 19(2):149–164.
Maskos, U., and Southern, E. M. 1992. Oligonucleotide hybridisations on glass supports: a
novel linker for oligonucleotide synthesis and hybridisation properties of oligonucleotides
synthesised in situ. Nucleic Acids Research 20(7):1679–1684.
Matthews, B. W. 1993. Structural and genetic analysis of protein stability. Annual Review
of Biochemistry 62(1):139–160.
McCoy, A. J., Chandana Epa, V., and Colman, P. M. 1997. Electrostatic complementarity
at protein/protein interfaces. Journal Molecular Biology 268(2):570–584.
McDonald, I. K., and Thornton, J. M. 1994. Satisfying hydrogen bonding potential in
proteins. Journal Molecular Biology 238(5):777–793.
220
Bibliography
Menke, M., Berger, B., and Cowen, L. 2008. Matt: Local flexibility aids protein multiple
structure alignment. PLoS Computational Biology 4(1):88–99.
von Mering, C., Krause, R., Snel, B., Cornell, M., Oliver, S. G., Fields, S., and Bork, P.
2002. Comparative assessment of large-scale data sets of protein-protein interactions.
Nature 417(6887):399–403.
Miller, M. P., and Kumar, S. 2001. Understanding human disease mutations through the
use of interspecific genetic variation. Human Molecular Genetics 10(21):2319–2328.
Minami, S., Sawada, K., and Chikenji, G. 2013. MICAN: a protein structure alignment
algorithm that can handle Multiple-chains, Inverse alignments, C(α) only models, Al-
ternative alignments, and Non-sequential alignments. BMC Bioinformatics 14(1):24.
Mintseris, J., and Weng, Z. 2003. Atomic Contact Vectors in Protein-Protein Recognition.
Proteins: Structure, Function, and Genetics 53(3):629–639.
Mirnezami, R., Nicholson, J., and Darzi, A. 2012. Preparing for Precision Medicine. New
England Journal of Medicine 366(6):489–491.
Mitchell, A., Chang, H.-Y., Daugherty, L., Fraser, M., Hunter, S., Lopez, R., McAnulla,
C., McMenamin, C., Nuka, G., Pesseat, S., Sangrador-Vegas, A., Scheremetjew, M.,
Rato, C., Yong, S.-Y., Bateman, A., et al. 2015. The InterPro protein families database:
The classification resource after 15 years. Nucleic Acids Research 43(Database issue):
D213–D221.
Mooney, S. 2005. Bioinformatics approaches and resources for single nucleotide polymor-
phism functional analysis. Briefings in Bioinformatics 6(1):44–56.
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Vizcáıno, J. A., Côté, R. G., Csordas, A., Dianes, J. A., Fabregat, A., Foster, J. M.,
Griss, J., Alpi, E., Birim, M., Contell, J., O’Kelly, G., Schoenegger, A., Ovelleiro, D.,
Perez-Riverol, Y., Reisinger, F., et al. 2013. The PRoteomics IDEntifications (PRIDE)
database and associated tools: status in 2013. Nucleic Acids Research 41(Database
issue):D1063–D1069.
Voet, D., and Voet, J. G. 2010. Biochemistry, 4th Edition. John Wiley & Sons.
Vogel, C., Bashton, M., Kerrison, N. D., Chothia, C., and Teichmann, S. A. 2004. Struc-
ture, function and evolution of multidomain proteins. Current Opinion Structural Bi-
ology 14(2):208–216.
Wang, Z., and Moult, J. 2001. SNPs, protein structure, and disease. Human Mutation
17(4):263–270.
Wang, Z., and Moult, J. 2003. Three-Dimensional Structural Location and Molecular
Functional Effects of Missense SNPs in the T Cell Receptor Vβ Domain. Proteins:
Structure, Function, and Genetics 53(3):748–757.
Ward, L. D., and Kellis, M. 2012. Interpreting noncoding genetic variation in complex
traits and human disease. Nature Biotechnology 30(11):1095–1106.
Waterhouse, A. M., Procter, J. B., Martin, D. M. A., Clamp, M., and Barton, G. J.
2009. Jalview Version 2: a multiple sequence alignment editor and analysis workbench.
Bioinformatics 25(9):1189–1191.
230
Bibliography
Wellcome Trust Case Control Consortium. 2007. Genome-wide association study of 14,000
cases of seven common diseases and 3,000 shared controls. Nature 447(7145):661–678.
Westbrook, J., Feng, Z., Jain, S., Bhat, T. N., Thanki, N., Ravichandran, V., Gilliland,
G. L., Bluhm, W., Weissig, H., Greer, D. S., Bourne, P. E., and Berman, H. M. 2002.
The Protein Data Bank: unifying the archive. Nucleic Acids Research 30(1):245–248.
Westbrook, J. 2012. PDBx Python Module. http://mmcif.wwpdb.org/docs/
sw-examples/python/html/index.html. Accessed: 2014-01-12.
Winter, C. 2006. SCOPPI: a structural classification of protein-protein interfaces. Nucleic
Acids Research 34(90001):D310–D314.
Wlodawer, A., Minor, W., Dauter, Z., and Jaskolski, M. 2007. Protein crystallography
for non-crystallographers, or how to get the best (but not more) from published macro-
molecular structures. The FEBS Journal 275(1):1–21.
Worth, C. L., Gong, S., and Blundell, T. L. 2009. Structural and functional constraints
in the evolution of protein families. Nature Reviews Molecular Cell Biology 10(10):
709–720.
Worth, C. L., Preissner, R., and Blundell, T. L. 2011. SDM–a server for predicting effects
of mutations on protein stability and malfunction. Nucleic Acids Research 39(Web
Server issue):W215–W222.
Wu, C. H., Apweiler, R., Bairoch, A., Natale, D. A., Barker, W. C., Boeckmann, B., Ferro,
S., Gasteiger, E., Huang, H., Lopez, R., Magrane, M., Martin, M. J., Mazumder, R.,
O’Donovan, C., Redaschi, N., et al. 2006. The Universal Protein Resource (UniProt): an
expanding universe of protein information. Nucleic Acids Research 34(Database issue):
D187–D191.
Xia, Y., and Levitt, M. 2004. Simulating protein evolution in sequence and structure
space. Current Opinion Structural Biology 14(2):202–207.
Xie, L., and Bourns, P. E. 2005. Functional coverage of the human genome by existing
structures, structural genomics targets, and homology models. PLoS Computational
Biology 1(3):222–229.
Yang, J., Roy, A., and Zhang, Y. 2012. BioLiP: a semi-manually curated database for
biologically relevant ligand-protein interactions. Nucleic Acids Research 41(Database
issue):D1096–D1103.
Yang, J. O., Oh, S., Ko, G., Park, S. J., Kim, W. Y., Lee, B., and Lee, S. 2011. VnD: A
structure-centric database of disease-related SNPs and drugs. Nucleic Acids Research
39(Database issue):D939–D944.
Yates, A., Beal, K., Keenan, S., McLaren, W., Pignatelli, M., Ritchie, G. R. S., Ruffier,
M., Taylor, K., Vullo, A., and Flicek, P. 2014. The Ensembl REST API: Ensembl Data
for Any Language. Bioinformatics 31(1):143–145.
Yates, C. M., and Sternberg, M. J. E. 2013a. Proteins and domains vary in their toler-
ance of non-synonymous single nucleotide polymorphisms (nsSNPs). Journal Molecular
Biology 425(8):1274–1286.
231
Bibliography
Yates, C. M., and Sternberg, M. J. E. 2013b. The effects of non-synonymous single
nucleotide polymorphisms (nsSNPs) on protein-protein interactions. Journal Molecular
Biology 425(21):3949–3963.
Ye, Y., and Godzik, A. 2003. Flexible structure alignment by chaining aligned fragment
pairs allowing twists. In Bioinformatics, ii246–255. Sanford Burnham Prebys Medical
Discovery Institute, San Diego CA, United States.
Yu, B., Sawyer, N. A., Chiu, C., Oefner, P. J., and Underhill, P. A. 2001. Dna mutation
detection using denaturing high-performance liquid chromatography (dhplc). John Wiley
& Sons.
Yue, P., Melamud, E., and Moult, J. 2006. SNPs3D: candidate gene and SNP selection
for association studies. BMC Bioinformatics 7(1):166.
Yue, P., and Moult, J. 2006. Identification and analysis of deleterious human SNPs.
Journal Molecular Biology 356(5):1263–1274.
Zajonc, D. M., Elsliger, M. A., Teyton, L., and Wilson, I. A. 2003. Crystal structure
of CD1a in complex with a sulfatide self antigen at a resolution of 2.15 A. Nature
Immunology 4(8):808–815.
Zamyatnin, A. A. 1972. Protein volume in solution. Progress in Biophysics and Molecular
Biology 24(C):107–123.
Zhang, Q. C., Petrey, D., Deng, L., Qiang, L., Shi, Y., Thu, C. A., Bisikirska, B.,
Lefebvre, C., Accili, D., Hunter, T., Maniatis, T., Califano, A., and Honig, B. 2012.
Structure-based prediction of protein-protein interactions on a genome-wide scale. Na-
ture 490(7421):556–560.
Zhang, Y., and Skolnick, J. 2005. TM-align: A protein structure alignment algorithm
based on the TM-score. Nucleic Acids Research 33(7):2302–2309.
Zhang, Z., Wang, Y., Wang, L., and Gao, P. 2010. The combined effects of amino acid
substitutions and indels on the evolution of structure within protein families. PLoS
ONE 5(12):e14316.
Zhanhua, C., Gan, J. G.-K., Lei, L., Sakharkar, M. K., and Kangueane, P. 2005. Protein
subunit interfaces: heterodimers versus homodimers. Bioinformation 1(2):28–39.
Zhao, C., and Sacan, A. 2015. UniAlign: protein structure alignment meets evolution.
Bioinformatics 31(19):3139–3146.
Zhao, N., Han, J. G., Shyu, C.-R., and Korkin, D. 2014. Determining effects of non-
synonymous SNPs on protein-protein interactions using supervised and semi-supervised
learning. PLoS Computational Biology 10(5):e1003592.
232
